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Nanoparticles are promising carriers for the purpose of controlled pulmonary drug delivery because 
they can reside in the airways and slowly release a drug into the lung tissue. However, development 
into the clinic of nanoparticle products for pulmonary delivery has been limited to date due to the lack 
of control over the drug release process from these small carriers. In this work the feasibility of 
generating an inhaled nanoparticle system that could be administered to the airways, penetrate the 
respiratory mucus and act as a reservoir from which drug release could be controlled was explored.  
Nanoparticle systems were fabricated using an emulsion phase inversion technique and a 
nanoprecipitation method to produce lipid nanoparticle (LNPs) and polymer nanoparticles (PVA 
NPs), respectively. The LNPs had a particle size of ca. 50 nm and the PVA NPs had a size of ca. 250 
nm respectively. Rifampicin was loaded into nanoparticles and the release was controlled using 2 
different permeabilisation strategies that were designed to encourage the drug liberation from the 
particles. Both permeabilisation strategies involved mixing a chemical agent with the nanoparticles to 
induce a carrier structural change to occur. Both LNP and PVA particles were shown to be capable of 
controlling the release of rifampicin using their permeabilisation agents. However, using a 
multidimensional diffusion model the LNPs were shown to penetrate through the mucus barrier more 









Therefore, the LNPs were used in all the subsequent work. A novel spray drying technique was 
designed to fabricate microparticles to deliver the LNPs into the lung using a dry powder inhaler. The 
LNPs were loaded with drug and the agent that initiated the permeabilisation mechanism was 
incorporated into with the LNPs in micropartcles with a suitable size for airway deposition. The 
incorporation of LNPs with the permeabiliser into the microparticles did not diminish the ability of 
the LNPs to control drug release. The fate of labelled LNPs was tracked following their 
administration to respiratory epithelial Calu-3 cells and macrophage U937 cell lines. LNPs were 
found to persist at the cell surface over 8 h when delivered to a Calu-3 cell monolayer, with less than 
10% of the applied particles being internalised into the cells. The permeabilisation process increased 
the particle uptake by both cell types which was thought to be a consequence of the particles 
distending upon exposure the permeabiliser. A co-culture model was developed containing the airway 
epithelial cells and macrophages. When the co-culture was exposed to the LNPs, the particles were 
found in both cell types, with a great proportion internalisated by macrophage cells.  
The ability of the LNP to distend upon exposure to a chemical permeabiliser controlled release, 
penetrate mucus and gain preferential entry into macrophage cells in the lung suggested they could be 
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SD Standard deviation 
SEM Scanning electron microscopy 
SPSS Statistical Package for Social Sciences 
TB Tuberculosis 
TEM Transmission electron microscopy 
TER Transepithelial electrical resistance 





























1.1 General introduction 
Drug delivery refers to the approach taken to transport a pharmaceutical agent to its desired 
site of action in the body (Park, 2014). Various routes of drug administration can be used and 
hence a number of different formulations and devices have been developed for drug delivery 
(Jain, 2014).  
There is increasing interest in the delivery of drugs viathe lungs to treat a variety of diseases. 
The large surface areas of the airways, abundant blood supply and thin epithelial layer render 
this route of delivery attractive to several types of therapeutic agents (Patton and Byron, 
2007). Inhaled medicines are most frequently characterized by a rapid onset of activity. This 
may be due to the rapid absorption of molecules across the respiratory epithelium and 
subsequent systemic exposure. This enables some parenterally administrated therapies to be 
delivered to the airways for either local or systemic action. The recent use of inhaled anti-
microbial therapiesis a good example of injectable agents being delivered via the lungs (Zhou 
et al., 2015). In the case of antibiotics, lung delivery results in a potent local action and 
minimal systemic exposure. However, the rapid clearance of molecules from the airways of 
the lung does limit the applicability of the inhaled route to some agents that would benefit 
from sustained local tissue or plasma concentrations. This could be solved if a good 
controlled release system could be developed for the lungs. 
The small size of nanomaterials provides the opportunity to generate controlled drug delivery 
in the lung (Ibrahim and Garcia-Contreras, 2013). However, nanomaterials must be non-
immunogenic and biocompatible if they are to reside in the airways for a sufficient length of 
time to provide controlled drug release (Kumari et al., 2010). The context of the lung airways 
offers particular challenges for nanosystem residence because the airways are highly sensitive 
to inflammation and they are highly efficient at clearing deposited materials. Achieving 
sustained therapeutic effects using a nanocarier requires the carrier to pass through the mucus 
after deposition in the airways, avoid mucocilliary clearance and rapid absorption. This 
challenge has yet to be overcome in a clinical setting and as a result there are no commercial 
systems that have managed to achieve controlled drug delivery via this mechanism in the 
pulmonary system.  
The most promising nanocarrier systems for lung delivery developed to date appear to be the 
lipid nanocarriers. This is because they have been shown to be easily produced and they do 




not stimulate an acute immune response upon administration. However, loading a drug into 
these carriers and controlling the drug release out of them remains a challenge. For example, 
it was difficult to encapsulate poorly soluble compounds such as saquinavir into the carriers 
(< 1% loading) (Beloqui et al., 2013) and an initial burst release (20% within 1 h) was 
observed when ibuprofen was loaded into the nanocarriers (Lamprecht et al., 2004). 
 
The use of an active drug release system may offer a solution to the problems experienced 
with nanosystems during inhaled drug delivery (Ganta et al., 2008). Stimuli responsive 
nanosystems can be induced to release their drug pay load in response to exogenous or 
endogenous triggers (Mura et al., 2013). Endogenous stimuli-responsive nanocarriers often 
respond to pathological triggers that generate a specific change inpH, redox or chemical 
microenvironment, which can be target as the release stimuli. For example, anticancer drug-
delivery systems take advantage of the slight difference of pH existing between healthy 
tissues (~7.4) and the extracellular environment of solid tumours (6.5–7.2) (Deng et al., 2011). 
This offers an interesting opportunity for drug delivery where the delivery system becomes 
an active participant in the process. However, the process of trigger release via endogenous 
systems can be patient specific due to the complex microenvironments encountered by the 
nanosystems. As a consequence exogenous triggers tend to be favoured in this field of 
research. External stimuli such as magnetic fields (Carregal et al., 2015) or ultrasound have 
been shown to be an effective means to induce payload release from nanocarriers (Yan et al., 
2013). As a consequence two stimuli-responsive nanosystems (using heat and a magnetic 
field) have reached the early stages of clinical trials (Mura et al., 2013), but issues associated 
with tissue-penetration depth and focusing (to avoid damage to healthy tissues) have 
hampered the development of these triggered delivery systems. For pulmonary administration, 
it is very desirable to design chemically triggered nanocarriers that have good degradability 
and biocompatibility. Ideally a chemical trigger would only mix with the nanocarrier upon 
administration and this mixing would lead to nanocarrier premeabilisation and drug release 
through the leaky nanocarrier. However, to design such a system consideration must be given 
to administration of such a carrier to the lung and its fate within the lung and this requires 








1.2 Lung structure and physiology 
The human respiratory track can be divided into two functional regions: the conducting zone 
and respiratory zone (Weibel and Gomez, 1962). The conducting zone consists of the 
pharynx, larynx, the trachea, bronchi and terminal bronchioles, a branching system with 
branches becoming progressively smaller in diameter and length (Patton, 1996). The 
respiratory zone consists of respiratory bronchioles, the alveolar ducts and alveolar sacs, 
where gas exchange occurs. With each division from the trachea (generation 0) to the 
respiratory airways (generation 17 onward), the number of airway branches is doubled, with 
marked increases in cross sectional area. The airways bifurcate an average of 23 times from 
the trachea to the alveolar sacs (Figure 1.1) (Weibel and Gomez, 1962), presenting a tortuous 
path for the inhaled air and any aerosolised ambient or therapeutic matter carried within it. 
 
Figure 1.1: Model of airways described by Weibel (Weibel and Gomez, 1962). 
The airway and alveolar epithelia line the lumen of the respiratory tract, and form an 
important primary barrier between the external environment and the internal physiology of 
the body. Progressive changes in the epithelial lining are observed along the length of the 
respiratory tract (Figure 1.2) (Patton and Byron, 2007). As the airway progresses from the 




conducting to the respiratory zone, the cell types alter to accommodate the specific functions 
and defence mechanisms for each region. The pseudo-stratified columnar epithelium of the 
airways is composed of three major cell types: basal (stem or progenitor cells), goblet (mucus 
secreting cells) and ciliated (involved in mucocillary clearance) (BéruBé et al., 2010). In the 
bronchioles, the ciliated cells are interspersed mainly by club cells. The epithelium becomes 
more cuboidal in nature as the bronchioles are approached. The alveolar epithelium is 
composed of two type cells; broad and thin squamous Type I cells (95%) provide a thin 
absorptive membrane for gas exchange, and compact Type II cells (5%) are responsible for 
lung surfactant production as well as vectorial transport of sodium from the apical to the 
basolateral surface(Matthay et al., 2005). 
 
Figure 1.2: Comparison of the lung epithelium at different sites within the lungs. From 
(Patton and Byron, 2007) 
 
The composition of the lung surface lining fluid also varies between the conducting and 
respiratory regions. In the conducting airways the lining fluid consists of two layers; a watery 
‗sol‘ in direct contact with the ciliated epithelial surface which is covered by a second patchy 
viscoelastic mucus gel layer (Lansley, 1993). The viscous mucus, comprising mainly water, 
glycoproteins, (mucins), proteins, electrolytes and lipids (Widdicombe and Widdicombe, 
1995), is secreted directly into the lumen by goblet cells and sub-mucosal glands, and can be 
up to 10 μm thick in the upper airways (Lansley, 1993). This layer becomes thinner when 




reaching the bronchioles and terminal bronchioles, around 3 μm in height. The mucus is 
absent in the respiratory regions, where a much thinner layer of surface lining fluid exists (0.1 
μm), to facilitate their function of gas exchange. In both regions the lining fluid is topped 
with a monolayer of highly surface active lung surfactant, comprising mainly phospholipids 
(85%), which serves to reduce the surface tension at the air liquid interface (Pérez-Gil, 2008). 
1.3 Particle deposition in the lungs 
Drug formulations, whether intended for local or systemic effect, must be effectively 
aerosolised to be administered to the lungs via inhalation (Dolovich and Dhand, 2011). This 
involves the generation of a fine dispersion of drug-containing particles or droplets which 
must be entrained within the inspired air. A proportion of the particles travelling through the 
respiratory system will be trapped after coming into contact with the wet airspace surfaces, a 
phenomenon with is known as deposition. Three types of devices,namely dry powder inhalers 
(DPI), pressurised metered dose inhalers (pMDI) and nebulisers are used routinely in clinical 
practice to generate aerosols (Thompson, 1998). Device parameters are critical in 
determining performance of the resultant aerosol. Typically delivery of 40-50% of the 
nominal dose to the pulmonary tree is considered a highly efficient system (Dolovich and 
Dhand, 2011). However, the drug formulations must themselves be optimised to achieve 
reproducible aerosolisation. As such the active pharmaceutical ingredient is often combined 
with excipients to facilitate its dispersion. Common inhaled excipients include lactose, 
hydrofluoroalkane propellants, surfactants (such as sorbitantrioleate) and co-solvents (such as 
ethanol) (Pilcer and Amighi, 2010). Selection of the appropriate device and formulation will 
depend on several factors, including the clinical indication, patient dexterity, treatment 
schedule and portability. 
There are three principal mechanisms that lead to pulmonary deposition: inertial impaction, 
gravitational sedimentation and Brownian diffusion, as summarized in Table 1.1. The relative 
contributions for a given formulation are dependent on aerodynamic particle diameter 
(Courrier et al., 2002). The aerodynamic diameter of a particle is equivalent to the diameter 
of a unit density sphere that has the same terminal velocity in still air as particle (Hinds, 
2012). The inertial impaction occurs during the passage through the oropharynx and large 
conducting airways if the particles possess a mass median aerodynamic diameter (MMAD) 
more than 5 µm. Particle ranges from 1 to 5 µm are predominantly influenced by 
gravitational force that occurs in smaller airways and respiratory bronchioles, where air 




velocity is lower. The deposition of particles smaller than 0.5 μm is governed significantly by 
diffusion, based on Brownian motion and can occur in the alveoli where air is more stationary 
and resides for longer periods, however very small particles can also be extensively exhaled 
(Labiris and Dolovich, 2003a). The effect of particle size on the deposition of aerosol 
particles in the human respiratory tract following slow inhalation is summarized in Figure 1.3. 
However it was proved that gravitational sedimentation was the main mechanism of particle 
deposition and dispersion when experiment was carried out under the microgravity condition 
(Darquenne et al., 2000).  
Table1.1: Mechanism of aerosol deposition. From (Yang et al., 2008) 
Site Size (µm) Mechanism of deposition Comment 
Large airways >5 Impaction Mostly deposition in 
segmental airways 




1-3 Gravitational sedimentation Improved with slow and 
deep breathe 
Alveoli ≤0.5 Brownian diffusion Mostly exhaled 
 
 
Figure 1.3: The effect of particle size on the deposition of aerosol particles in the human 
respiratory tract following slow inhalation (From Patton & Byron, 2007) 
Targeting therapeutics to achieve preferential lung deposition for systemic or local delivery 
can be accomplished by altering the aerosol properties and physiology including particle size, 
density, surface properties or shapes to direct them to the peripheral or central regions of the 




lungs as required. However, the site, extent and efficacy of particle deposition after inhalation 
is also influenced primarily by other ventilatory factors like breath pattern, flow rates and 
tidal volume, determining the airflow velocity and the residence time in the respiratory tract 
(Byron and Patton, 1994). Depending on the particle size, shape and ventilation parameters, 
deposition occurs in all regions of the lung: the airways and the alveoli (Heyder et al., 1986; 
Patton et al., 2010). 
1.4 The fate of inhaled drugs 
Once deposited on the surface of airways, the fate of an aerosolised drug formulation depends 
on their solubility and their landing site, because deposition within the lung is a complex 
function of kinetics of absorption and non-absorptive clearance mechanisms (Sakagami, 
2006). Drugs in the particulate forms first undergo wetting in the lung surface lining fluids, 
regardless of the nature of the materials surfaces (Geiser et al., 2003). The surfactant will then 
help particulate matter to sink into the fluid, passing first through the gel phase and then the 
sol phase. If the deposited matter is fairly soluble in body fluids, it can undergo dissolution 
and enter this will make the agent available for cellular absorption. For particulates that are 
relatively insoluble, clearance is governed mainly by the mechanical removal by mucociliary 
clearance and phagocytosis by alveolar macrophages. Importantly, these mechanisms occur 
simultaneously, which makes it more difficult to study each of them individually (Ibrahim 
and Garcia-Contreras, 2013). Diseases of the lung can alter the fate of inhaled agents, eg it 
can modify the mucus production which determines the pharmacokinetics and 
pharmacodynamics of the administered medicines (Wang et al., 2014).  
1.4.1 Absorption 
Solubilised drug molecules can be rapidly cleared from the airways across the epithelial 
barrier, either transcellularly through the epithelial cells, or paracellularly between adjacent 
cells of the respiratory tract into the interstitium and then to blood and lymph (Ferin and 
Oberdörster, 1992; Patton, 1996). Transcellular drug transport occurs primarily through 
passive diffusion, but can involve active carrier mediated processes (including by P-
glycoprotein or multi drug resistance proteins) for certain drug substrates (Schmid et al., 
2009). Transcytosis can also occur and this process is important for large macromolecules 
and nanosized particulates (Bosquillon, 2010; Gumbleton, 2001). For example, inhaled 
human insulin has been suggested to achieve and maintain effective glycaemic control as a 




result of absorption across epithelia cells due to transcytosis (DeFronzo et al., 2005). Passive 
transcellular diffusion for all molecules depends on drug physiochemical properties, such as 
molecular weight, charge and hydrophobicity (log P). Small lipophilic molecules tend to 
readily diffuse through the lipid bilayers of cells. The alternative paracellular route is 
commonly used by hydrophilic molecules that are small enough to filter through the cellular 
junctions (Patton and Byron, 2007). The junctional complex between adjacent cells includes 
the tight junction and the adherens junction, which together form a selective permeability 
barrier at the apical border of the epithelium, with a molecular weight cut off of 40 kDa 
(Patton, 1996). Once molecules have translocated to the blood circulation, they can be 
distributed throughout the body. 
1.4.2 Mucociliary clearance (MCC) 
Insoluble particles that deposit in the conducting airways (from generations 0 to 16) can 
become entrapped in the upper viscous mucus layer and removed from the respiratory tree in 
a host defence mechanism known as mucociliary clearance (Lansley, 1993). Driven by ciliary 
beating, inhaled particulate materials that consist of slowly dissolving or insoluble materials 
are most often trapped in the mucus layer and moved up to the larynx where they are 
swallowed into the gastro-intestinal tract (Fulford and Blake, 1986). Cilia beat in 
coordination and adjust their frequency and phase of beating in response to neighbouring cilia, 
which is an important parameter for mucociliary transport (Sleigh et al., 1988). The average 
transport velocity in the human trachea has been estimated at 3-10 mm/min (Yeates et al., 
1975). Previous work showed that insoluble particles larger than 6 μm are cleared from the 
bronchial airways by MCC in 24 h, while relatively long retention of smaller particles in the 
conducting airways has been observed (Kreyling et al., 2006). 
1.4.3 Macrophage uptake 
Clearance of the slowly dissolving and insoluble particulates not removed by mucociliary 
clearance from the respiratory region is predominantly by macrophage phagocytosis. Where 
mucociliary clearance is absent, macrophages patrol the alveolar surface as the predominant 
clearance mechanism. According to the anatomical location, four populations of macrophages 
in lungs can be distinguished: pleural macrophages, intravascular macrophages, interstitial 
and surface macrophages, which all have specific phenotypes and different functions (Geiser, 
2010). Macrophages scavenge and engulf particulate matter, a process which is facilitated by 




the adsorption of complement proteins and opsonisation factors onto the surface of the 
particles (Geiser, 2010). Macrophage uptake of material deposited in the airways is rapid and 
believed to complete in 6-12 h after deposition of particles in the alveoli, however this 
process depends on the particle size, potential and composition of coating material (He et al., 
2010). The optimal particle size for phagocytosis by alveolar macrophages has been 
estimated to be 1-3 µm. Larger particles can still be removed by these cells but the rate of 
phagocytosis is progressively slower as the particle size increases beyond 3 µm (Chono et al., 
2006). Particles that deposit in the airways of the lung with sizes less than 0.26 µm can 
escape from phagocytosis by macrophages (Sharma et al., 2010). It appears that there are 
significant particle landing site-dependent effects on the effectiveness of this process (Geiser, 
2010). Once internalized in the macrophages, the particulates will be either disintegrated or 
accumulated in the lymphatic system. A small fraction of the particle carrying macrophages 
will migrate to the ciliated airways where they are removed by the MCC (Schmid et al., 
2009). 
1.5 Controlled drug delivery 
Despite the number of effective clearance mechanisms encountered by inhaled medicines, 
inhalation therapy represents an attractive application route for the targeted delivery of a 
number of active agents. The local application of therapeutic agents to the respiratory system 
in particular has several advantages over other routes of administration, like increased 
selectivity, high local concentration and lower systemic exposure. For these reasons the local 
delivery of inhaled agents is theprevalent approach in the treatment of respiratory diseases 
(Courrier et al., 2002). There are a wide range of inhalation products that have been 
commercialised (Table 1.2). The majority of these products administer locally acting drugs 
for treatment of lung diseases.  However, in addition, as inhalation represents an attractive 
non-invasive alternative for systemic delivery of biopharmaceuticals (e.g. peptides and 
proteins) there is an emerging market for these products. The lower enzymatic activity 
(compared to the oral route), large alveolar surface area and thin epithelial air-blood barrier 
allow rapid absorption of macromolecules from the alveolar airspace (Patton and Byron, 
2007), but as their development is time-consuming and costly there arerelatively few 
commercial products that currently exist.  
 




Table 1.2: Commercial inhalation products 
Therapeutic usage Drug classifications Drugs Inhalation device 






 Long-acting beta-2 
agonist 
Salmeterol pMDI, DPI 
 Anticholinergic 
agents 








Cystic fibrosis Antibiotics  Tobramycin  Nebulizer, DPI 






Pulmonary surfactant Phospholipids Endo-tracheal tube 
Analgesia  
 
Opioids  Fentanyl  Novel inhaler 
Diabetes  
 
Peptides  Insulin  DPI 
Parkinson‘s disease Psychoactive drug Levodopa  DPI 
Despite their routine clinical use, existing inhaled formulations suffer from rapid elimination 
from the airways which decreases the initial high local concentrations in lung tissue and 
results in repeated administration and poor patient compliance (Gessler et al., 2008). This 
places a significant burden on the patient, especially where the disease state is chronic in 
nature. Controlled release formulations that are able to regulate the delivery of therapeutic 
agents over time would be highly advantageous for the treatment of both local and systemic 
disease states (Hickey, 2014; Loira-Pastoriza et al., 2014). 
1.5.1 Drug modification 
Increasing a compound hydrophobicity, encouraging tissue binding and increasing an agents 
molecular mass can be considerated as molecular engineering stratagies to prolong the 
duration of therapeutic agents in the lung. The prolonged absorption of fluticasone propionate 
relative to the other inhaled corticosteriods was a consequence of molecular engineering to 




make the compound more hydrophobic through a prodrug (Winkler et al., 2004). Long acting 
beta agonists, e.g salmeterol is an example of an agent that has been structurally modified 
from the shorter acting salbutamol to provide sustained bronchodilation (lasting up to 12 
hours) through an increased tissue binding (Kips and Pauwels, 2001). Furthermore, 
modification of the lipophilic compound, pentamidine has been shown to increase binding to 
the lung tissue (Byron, 1993). Conjugating positive charge to a drug with a water-soluble 
inert ligand such as polyethylene glycol (PEG) is another strategy that can increase the agents 
molecular weight, which reduces clearance (Veronese and Pasut, 2005). A recent study 
demonstrated that conjugation of antibody fragments to  PEG increased pulmonary residence 
time through mucoadhesion and bypass of alveolar macrophages (Koussoroplis et al., 2014). 
However, all these afforementioned approaches are based on specific modifications to 
individual active agents. Generating a drug delivery platform technology that could be 
applied to a range of active agents is more desirable. 
1.5.2 Microparticulate carriers 
The use of microsized carriers can enhance lung retention. This strategy avoids chemical 
modification, which may cause adverse effects or modify the pharmacology of a drug.  A 
number of polymer carriers have demonstrated slow dissolution in lung fluid. Carriers 
typically slow drug dissolution down by forming a barrier, which protects the drug from 
interacting with the dissolution fluid (Pilcer and Amighi, 2010). Of all the polymer systems 
developed for inhaled delivery poly(lactic-co-glycolic acid) (PLGA) represents the most 
investigated system for the preparation of sustained-release drug profile (Beck-Broichsitter et 
al., 2012; Ungaro et al., 2012). PLGA has a number of advantages over other polymers used 
in drug delivery because it is biodegradable and biocompatible (Anderson and Shive, 2012). 
Chitosan is another polymer employed to improve drug absorption and control drug release. 
Chitosan has the added advantage that it has mucoadhesive properties, but it also can act as a 
penetration enhancer and this is seen to be problematic (Takeuchi et al., 2001). The rate of 
drug release can be tailored by selecting an appropriate molecular weight of chitosan as a 
drug release modifier in the formulation (Learoyd et al., 2008). Hyaluronic acid (HA) has 
also attracted the attention of scientists working on sustained respiratory delivery. Inhaled 
sodium hyaluronate insulin-containing microparticles were shown to prolong insulin release, 
resulting from the polymer‘s mucoadhesive and viscosity enhancing effects (Morimoto et al., 
2001; Surendrakumar et al., 2003). However, an inhaled controlled release microparticulate 




formulation is yet to be commercialised. This may be attributed to concerns over the long-
term use of relatively new excipients in the lungs and the associated regulatory challenge this 
entails. 
The use of large porous particles (LPPs) was an innovative strategy to provide a drug carrier 
that avoids rapid pulmonary clearancedue to relatively lower mass densities (0.4 g/cm
3
) and 
larger diameter (> 5µm) (Edwards et al., 1997). Large porous particles are readily dispersed 
due to the large geometric size, but theirsmall aerodynamic size allows the particles to escape 
impaction in upper airways and penetrate into deep lung. Furthermore, large geometric size 
prevents their uptake by alveolar macrophages (Cook et al., 2005). Previous work showed 
doxorubicin release from PLGA microparticles over 2 weeks, suggesting that porous large 
PLGA microparticles have great potential as a long-term inhalation agent for the treatment of 
lung cancer (Kim et al., 2012). This technique has been widely used using various porogens 
and preparation techniques for controlled release profiles (Kim et al., 2006; Rawat et al., 
2008; Ungaro et al., 2006;Yang et al., 2009). Additionally, nanoparticles can be encapsulated 
into porous particles for drug delivery to specific sites of the body, known as porous 
nanoparticle-aggregate particles (PNAP) (Tsapis et al., 2002). The merits of nanoparticle and 
large porous particles were innovatively combined in this formulation. Sung et al. (2009) 
showed that in vitro release of rifampicin-loaded PNAPs resulted in an initial burst followed 
by a sustained release over 8 h. Similarly, prolonged systemic levels of rifampicin were 
observed after delivery to guinea pigs by insufflation compared with porous particles 
containing free rifampicin (Sung et al., 2009). Despite the achievement of LPPs for controlled 
pulmonary drug delivery, there are some difficulties in adjusting drug release, assessing the 
risk of polymer accumulation within the lungs and scaling up manufacture. Consequently, 
more efforts are needed to eventually realize this delivery system from bench to bedside.  
Swellable microparticles are another promising strategy to sustain pulmonary release. Once 
deposited on the lung fluid lining, their size increases significantly by swelling and drug can 
be released in a controlled manner. El-Sherbiny, Smyth et al. (2010) synthesized PEG-grafted 
N-phthaloyl chitosan (NPHC) copolymer, which self-assembled into drug-loaded 
nanoparticles and were encapsulated in sodium alginate semi-interpenetrating microspheres 
(El-Sherbiny and Smyth, 2010). They found that increasing alginate content in the 
microspheres tended to decrease the percentage of bovine serum albumin (BSA) released.  




1.5.3 Nanocarriers for pulmonary drug delivery 
a) Liposomes 
Liposomes are colloidal vesicles formed of lipid bilayers that have been shown as suitable 
drug carrier systems. Liposomes can encapsulate both hydrophilic and hydrophobic drugs. As 
lipids are used to prepare liposomes they have a good compatibiliy with the lung tissue. A 
range of different drugs have been encapsulated in liposomes and released over a sustained 
period (Beck-Broichsitter et al., 2013; Hajos et al., 2008). For example, a liposome systems 
have been used to retard the  rapid absorption of insulinin mouse alveoli and this reduced 
drug induced side-effects (Huang and Wang, 2006). More recently, pulmonary delivery of 
liposomes in a rat model showed that the liposomes were effectively distributed in the 
respiratory tract and lungs, and that the release of salbutamol sulfate (SBS) from liposomes 
was sustained for at least 48 hours (Chen et al., 2012). Pharmacodynamic analysis in a guinea 
pig model showed that the anti-asthmatic effect of SBS liposomes persisted for up to 18 
hours, whereas that of free SBS solution was less than 8 hours. Another inhaled liposomal 
ciprofloxacin formulation, known as Pulmaquintm is in phase 3 clinical studies for treatment 
of non-cystic fibrosis bronchiectasis (Serisier et al., 2013). It has been shown to provide a 
burst release followed by a sustained release over 24 h. However, a major challenge 
associated with conventional liposomal formulations, particularly for pulmonary delivery, is 
long-term instability (Allen and Cullis, 2013). Physicochemical property changes during the 
dehydration process that are used to store these formulations can create problems (He et al., 
2010). Therefore the use of a colloidal system with similar material properties to liposomes, 
but greater structural stability could prove to be highly advantageous in the context of 
controlled pulmonary delivery. 
b) Micelles/dendrimers 
Micelles are self-assembling nanosized colloidal particles with a hydrophobic core and 
hydrophilic shell (Torchilin, 2007). At low concentrations, the amphiphiles exist as 
monomers. Above the critical micelle concentration (CMC), the monomers self-assemble to 
form micelles. Micelles are used as carriers of poorly soluble compounds where 
solubilization occurs in the micelle core. Gill et al. (2011) evaluated the potential of 
paclitaxel loaded micelles fabricated from PEG5000 as a sustained release system following 
pulmonary delivery (Gill et al., 2011). The results showed the micelles retarded paclitaxel 
release over 8 h in vitro. More recently, Hu et al. (2014) showed aerosolized PEG–PLGA 




micelles were a promising carrier for pulmonary sustained release of labile drugs (Hu et al., 
2014). Dendrimers are three-dimensional structures similar to micelles, also known as 
unimolecular micelles, which have been proved as successful carriers in different routes of 
drug administration (Cheng et al., 2008). Several studies have shownthat dendrimers can 
sustain drug release within the airway tract. Kaminskas et al. (2014) explored the conjugation 
of a 56 kDa PEGylated polylysine dendrimer to doxorubicin to promote the controlled and 
prolonged exposure of lung-resident cancers to cytotoxic drug (Kaminskas et al., 2014). The 
dendrimer sustained doxorubicin in the lungs for 7 days compared to rapid absorption of free 
drug. 
c) Nanoparticles  
Nanoparticles for medical applications are defined as solid colloidal particles of 1 to 1000 nm 
in diameter (Duncan and Gaspar, 2011). In the area of drug delivery nanoparticles are 
generally 50 nm or larger in size (De Jong and Borm, 2008). The active therapeutic agent is 
either dissolved, entrapped or encapsulated within the nanocarrier, or alternatively absorbed 
or attached to the surface of the matrix (Sahoo and Labhasetwar, 2003). Depending on their 
structures and morphologies, nanoparticles can be further classified as matrix (nanosphere) or 
vesicular structures (nanocapsule). Nanospheres are matrix systems in which the therapeutic 
agent is physically and uniformly dispersed, whereas nanocapsules are vesicular systems in 
which drug is usually contained within a cavity surrounded by a solid or liquid core that is 
encapsulated by an outer shell. The advantages of using nanoparticles for drug delivery result 
from their small size that can penetrate through mucus and from their degradation if made 
from biodegradable materials which can allow sustained drug release within the target site 
over a period of time (Thomas and Klibanov, 2003). A wide range of materials have been 
used to fabricate nanoparticles for various applications with different properties and release 
characteristics for the encapsulated therapeutic agent (Zhang et al., 2008). The materials 
employed to fabricate nanocarriers for drug delivery can broadly be categorised as inorganic 
(elements such as silica and alumina) or polymeric (naturally occurring such as gelatin and 
albumin, or synthetic such as poly(cyanoacrylate)) (Parveen et al., 2012). When considering 
their use in inhaled formulations it is imperative that the materials used do not elicit an acute 
inflammatory response or accumulate following chronic dosing (Dailey et al., 2006). 
Although inorganic nanoparticles possess good stability and demonstrated successes in 
imaging and treatment of tumors (Huang et al., 2006), they are not well biodegraded and 




hence raise concerns over their biopersistence and long term toxicity (Huang et al., 2011). 
Biodegradable polymers are thought to be more attractive when considering repeat human 
exposure.  Polymers can undergo hydrolysis upon implantation into the body, forming 
biologically compatible and metabolizable moieties that are eventually removed from the 
body. There are various potential applications of nanoparticles for delivery of therapeutic 
agents to the cells and tissue (Panyam and Labhasetwar, 2003).  Biodegradable nanoparticles 
formulated from PLGA have been extensively investigated for sustained and 
targeted/localized delivery of different agents including plasmid DNA, proteins and peptides 
and low molecular weight compounds (Ungaro et al., 2012). 
Nanoparticles offer several advantages over larger particles due to their small size. Compared 
to micro-sized carriers, nanoparticles can penetrate through small capillaries and access 
individual cells, thus allowing drug accumulation at the required site (Panyam and 
Labhasetwar, 2003). Therefore, theoretically the unwanted side effects and the toxicity of the 
therapeutic agent is reduced and the therapeutic efficacy is enhanced. Another study 
demonstrated that pulmonary epithelial cells internalize particles 0.5 µm or smaller 10 times 
more than 1 µm particles and 100 times more than 2 or 3 µm particles (Foster et al., 2001). In 
addition, nanoparticle formulations have been used to enhance the bioavailability of poorly 
soluble drugs due to their large surface area to volume ratio (Gonçalves et al., 2016). Passive 
targeting has also been attempted following the inhalation of nanoparticles as a means to treat 
lung diseases (Azarmi et al., 2008). Furthermore, the use of biodegradable materials for 
nanoparticle preparation allows the potential for prolonged drug release (Gu et al., 2008). 
Many applications of nanoparticles have been designed to exploit the body‘s normal or 
pathological states, depending on the desired therapeutic target. For example, the enhanced 
permeation and retention effect is well described in the literature and results in passive 
targeting by nanoparticles through ‗leaky‘ vasculature, for example in and around tumour 
sites (Peer et al., 2007). When compared to other nanocarriers, such as liposomes, 
nanoparticles confer the advantages of high payload encapsulation efficiency, good stability 
and a capacity to resist solvent entry over prolonged storage periods (Hans and Lowman, 
2002). Furthermore, nanoparticles can be used to protect the loaded therapeutic agent from 
degradation (Chalasani et al., 2007). The advantages and disadvantages are summarized in 
Table 1.3. To accomplish controlled pulmonary delivery, innovative carriers that possess 
good release properties are needed to overcome the airway clearance machanisms. 










 Simple and practical manufacture 
process with mature preparation 
techniques 
 Unflavorable fluidization and 
dispersibility 




 Decreased tendency to aggregation 
and decreased phagocytosis by 
alveolar macrophages 
 Higher aerosolization efficiency 
 Lack of universal preparation 
method and poor control of 




 Diminished phagocytosis by 
alveolar macrophages 
 Unfavorablefluidization and 
dispersibility 
 Challenging to customize drug 
release pattern 
Liposomes   Tremendous versatility in particle 
size and physical characteristics 
 Solubilize poorly soluble drugs, 
facilitate alveolar macrophage 
delivery  
 High production cost 
 Drug leakage owing to the relative 
instability during storage and 
nebulisation 






 Escape alveolar macrophage 
clearance  
 Unclear pulmonary nanotoxicity 
Solid lipid 
nanoparticles 
 Biocompatible, more stable than 
liposomes under nebulization, easy 
to scale-up  
 Poor drug loading, elusive drug 






 Decreased tendency to aggregate  
 Escape alveolar macrophage 
clearance  








1.6 Administration of inhaled nanocarriers 
The respirable fraction of an inhalable powder is generally the fraction of particles with an 
aerodynamic diameter ranging between 1 and 5 µm (Patton and Byron, 2007). Most 
nanoparticles used for inhaled delivery find it difficult to deposit in the respiratory tract. 
These small particles can be subjected to exhalation, making the direct adminstration of 
nanoparticles for pulmonary delivery problematic. In addition, it is difficult to physically 
stabililse nanoparticles during the aerosolisation process (Abdelwahed et al., 2006). 
Generally, to try and overcome these issues nanoparticles are dispersed in a liquid or solid 
formulation for inhaled delivery. The simplest means of achieving this is via nebulisation of a 
nanoparticle suspension (McCallion et al., 1996).   
During nebulisation a liquid is broken up by compressed gas flow into anaerosol with useful 
size for airway deposition. The advantage of nebulizers is that no special inhalation 
techniques are needed for optimum delivery (Labiris and Dolovich, 2003b). Another 
associated advantage is the rapid liberation of nanoparticles from the micro-droplets upon 
contact with the lung surface lining fluids, as the spreading of the aqueous vehicle would be 
immediate. However, the nanoparticles must be resilient enough to withst and the shear 
forces experienced during the nebulisation process. A major drawback is that many 
nebulisers need compressed gas or a compressor to operate and the delivery process is 
relatively time consuming. Furthermore, the poor efficiency of nebulising drug suspensions is 
a major limitation to their use (Knoch and Keller, 2005). 
An alternative approach to enable effective pulmonary administration of nanoparticles is to 
formulate nanoparticle-containing microparticles of respirable size for inclusion in dry 
powder/ pressurised metered dose inhalers. Pressurised metered-dose inhaler (pMDIs) are 
portable, convenient, multi-dose devices that use a propellant such as hydrofluoroalkanes 
(HFAs) under pressure to generate a metered dose of an aerosol through an atomisation 
nozzle. No safety concerns have been identified with their use in healthy individuals or 
patients with asthma as hydrofluoroalkanes are non-toxic, non-flammable, and chemically 
stable. However, typically less than 50% of the emitted dose has been reported to deposite in 
the lung (Nyambura et al., 2009), which limitsthe administertation of high doses. A variety of 
parameters affect the delivery efficiency of an pMDI, such as a patient‘s breathing pattern, 
inspiratory flow rate and hand–mouth co-ordination (Smyth, 2003). Dry powder inhalers 
(DPIs) are the most innovative devices for both local and systematic  effect and for delivery 




of a range of drugs. There is a wide range of DPI devices on the market, from single-dose 
devices loaded by the patient to multiunit dose devices (Ninane et al., 2015). DPIs eliminate 
the co-ordination difficulties associated with the pMDI. However, DPIs in use today are 
breath actuated and are dependent on a patient‘s inspiratory flow rate. Active DPIs are being 
developed that reduce the importance of a patient‘s inspiratory effort so that the generation of 
a respirable aerosol becomes independent of inspiratory flow rate but these systems are not 
yet very popular as they remain expensive (Dolovich and Dhand, 2011). Strageties to 
enhance delivery efficiency have been studied. For example, a dry powder inhaler with the 
potential to control particle deposition and sustain release to the lung by encapsulating 
nanoparticle in large porous PLGA particles has been formulated (Arnold et al., 2007). Also 
mannitol microparticles containing chitosan nanoparticles were reported to allow efficient 
nanoparticle liberation upon incubation with aqueous media (Grenha et al., 2007).  
1.7 Fate of inhaled nanocarriers 
The fate of nanoparticles after landing in the respiratory tract is difficult to study in vivo. 
Generally, the first barrier nanoparticles encounter is the surfactant on top of the airway 
lining fluid. It is important to understand whether the nanoparticle properties are retained 
upon their suspension in such biological fluids as physical instability and aggregation will 
result in the loss of their size specific advantages and may have deleterious effects on drug 
delivery (Madlova et al., 2009). It has previously been shown that small metal oxide 
nanoparticles rapidly agglomerated in biological fluids, which could be due to a high number 
density (Limbach et al., 2005). Similarly, polystyrene nanoparticles (300 nm) were found to 
aggregate in cell culture medium despite being physically stable in aqueous media (Madlova 
et al., 2009). On the other hand, there is interaction between nanoparticles and pulmonary 
surfactant system, which could significantly impact on biophysical surfactant function, 
surfactant metabolism, particle clearance, and particle-induced toxicity (Schleh and Hohlfeld, 
2009). Following wetting in the lung surface lining fluid there are several competing 
pathways that nanoparticles may follow, including mucociliary and phagocytic clearance, as 
well as prolonged retention, cellular uptake and epithelial barrier penetration (Figure 1.4). 
Two major mechanisms,the mucociliary escalator and macrophage clearanceare involved in 
the clearance of particles in the lungs. The mucociliary escalator eliminates particles 
deposited in the airways.  





Figure 1.4: Potential pathways determining the fate of inhaled nanoparticles. (From Zhang et 
al., 2011) 
The mucociliary escalator eliminates particles deposited in the airways. A major role of the 
respiratory mucus gel is to trap inhaled particles so that they can be swept from the airways 
by mucociliary clearance, thereby defending the lungs against pathogens and toxic materials. 
Mucus has been considered as a critical barrier to nanoparticle therapies (Lai et al., 2009). 
The primary mechanism by which mucus gels efficiently trap foreign particulates is the 
formation of polyvalent adhesive interactions (Lai et al., 2009). The high density of 
hydrophobic domains, coupled with the flexible nature of mucin fibers, allows efficient 
formation of multiple low-affinity adhesive interactions with hydrophobic regions on the 
surfaces of foreign particulates. Polyvalent adhesive interactions with mucus can be achieved 
via electrostatic interactions as well. Since the glycosylated regions of mucin fibers are 
densely coated with negative charges, mucus can also bind positively charged particles with 
high avidity. On the other hand, a size filtering mechanism stops the transport of particles 
with diameter larger than pore size.  
The slow pulmonary clearance of inhaled particulates is usually attributed to phagocytic 
uptake by macrophages and their subsequent slow migration to the mucociliary escalator and 
lymph (Moller et al., 2008). However, macrophage mediated uptake of nanoparticles with a 
size of less than 100 nm is thought to be limited due to less efficient particle recognition 
(Geiser, 2010). In a study using 30 nm titanium nanoparticles, only 0.1 % of the particles 




were found to be internalised by macrophages following bronchoalveolar lavage at 24 h 
(Geiser et al., 2008). Macrophage uptake by nanoparticles is also influenced by surface 
properties. In vitro investigations have shown that polymeric nanoparticles with high surface 
charge were phagocytized more efficiently by murine macrophage (He et al., 2010). 
Nanocarriers that are not well cleared by phagocytic or mucociliary clearance have a greater 
opportunity to interact with the epithelial surface, where they may be retained, internalised or 
translocated. Although cellular uptake and/or epithelial translocation may be considered 
attractive for certain drug delivery applications, this raises concerns about the potential 
adverse effects and toxicities associated with nanoparticle use. Several routes for nanoparticle 
entry into non-professional phagocytic cells have been proposed (Chou et al., 2011). 
Internalisation may be receptor mediated (via clathrin or caveolin) or result from more 
passive interactions at the cell membrane surface (macropinocytosis, direct diffusion). The 
uptake of fluorescently labelled drug delivery nanoparticles by cultured airway epithelial cell 
layers has been reported to be up to 10% of the applied dose (Madlova et al., 2009). 
Nanoparticle translocation across the epithelial barrier may be a result of transcellular or 
paracellular transport, but the latter will probably be limited for drug delivery nanoparticles 
by their size. The tight junctions between adjacent cells are thought to restrict particle 
passage when they possess a size of > 10 nm (Lin et al., 2012). Pulmonary translocation has 
been demonstrated in animal models and it appears that smaller nanoparticles are translocated 
to a greater extent than larger nanoparticles (Kreyling et al., 2009). 
1.8 Nanocarrier loading and release 
When acting as vectors to facilitate the delivery of therapeutic agents, nanoparticles should 
display a high drug loading capacity, good drug retention during storage and transit, and 
effective drug release when at the intended site of residence/action. Normally the first 
important point to judge the suitability of a drug carrier system is its loading capacity. Drug 
loading into nanoparticles can be achieved by two methods: one by incorporating the drug at 
the time of nanoparticle production and second by adsorbing the drug after the formation of 
nanoparticles by incubating them in the drug solution (Soppimath et al., 2001). Several 
factors determine the loading capacity including solubility of drug in the selected matrix; 
miscibility of drug in the second phase and chemical and physical structure of the matrix 
(Müller et al., 2000). For example, the formation of highly crystalline particles with a perfect 
lattice has been demonstrated to lead to drug expulsion when the matrix was made of lipid 




(Westesen et al., 1997). Although some strategies can be used to entrap more drugs within 
particle matrix physically or chemically, drug leaking during manufacture, storage and transit 
is still a major challenge (Emeje et al., 2012).  
The kinetics of drug release from nanoparticles isan essential feature of their design (Modi 
and Anderson, 2013). However, there is no standardised release method that has been 
established to test nanocarrier drug release. Dialysis is one of the most commonly used 
methods for the determination of drug release from nanoparticles. The reason for the 
popularity of dialysis over other methods (e.g., ultracentrifugation and ultrafiltration) is that 
the additional step of separating nanoparticles from the free drug at various time points 
during the kinetic study is eliminated (Zambito et al., 2012). However, a major problem 
during the release with dialysis is the chemical stability of drug in dialysis medium. In terms 
of other methods, appropriate separation of the particles from the liquid phase in which they 
are suspended is necessary to distinguish the particle-bound and free drug. The most reliable 
way to separate the nanoparticles from the solution containing unbound drug is 
ultracentrifugation. This process can be achieved by ultracentrifugation or ultrafiltration (Cui 
et al., 2006). The external pressure applied for separation in other methods can disturb the 
equilibrium, and incomplete separation can lead to significant measurement errors (Wallace 
et al., 2012). 
A major problem with nanoparticles as drug carriers is burst-release. In general drug release 
rate depends upon drug solubility, drug diffusion through the nanocarrier structure and 
biodegradation of the matrix materials. Passive drug release from nanoparticles can occur via 
desorption of surface bound drug, by drug diffusion through the carrier matrix/membrane, by 
carrier erosion, or via a mixture of these processes (Kumari et al., 2010). For a number of 
nanoparticles a burst-release phase can been observed followed by a slow-release phase, or 
phases, associated with drug diffusion or carrier erosion (García-Díaz et al., 2015). The drug 
release profiles are dependent on production parameters and also the nature of matrix. 
Premature release from nanoparticle systems is problematic as it means that the presentation 
of the drug molecules at the point of administration is different to that intended, i.e. the 
release drug will be free to be absorbed as a simple drug solution rather than drug-loaded 
nanoparticles, which can influence the resultant biopharmaceutical profile. Furthermore, the 
initial burst can liberate a significant portion of drug in a short period, which can lead to acute 
toxicity, and / or rapid clearance and thus a low bioavailability. Therefore a means to prevent 




undesirable premature drug losses would be of considerable benefit to prolong the shelf life 
of nanoparticles. On the other hand, incomplete payload release can be an issue associated 
with nanoparticles. Although slow and sustained release profiles from nanoparticles are 
highly desirable, systems exhibiting close to zero release over a period of days would be 
unsuitable for pulmonary delivery where local inflammation is a concern (Shvedova et al., 
2005). High drug concentration resulting from efficient drug liberation from carriers is a 
critical prerequisite to achieve pharmacological effects. Given the above, a strategic approach 
to controlled release appears to be the design of nanocarriers that display sufficient drug-
carrier affinity to prevent premature drug leakage during manufacture, storage and transit, 
coupled with an efficient drug liberation mechanism to elicit release in situ. 
1.8.1 Active drug release from nanocarriers 
Nanoparticulate carriers could be beneficial in pulmonary drug delivery, but they must meet 
the conflicting demands of payload retention prior to dosing and effective release upon 
administration, especially when formulated as a nanosuspension (Sun et al., 2012). It has 
been suggested that this can be achieved by actively modifying the nanocarrier upon delivery 
so that drug release is optimised. Active drug release can be broadly classified into two 
categories: chemical or physical (Ganta et al., 2008). Active chemical triggers can induce a 
changeby modifying the functional groups of the material used to produce the nanocarrier 
and this can induce a range of subsequent events, e.g. it can stimulate the degradation of 
particles to cause the release of drug from the carrier (Chen et al., 2010; Du et al., 2011). The 
chemical that induces a change can be either exogenous or endogenous. Physical strategies in 
contrast often employ external devices to induce an environmental change such as a change 
in temperature, ultrasound or magnetic field (Oliveira et al., 2013; Wei et al., 2009; You et al., 
2010). The most significant potential advantage of activenanocarrier delivery systems is 
better drug targeting compared to conventional systems, i.e. the drug is only released when 
needed. 
In the context of inhaled medicines exogenously triggered active drug delivery systems seem 
preferable as they do not suffer from the inherent biological variability introduced by the 
patient. Several active drug release from nano-systems have been described in the literature, 
but their suitability for pulmonary delivery remains unclear (Al-Ahmady et al., 2012; Lo et 
al., 2010; Zhao et al., 2009). Particular consideration must be given to the biocompatibility of 
the active drug release trigger as the lung is susceptible to inflammation (Bhattacharya et al., 




2013; Shvedova et al., 2012). Furthermore, active drug release carrier systems must possess 
sufficient responsiveness to the release trigger to enable drug liberation. These two issues can 
generate a paradox for inhaled drug delivery as highly reactive nanoparticles can induce 
detrimental biological effects, for example by disrupting heomoeostasis or eliciting 
inflammatory responses whereas unreactive nanoparticle systems are poorly responsive to 
active release systems (Beyerle et al., 2011). It is difficult to find an existing nanosystem that 
satisfies the controlled release profile required for pulmonary airway administration. 
1.8.2 Types of active drug release 
The design of nanocarriers sensitive to stimuli may represent an attractive option for 
controlled drug delivery. The wide range of stimuli able to trigger the drug release at the right 
place and time, and the diversity of responsive materials that can be assembled in different 
architectures, allow great flexibility in the design of stimuli-responsive systems (Stuart et al., 
2010). 
a) Thermo responsive 
Thermoresponsive drug delivery is among the most investigated stimuli-responsive strategies, 
and has been widely explored in oncology. Ideally, thermosensitive nanocarriers should 
retain their load at body temperature (~37 °C), and rapidly deliver the drug within a locally 
heated tumour (~40–42 °C). Thermoresponsive systems are generally liposomes, or polymer 
micelles or nanoparticles made of specific materials that exhibit a lower critical solution 
temperature (Al-Ahmady and Kostarelos, 2016). Liposomes are perhaps the most advanced 
thermoresponsive nanosystems, as shown by their use in several clinical trials. More recently, 
improved liposomal formulations have been shown to release their loads shortly after the 
onset of hyperthermia (~40–44 °C) (Kono et al., 2015). The challenge in the design of 
thermoresponsive nanodevices lies in the use of materials that are both safe and sensitive 










b) pH responsive 
pH variations have been exploited to control the delivery of drugs in specific organs (such as 
the gastrointestinal tract or the vagina) or intracellular compartments (such as endosomes or 
lysosomes), as well as to trigger the release of the drug when subtle environmental changes 
are associated with pathological situations, such as cancer or inflammation (Gerweck and 
Seetharaman, 1996). This strategy involves the use of polymers with ionizable groups that 
undergo conformational and/or solubility changes in response to environmental pH variation. 
For example, chitosan swelling induced on amino-group protonation (pka ~6.3) leads to the 
release of encapsulated tumour necrosis factor alpha (TNF-α) in the local acidic environment 
of tumour tissue (Deng et al., 2011). pH-mediated triggered delivery of proteins into ischemic 
areas was achieved with piperidine- and imidazole-modified PEG–poly(β-aminoester) 
micelles (Min et al., 2010). Because of the broad range of pH found throughout the 
gastrointestinal tract, pH-responsive systems for oral drug delivery have been designed to 
protect drugs from the harsh conditions found in the gastric region and to improve their 
absorption in the intestine (Wang and Zhang, 2012). At the cellular level, the acidification of 
endosomes (pH ~5–6) and their fusion with lysosomes (pH ~4–5) is another pH gradient that 
can be used for effective intracellular drug accumulation. Nanoplexes that expand in response 
to a mildly acidic pH to afford rapid release of peptides have been conceived using natural 
glycosides (Weng et al., 2015).  
c) Redox responsive 
Disulphide bonds, prone to rapid cleavageby glutathione (GSH), can be used to attain redox 
sensitivity as a high redox potential difference (∼ 100–1000 fold) exists between the reducing 
intracellular space and oxidizing extracellular space (Saito et al., 2003). For example, a 
thiomer-based nanoparticulate gene delivery system was developed (Schmitz et al., 2007). 
Thiol groups prone to oxidation were immobilized on the polymeric backbone of chitosan in 
order to incorporate the property of extracellular stability and intracellular gene release by 
forming reversible disulfide bonds. The highest efficiency was observed in transfection 
studies performed in a Caco-2 cell culture. GSH-sensitive crosslinking agents can be 
incorporated in the core of the micelles, leading to rapid micelle disassembly followed by 
specific intracellular release of hydrophobic drugs (Li et al., 2011). In addition, liposomes are 
the candidates for redox-sensitive systems as well (Ong et al., 2008). However, designing 




these systems to be sensitive to discrete variations of pH and redox potential is not 
straightforward.  
d) Chemical responsive 
Triggered delivery systems that do not use specialist equipment for administration and where 
the process can be easily controlled, e.g. systems requiring co-administration of chemical 
triggers, offer a more convenient approach. Surfactant-induced leakage from liposomes has 
been studied. For example, Pluronic F127 (PF127) is a biocompatible tri-block copolymer, 
which can interact with lipid bilayer of liposomes and make leakage that allow the release of 
hydrophilic substance from liposome interior (Kim et al., 2014). Similarly, lipid nanoparticles 
engineered with a solid outer shell, could be selectively and rapidly permeabilised using the 
amphiphilic polymer Pluronic
®
 L62D as a chemical trigger (Chana et al., 2015). Apart from 
surfactant, sugar can be used to trigger copolymers through hydrolysis (Roy et al., 2008). 
Similarly glucose-induced swelling attributed to the slow reaction between glucose and 
phenylboronic acid (PBA) groups enabled microgel suitable for sustained drug delivery 
(Xing et al., 2011). Some polymer films such as poly (2-vinylpyridine) is also responsive to 
cholesterol molecules, thus the material can be used to manufacture stimuli responsive 
nanomaterials for controlled release (Stuart et al., 2010). However only surfactant have been 
tested for pulmonary drug delivery.  
1.9 Inhaled nanoparticle carriers used for anti-tuberculosis drugs 
The advantages of local delivery to the primary site of infection, the lung, alongside the 
potential merits of nanotechnology make treatment of tuberculosis (TB) by inhalation of anti-
TB drug-loaded nanocarriers an attractive prospect (Choudhary and Devi, 2015). TB is a 
highly contagious chronic granulomatous bacterial infection and is the second leading cause 
of death from an infectious disease worldwide after human immune virus (HIV) deficiency. 
Tuberculosisis a lethal infectious respiratory disorder which was considered a disease of the 
past, but about 30% of the world populations are afflicted with TB. According to The World 
Health Organization (WHO) guideline reports, the recent estimates in 2015 were 9 million 
incident cases of TB with 1.4 million TB deaths (Global Tuberculosis Report 2015).  
TB is triggered by different strains of Mycobacteria, among them Mycobacterium 
tuberculosis, a slender, acid-fast, non-motile gram-positive bacilli being the most common 




strain which may attack any part of body (Smith, 2003); 80% of infections are pulmonary TB 
and also advance as extrapulmonary TB in the central nervous or circulatory systems or 
elsewhere in the body (Dube et al., 2012). Mycobacterium tuberculosis has a complex cell 
wall, composed of long-chain fatt acids, glycolipids, peptidoglycan and proteins (Barry et al., 
2009). Primary TB occurs within the first year or so after exposure and is the result of an 
uncontrolled initial infction. The majority (90%) of infected humans effectively contain the 
bacteria and are defined as having latent TB infection (Choudhary and Devi, 2015). A 
relatively smaller proportion of people who are infected with M. tuberculosis will develop TB 
disease. Risk of developing active disease varies conferring to time since exposure, age and 
host immunity (Newton et al., 2008). The lifetime risk of infection activation for a latently 
infected human has been estimated to be 2-23%.  
Onced inhaled, most M .tuberculosis organisms will settle in the upper respiratory epithelium, 
where they are likely be expelled by the mucociliary escalator. The few bacteria reaching the 
deep lung are phagocytosed by alveolar macrophages and either killed or else survive to 
initate an infection (Ernst, 2012). The fate of the bacillus within the infected cell depends on 
the type and activation state of cell found. It is believed that a bacillus is able to survive 
within a macrophage if the phenotype of the phagocytic cell interacting with M. tuberculosis 
displays an anti-inflammatory phenotype also known as alternative activation state. Once 
inside the phagocyte, the mycobacteria modulate the behaviour of its phagosome by 
preventingits fusion with acidic, hydrolytically-active lysosomes (Smith, 2003).  
Over the next 2 to 3 weeks, surviving organisms multiply, kill their host macrophages and 
release more bacillus infecting additional host cells. Pulmonary inflammation due to 
interaction of bacillus with macrophages and other cells results in recruitment of monocytes, 
neutrophils and primed T-cells and B-cells to lungs, culminatingin the formation of 
granulomatous lesions (Dartois, 2014). In its early stage, the granuloma has a core of infected 
macrophages enclosed by foamy macrophages and other monomuclear phagocytes, 
surrounded by lymphocytes. At the same time, there is a noticeable increase in the number of 
foamy macrophages responsible for the accumulation of casuous debris in the centre of the 
granuloma (Byrne et al., 2015).  
Tuberculosis treatment represents a challenge which requires prolonged treatment times. 
Treatment may last for months especially in the case of immunosuppressive patients and 
those with multidrug-resistance tuberculosis (Mukherjee et al., 2004). Since the control of 




bacterial resistance appears to be unsatisfactory, treatment with anti-tubercular (anti-TB) 
drugs is the only option available. The principal objective of chemotherapy in TB patients is 
the eradication of the whole bacillary load.  Modern therapy relies on a combination of potent 
first-line antituberculosis drug which includes: isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) (Table 1.4). In the case of multidrug-resistant 
(MDR-TB), in which the bacillus is resistant to these drugs, second-line drugs such as 
cycloserine, ethionamide and fluoroquinolones will be employed. Overall first line drugs are 
mainly bactericidal and combine a high degree of efficacy with a relative low toxicity to the 
patient during treatment, while second line drugs are mainly bacteriostatic and have lower 
efficacy and are usually more toxic. Thus, using second-line agents for TB treatment is not 
favored. Effective TB chemotherapy must include early bactericidal action against rapidly 
growing organisms and subsequent sterilization of dormant populations of bacillus. Multi-
drug therapy is necessary for the treatment of active TB as single drug therapy of TB may 
result in development of drug resistance (Gandhi et al., 2010). According to WHO guidelines, 
the standard regimen for TB treatment uses a combination of rifampicin, isoniazid, 
pyrazinamide, and thambutol for 2 months followed by using rifampicin and isoniazid for 
further 4 months (Organization, 2015). 
Table 1.4: Anti-tuberculosis drug regime (British National Formularly, 2015) 
 Initial phase Continuous phase 
Duration  Two months Four months 
Antibiotics (Dose) Rifampicin (450-600 mg) 
Isoniazid (300 mg) 
Ethambutol (15 mg/kg) 
Pyrazinamide (1.5-2 g) 
Rifampicin (450-600 mg) 
Isoniazid (300 mg) 
Frequency  Daily  Daily  
To date the only routes of antituberculosis drug administration are the oral and parenteral 
routes. Although the oral and parenteral therapies are effective in treatment of TB, several 
studies reported some undesirable side effects leading to treatment interruption (Yee et al., 
2003). Furthermore, prolonged administration of high doses is needed in the case of oral 
therapy as only small proportions of dose reach the lung, leading to side effects due to high 




systemic exposure. For example, some side effects such as nausea, hepatotoxicity associated 
with acute renal failure have been reported by rifampicin when taken orally (Poole et al., 
1971). In terms of parenteral route, the pain and inconvenient use make it not so highly 
acceptable. Consequently, the development of pulmonary anti-TB drug delivery systems with 
the ideal of increasing local drug concentration in the lungs and decreasing systemic side 
effects offers a potential value in TB treatment.  
Several inhalable nanocarriers have been tested for local pulmonary delivery of drugs to treat 
tuberculosis (Costa et al., 2016). Polymeric nanoparticles have been tested for drug delivery 
to the lungs. A commonly investigated example of a natural polymer suitable for pulmonary 
delivery is PLGA, which has been greatly focused on as a carrier for anti TB drugs due to its 
high biodegradability and biocompatibility and low systemic toxicity. For example, Pandey et 
al. (2003) encapsulated anti-TB drugs into PLGA nanoparticles and evaluated their suitability 
for pulmonary delivery (Pandey et al., 2003). Prolonged drug retention in the lung and 
enhanced drug bioavailability of nebulized loaded nanoparticles was proved compared to oral 
administration of the drug. Similarly, porous nanoparticle-aggregate particles (PNAPs) were 
produced to examine the the encapsulation of rifampicin within PLGA nanoparticles and 
pharmacokinetic profiles (Sung et al., 2009). The results illustrated that rifampicin was 
released andmaintained its level in the lung over 8 h while free drug was cleared rapidly. 
Furthermore, a novel four-fluid nozzle spray drier has been established to produce 
rifampicin-PLGA microspheres.The results revealed that these carriers had good in vitro 
aerosol performance and enhanced uptake by alveolar macrophages compared to 
microspheres that were manufactured by a traditional two-fluid spray drier. Additionally, 
natural polymers, like chitosan and alginate have been employed to produce inhalable anti-
TB drug delivery systems. In vivo pharmacokinetic and pharmacodynamic studies agree with 
previous data that respirable alginate nanoparticles had higher relative bioavailability 
compared to oral free drug (Zahoor et al., 2005). Thus, polymer based nanoparticles 
encapsulating anti-TB drugs have been demonstrated to be safely used for pulmonary 
tuberculosis treatment.  
Liposomes are considered to be the simplest drug delivery systems for the treatment of 
pulmonary infections. The greatest advantage over other nanocarriers is the composition as 
they contain phospholipids similar in structure to that of pulmonary surfactants, resulting in 
high safety and decreased local irritation of the lung (Cipolla et al., 2014). Similary to 




previously listed nanocarriers, liposomes are capable of increasing absolute bioavailability of 
aerosolised encapsulated drug and prolonging drug concentration in the lungs (Zaru et al., 
2007). Furthermore, a higher antimycobacterial effect against Mycobacterium bovis was 
found by the encapsulation of isoniazid in liposomes compared to free drug (Rojanarat et al., 
2011). However, the use of liposomes in TB inhalation therapy is limited by the lack of 
stability studies and clinical evaluation.  
Although studies provided positive outcomes encouraging the use of nanocarriers in TB 
inhalation therapy, there are still some limitations and drawbacks in the application (Sosnik et 
al., 2010). None of the studies being tested now are dynamic systems, which makes the 
sustained release in the lungs unachieveable. Nanomaterial toxicity is another challenged 
concern. The interaction of nanoparticles with lung tissues and the long-term accumulation of 
inhaled nanocarriers in the lungs may lead to many toxic pulmonary issues such as 
pulmonary inflammation, fibrosis and lung cancer (Nel et al., 2006). Additionally, 
translocation and extrapulmonary delivery of inhaled nanocarrier may induce toxicity and 
adverse effects (Borm and Kreyling, 2004). On the other hand, cellular targeting delivery of 
anti-TB carriers is still a big challenge. Thus, it is of great importance to design a dynamic 
nanocarrier system suitable for controlled drug delivery to the lungs and thoroughly 
understand the complex nature of nanocarrier influence on biological systems. 
1.10 Aims and scope of PhD 
The overall aim of this thesis was to develop a new method to actively release drugs from 
nanoparticles intended for pulmonary delivery. Given the literature described in the 
introduction there are several key considerations when developing an active drug release 
nanoparticle system (Figure 1.5), for example, delivery of a drug to the airways using a 
nanoparticle system requires engineering of a micro-sized carrier in order to maximise 
deposition in the pulmonary tree (a), the liberation of the nanoparticles from the micro-sized 
carrier must occur efficiently after contact with the lung surface lining fluid (b), penetration 
of nanoparticles must occur through mucus in order to reach the epithelial surface (c), the 
nanoparticles must avoid clearance by the mucociliary escalator (d), the nanoparticles should 
reside at the epithelial barrier for a prolonged period of time (e), they should avoid rapid cell 
uptake (f). Ideally if the nanocarrier is to control drug release it should also aim to release the 
drug at the epithelial surface (e) and liberate their entrapped actives in a controlled manner.  





Figure 1.5: Considerations for an inhaled dynamic nanoparticle system: a) nanoparticle 
administration and b) liberation from a respiratory formulation, c) mucus permeation, d) 
mucociliary clearance, e) retention at mucus-epithelium interface and dynamic drug release 
and f) cell uptake. 
It was anticipated that the delivery of nanoparticles to the lungs in this project would be 
achieved by incorporating a novel rifampicin-loaded nanosystem in an inert carrier to 
produce particles in inhalable size for deposition in the lungs. The formulation was designed 
such that after deposition within the pulmonary tract, the carrier matrix will readily release 
the nanoparticles. The nanoparticles should then penetrate through the mucus barrier rapidly 
and be retained at the mucus-epithelium interface, where the therapeutic payload can be 
released in a controlled manner at the targeted disease site.  
The following objectives were set in order to help fulfil the overall aim:  
 To manufacture nanoparticles that actively release their drug payloads in a controlled 
manner, 
 To investigate the mechanisms of active release from nanoparticles, 
 To assess nanoparticle diffusion through mucus barrier, 
 To load nanoparticles into microparticles for inhalation, 
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The potential of nanoparticles to function as carriers for drug delivery has received 
considerable interest over the last decade (Farokhzad and Langer, 2009; Parveen et al., 2012; 
Peer et al., 2007). It has been shown that they can act as an effective delivery system that 
provide opportunities to target the delivery of drugs, improve solubility of poorly-water-
soluble drugs, enhance bioavailability and reduce immunogenicity (Park et al., 2009; Zhang 
et al., 2008). 
The incorporation of inhaled drugs into nanoparticles has also been shown to solve some of 
the issues associated with the rapid clearance of agents delivered to the airways. For example, 
nanoparticles have been able to penetrate the mucus rapidly (Shan et al., 2015). Furthermore, 
nanoparticles may be able to evade clearance by macrophages and enter the respiratory 
epithelium more easily than larger-sized particles as alveolar macrophages are highly 
efficient at phagocytosing particles in the 1-3 µm range (Champion et al., 2008). But 
achieving a controlled drug release from the particles still remains problematic. 
Currently available inhalation products on the market are mainly rapid release formulations, 
although numerous efforts have made to develop controlled release delivery systems (Loira-
Pastoriza et al., 2014). Achieving controlled release in the lung using a non-toxic delivery 
system requires the nanoparticle to reside at the epithelial cell surface for a prolonged length 
of time. This is a challenge and as yet no commercial system has managed to achieve in the 
pulmonary system. One reason why this is the case is it is difficult to achieve payload 
retention prior to dosing and effective release upon administration, especially when 
nanoparticles are formulated as a nanosuspension (Zhao, 2010). The initial burst release is the 
most challenging problem in the development of controlled drug release using nanoparticles 
(Natarajan et al., 2014). It occurs during the first minutes of contact with the external medium 
and can liberate a significant portion of drug in a short period which can lead to acute toxicity, 
and / or rapid clearance and thus a low bioavailability. This rapid drug liberation from the 
nanoparticles can lead to acute toxicityand rapid clearance, thus a low bioavailability which is 
unhelpful in vivo (Danhier et al., 2009; Janes et al., 2001).  
Improving the affinity of the drug for the carrier, e.g., by forming ion-pairs in the carrier 
matrix (Holmkvist et al., 2016; Natarajan et al., 2014; Pinkerton et al., 2012), can reduce the 
passive release and even facilitate drug release overseveral days (Mukherjee et al., 2008), but 




such a slow release can lead another problem, incomplete drug liberation. If the drug release 
is too slow therapeutic index might be not maintained over a relatively long period. If 
nanoparticles do not liberate entire payload then this can also limit their applicability to only 
very potent molecules.  
It has been shown that lipid nanocapsules can reside in the lung for up to 2 days (Patel et al., 
2016). The ideal scenario for controlled drug to the lung is to use a system, which allows 
strong retention of the drug during formulation storage and complete liberation upon delivery. 
This is very difficult to achieve passively and hence there is a need to develop active release 
strategies that will facilitate controlled drug delivery from nanoparticles when they are 
administered to the lung. 
Nanoparticles that respond to shell permeabilisation can provide active drug release and thus 
they provide one potential solution to the issues faced during the development of a controlled 
release nanoparticle for local delivery to the lung. The systems involve the modification of 
material properties by varying environmental conditions after administration using a chemical 
or physical stimulus to permeabilise the shell of the nanocarrier to facilitate drug release 
(Mura et al., 2013). The most significant advantage of active drug release nanoparticle 
systems is better drug delivery targeting compared to conventional system, i.e. the drug is 
only released when needed. 
The aim of this Chapter was to investigate the drug release of rifampicin, a model drug, from 
two different nanoparticles that had the potential to display active drug release in response to 
a chemical permeabilisation process. A polymer shelled nanoparticle, constructed with a lipid 
benzyl benzoate core, a phospholipid intermediate layer and an outer poly(vinyl alcohol) 
(PVA) shell, was compared with alipidic shelled nanoparticle, which contained a triglyceride 
core and a semi-solid phosphatidylcholine / PEG hydroxystearateshell. Both nanoparticles 
have been shown to be biocompatible with lung airway cells (Chana et al., 2015; Madlova et 
al., 2009a) and their inflammatory potential in vivo has been assessed (Jones et al., 2014). 
The shell permeabiliser for the lipid nanoparticle was a Pluronic surfactant, which had 
previously been shown to induce distension of the carrier when a dye was loaded into it 
(Chana et al., 2015). To modify the PVA carrier an aliquot of an acidic buffer was incubated 
with the carrier in attempt to modify the hydrolysis of the polymer. To better understand how 
the model drug was released from the nanoparticles, two pH conditions 7.4 and 4.2 were 
selected as they had some relevance to in vivo conditions, i.e. they mimicked the 




physiological pH of the lung airways and lysosomal compartments respectively (Mindell, 
2012). In addition, the Chapter sought to investigate in detail how the particle modification 
changed the nanoparticle properties during drug release and test the robustness of the 























Medium chain triglycerides (Labrafac
® 
lipophile 1349), purified phosphatidylcholine (> 90 %) 
from soybean lecithin (Epikuron
®
 200) and PEG 15 hydroxystearate (Solutol
®
 HS15) were 
kindly supplied by Gattefossé S.A. (Saint-Preist, France), Cargill GmbH (Germany), and 
BASF (Ludwigshafen, Germany), respectively. Pluronic
® 
L62D was sourced from BASF 
(New Jersey, USA). Poloxamer 188 was from BASF (Ludwigshafen, Germany). Sodium 
chloride, sodium hydroxide, poly(vinyl acetate), benzyl benzoateand rifampicin (≥ 97%, high 
performance liquid chromatography HPLC grade) were purchased from Sigma Aldrich 
(Gillingham, UK). HPLC grade water, ethanol and methanol were obtained from Fischer 
Scientific (Leicestershire, UK). 
2.3 Methods 
2.3.1 Fabrication of lipid shell nanoparticles 
Lipid shell nanoparticleswere manufactured via precipitation from a stable emulsion 
following repeated phase inversion, as previously described by Heurtault et al (Heurtault et 
al., 2002). Medium chain triglycerides (17% w/w), phosphatidylcholine (1.75% w/w), PEG 
hydroxystearate (17% w/w) and a 3% w/v sodium chloride aqueous solution (64.25% w/w) 
were mixed at room temperature and then heated to 85°C at a rate of 4°C per minute, with 
continuous magnetic stirring. The mixture was then allowed to cool to 60°C. The temperature 
of the mixture was cycled between 60°C and 85°C a total of three times. Within this 
temperature range phase inversion occurred, with an oil-in-water emulsion being converted to 
and from a water-in-oil emulsion. Following the final heating cycle, the emulsion was 
allowed to cool to 72°C, at which point 25 mL of ice-cold water was added, causing 
nanoparticle generation. The suspension was stirred for 5 min then made up to a final volume 
of 50 mL using deionised water. Lipid shell nanoparticle suspensions were purified of excess 
excipients and larger particulate matter via centrifugation (Beckman L8-80 ultracentrifuge, 
Beckman Coulter, Buckinghamshire, UK) at 110,000 g and 25°C for 1 h. The suspension 
separated into three distinct layers; an upper gel like layer, a middle lipid shell nanoparticle 
suspension layer, and a bottom sediment layer. The purified suspension layer was used for 
further experimental work. 
 




2.3.2 Synthesis of poly(vinyl alcohol) 
The synthesis of PVA used to produce the nanoparticles was based on direct saponification 
method. PVA 32% hydrolysis was produced from a poly(vinyl acetate) via a stiochiometric 
reaction according to reaction (Chana et al., 2008). For 40% hydrolysis, for example, the 
starting mass of PVAc was 1 g, this provided 0.01163 moles of the vinyl acetate monomer 
and thus 0.004652 moles of NaOH was required to achieve 40% hydrolysis, assuming a 100% 
reaction efficiency. The concentration of NaOH solution was 0.18608 g/mL and this was 
added dropwise to 1 g of PVAc dissolved in 8 mL of acetone in a round bottom flask with a 
small 12 mm magnetic stirrer. The materials refluxed for a period of 1.5 hour (heating level 5, 
~80 °C) with continuous mild magnetic stirring and then the solution was transferred to a 50 
mL beaker and placed in the fume hood to allow the organic solvent to evaporate overnight. 
A purification step was employed to remove sodium acetate by-product. Purification was 
conducted by adding 5 mL of preheated 80 °C deionised water and incubating the solution for 
5 minutes, filtering through a 47-μm cellulose nitrate membrane under the vacuum and 
collecting the product. The purified polymer was placed on a grease proof paper weighed 
previously, dried at 80°C overnight and the amount of product was weighed on the 
subsequent day to generate a yield. 
2.3.3 13C nuclear magnetic resonance analysis of poly(vinyl alcohol) 
To determine the percentage hydrolysis of the polymer nuclear magnetic resonance (NMR) 
analysis was performed on 60 mg of dried PVA sample dissolved in 660 μL of methanol-D4 
and 330 μL of deionised water. Samples were heated gently at 60°C in water bath for a while 
to aid the solubility of PVA until the solution was totally transparent. A 600 μL aliquot of the 
sample was used for the measurements which were conducted at 100.61 MHz frequency 
using a temperature of 24°C. Triplet measurements were performed. The percentage 
hydrolysis was calculated according to the previously detailed method (Chana et al., 2008). 
2.3.4 Fabrication of poly(vinyl alcohol) shell nanoparticles 
Poly(vinyl alcohol) PVA shell nanoparticles were manufactured by nanoprecipitation. In 
order to optimise the formulation, the fabrication was conducted using different polymers. 
Briefly 20%, 40% and 80% hydrolyzed PVA was used with the amount ranging from 0 to 
100 mg in the recipe. Citrate buffer was prepared by adding 40 mL of 0.1 M citric acid 




solution to 60 mL of 0.1 M sodium citrate solution and adjusted to achieve a pH of 4.8. 
Poloxamer 188 (0.5 % w/v) was added to citrate buffer and made up to a volume of 100 ml. 
Methanol:water 9:1 was used as organic solvent. A mixture of 50 mg PVA and 75 mg of 
Epikuron phospholipids was dissolved in 5 mL and 10 mL of organic solvent respectively. 
An aliquot of 0.33 mL of benzyl benzoate was added to the methanol/water mixture to 
complete the organic dispersing phase. To fabricate the nanoparticles, the aqueous phase (30 
mL) was homogenized at 5000 rpm for 2 minutes and then 15 mL of the organic phase was 
added drop-wise, at a speed of 8 mm/min, using a syringe pump. The homogenization 
process was continued for 10 minutes. The suspension produced was transferred to the fume 
hood and left to stir overnight to remove the organic solvent. The suspension was centrifuged 
at 4000 rcf for 5 minutes at 20 °C to remove large particle contamination. 
2.3.5 Nanoparticle characterization 
Nanoparticle size was analysed using photon correlation spectroscopy (PCS) (Zetasizer Nano, 
Malvern Instruments, Worcestershire, UK). All measurements were carried out at a scattering 
angle of 173° using water as the dispersant (refractive index 1.33, viscosity 0.8872 cP at 
37°C). Each measurement comprised 10-14 runs and was performed in triplicate for each 
sample. Mean diameters obtained from the size-intensity frequency distributions were 
reported. To investigate the effect of suspension concentration on the accuracy of the size 
measurement, and to determine the absolute nanoparticle diameter, analyses were performed 
on particle suspensions serially diluted with HPLC grade water (n = 3). Mean diameter was 
plotted against suspension concentration, and the y-axis intercept following linear regression 
analysis was determined as the absolute diameter. The zeta potential of the nanoparticles was 
determined as a function of their electrophoretic mobility (Zetasizer Nano, Malvern 
Instruments, Worcestershire, UK). Samples were analysed following dilution with HPLC 
grade water. Each measurement comprised between 50 to 100 runs and was performed in 
triplicate at 37°C.In order to determine the solid content (mg/mL) of the purified 
nanoparticles, 0.5 mL aliquots were transferred to Amicon centrifuge tube and spin for 30 
min. Then the inner cells were removed and dried in a fume hood until a constant mass was 
recorded. 
 




2.3.6 HPLC analysis of rifampicin 
HPLC quantification of rifampicin was performed using a Jasco HPLC pump and a dual 
absorbance detector. The column used was a reversed-phase C18. UV detection was 
performed at 335 nm. The mobile phase consisted of acetonitrile:PBS buffer (40:60 % v/v) 
pH 7.4 at a rate of 1 mL/min. 20 µl of sample injection volume was employed throughout. 
Calibration standards were produced using a 1 mg/mL rifampicin stock solution in methanol. 
Six serial dilution of the stock generated calibration standards in the range of 0.1-0.002 
mg/mL. Calibration plots were constructed for rifampicin in standard solutionsby plotting the 
concentration verse peak area. The linearity of the calibration plots were evaluated using least 
square regression analysis. Intra-day and inter-day variation was assessed by determining the 
coefficient of variation (CV). The limit of detection (LOD) and the limit of quantification 
(LOQ) of the system were also determined. 
2.3.7 Chemical stability of rifampicin 
The chemical stability of rifampicin was determined by measuring the recovery of rifampicin 
from buffer solution. Briefly, solution of rifampicin in PBS buffer pH 7.4 was prepared and 
was constantly stirred at 37°C. At pre-determined time points, samples were withdrawn from 
the solution and analysed by HPLC and the recovery of rifampicin was evaluated.  
2.3.8 Nanoparticle loading 
For lipid shell nanoparticles, rifampicin was incorporated into the carriers by addition to the 
triglyceride phase as a 0.5% w/v acetonic solution. The acetone was removed by evaporation 
before continuing with the manufacture protocol. In order to try and enhance the interaction 
between rifampicin and oil, two counterions, sodium stearateand sodium ethyl acetate were 
combined with rifampicin at the molar ratio of 1:20 during the manufacture.For the 
fabrication of drug loaded PVA shell nanoparticles, 15 mg of rifampicin was dissolved in the 
organic phase and the manufacture was repeated as optimised previously. Amicon centrifugal 
device was used for loading assessment. The amount of each probe contained in a) the 
purified suspension as a whole, b) the nanoparticles only and c) the continuous phase was 
assayed by appropriate dilution of each compartment. The nanoparticles were separated from 
the continuous phase using Amicon ultra 0.5 centrifugal filter devices with ultracel 100 
membranes (100 kDa molecular weight cut off) (Millipore, UK). Aliquots of 0.5 mL were 




removed from the purified nanoparticle suspension and placed in the sample reservoir of the 
filter devices and centrifuged for 30 min at 14,000 g at ambient temperature (Biofuge Pico 
centrifuge, Heraeus, Buckinghamshire, UK). During this process any free drug in the 
continuous phase passed through the filter into the receiver chamber, and the nanoparticles 
were retained on the filter. The filtrate was diluted with water and subjected to HPLC 
analysis. The nanoparticles were dissolved in methanol and subjected to HPLC analysis. The 
drug recovery and loading efficiency of the purified nanosuspensions were calculatedusing 
Equations 2.1 and 2.2, respectively: 
Drug recovery =
Mnanoparticle  + Mfiltrate
Msuspension       
    Equation 2.1 
Loading efficiency  % =
Mnanoparticle
        Minput            
  Equation 2.2 
Where Msuspension was the mass of drug in the nanoparticle suspension; Mnanoparticle was the 
mass of drug encapsulated into the nanoparticle; Mfiltrate was the mass of drug in aqueous 
filtrate and Minput was the mass of drug added during manufacture. 
2.3.9 Release of rifampicin from nanoparticles 
To characterize rifampicin release from the lipid shell nanoparticles, the drug remaining in 
the carrierswith and without prior exposure to shell permeabiliser Pluronic L62D was 
measured. When the lipid nanoparticle permeabliser was used it was mixed with the purified 
nanoparticle suspensions at a Pluronic: nanoparticle ratio of 1:0.5 w/w. The release of the 
lipid shell nanoparticles was determined by dialyzing the nanoparticle suspensions against 
PBS buffer (1.6 mg nanoparticle per mL buffer) either at pH 7.4 and 4.2, 37°C. For the PVA 
shell nanoparticles without the shell permeabiliser the suspensions generated by the 
manufacture method were mixed with PBS pH 7.4 in a 1:1 v/v and the drug release 
determined by dialysis. To permeabilise the PVA shell nanoparticles PBS pH 4.2 buffer was 
added to nanoparticle suspension in a 1:1 v/v and the mixture was transferred to a dialysis sac 
and dialysed against 500 mL of PBS buffer at either pH 7.4 or pH 4.2 to determine the drug 
release. The rifampicin solubility was measured to be 1550 μg/mL at pH 7.4 and 750 μg/mL 
at pH 4.2 and therefore sink conditions were maintained in all the release experiments (total 
loading per 500 mL was ca. 1.2 mg). To monitor the drug release from all the nanoparticle 
experiments 0.5 ml aliquots were removed from dialysis the tubing containing the 
suspensions (12-14 kDa molecular weight cut off) at a series of pre-determined time points 
and rifampicin content in the nanoparticles was measured by HPLC (as detailed in the 




loading assessment method). The drug content remaining in the nanoparticles was calculated 
according to Equation 2.3: 
Release  % =
M0 – Mt
M0
     Equation 2.3 
Where M0 was the mass of drug in nanoparticleat t0 and Mt was the mass of drug in 
nanoparticle at a time point. 
2.3.10 Size changes of permeabilised lipid nanoparticles 
Changes in the size of the lipid nanocarries in response the shell permeabiliser were measured 
after the suspensions were exposed to Pluronic surfactant using identical conditions as in the 
release study. At regular intervals between 30 min and 24 h post permeabiliser exposure 
samples were taken from the dialysis tubing where the particles were being suspended and 
the particle size was measured. PCS was also used to study the effect of pH on the ability of 
surfactant to aggregate. Surfactant solutions of 1 to 100 mg/mL were prepared in PBS at the 
two pHs 7.4 and 4.2 as used in the release study. The derived count rate of the solutions were 
measured and the critical micelle concentration (CMC) of the surfactant in each of the pH 
conditions was determined by estimating where the two linear models applied to the derived 
count rate data intercepted. The lipid nanoparticles were also visualised using transmission 
electron microscopy (TEM) before and after exposure to the shell permeabiliser. The 
suspension (3 μL) was applied to a Pioloform-coated copper grid and allowed to settle for 
one min. Excess suspension was blotted away with filter paper and the grid washed twice 
over distilled water before negative staining with 3 μL of an aqueous 1% uranyl acetate 
solution. The grids were allowed to dry before examination with a Tecnai T12 electron 
microscope (FEI, Oregon, USA). 
2.3.11 Size changes of permeabilised Poly(vinyl alcohol) nanoparticle  
The particle size of the polymer nanoparticles had been previously determined not to change 
(~250 nm after permeabilisation) in preliminary work and hence changes in the chemical 
composition of the carrier matrix upon exposure to the shell permeabiliser were characterised 
using Fourier transform infrared spectroscopy (FTIR) (Perkin Elmer, Beaconsfield, UK). The 
FTIR spectrometer was fitted with a DuraSamplIRII diamond attenuated total reflectance 
attachment (Smiths detection, Warrington, UK). Each sample was applied in its liquid state to 
the diamond and 32 scans were performed to generate the spectra. Peak positions were 




determined using Spectrum One software (version 6). Intensities of peaks referring to O-H 
and C-O bonds were specifically analysed in order to search for changes in the polymer 
hydrolysis over time. Nanoparticle size change before and after the shell permeabiliser were 
captured by TEM as described above. 
2.3.12 Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. The normality (Sapiro-Wilk) 
and homogeneity of variances (Levene‘s test) of the data were assessed prior to statistical 
analysis. The transport data were analysed statistically using T-test or Mann-Whitney test. 





















2.4.1 Nanoparticle characterization 
NMR analysis of PVAc polymer showed mean hydroxylation values of 14.8 ± 2.0%, 31.9 ± 
1.4% and 56.4 ± 3.3% for PVA20%, PVA40% and PVA80% respectively, which were a slightly 
lower than targeted value (Figure 2.1). Different percentage polymer hydrolysis seemed to 
have no great effect on physiochemical properties of PVA shell nanoparticles (Table 2.1). 
PCS of the purified suspensions revealed a unimodal, normally distributed particle population 
in the nanometre size range (Figure 2.2). The blank lipid shell nanoparticles and the polymer 
shell nanoparticles had a mean diameter of ca. 50 and 250 nm and a polydispersity index of 
0.074 ± 0.02 and 0.143 ± 0.02, respectively (Table 2.1). The lipid nanoparticles recorded a 
zeta potential of -3.46 ± 0.60 mV whilst the polymer nanoparticles had a zeta potential of-
0.27 ± 0.45 mV. In order to investigate if the dispersion media was having a significant 
influence of the PCS data, the particle size measurements were repeated upon serial dilution 
of the nanoparticlesuspensions. The size measured upon dilution was consistent for the lipid 
shell nanoparticles over the tested dilution range, the effective diameter, i.e. the predicted size 
at infinite dilution was 49 nm (Figure 2.3). However, the size of the polymer shell 
nanoparticles reduced in size upon dilution due to the interference of the water soluble 
stabiliser with the size measurements and gave an effective hydrodynamic diameter of 204 
nm (Figure 2.3). 





Figure 2.1: NMR of 10%, 32% and 56% hydrolyzed PVA and corresponding calculation.  





Figure 2.2: Representative size distribution (intensity weighted) of (A) lipid shell 
nanoparticles and (B) 32% PVA shell nanoparticles following 1/1 v/v dilution with water, as 











































Figure 2.3: Determination of nanoparticle absolute hydrodynamic diameter following linear 
regression of nanoparticle size versus suspension concentration (mg/mL) using (A) lipid shell 
nanoparticles and (B) 32% PVA shell nanoparticles. Data represent mean ± standard 










































y = 12.995x + 203.939




Table 2.1: Size, polydispersity, zeta potential and solid content for unloaded (blank) and 
rifampicin-loaded lipid shell nanoparticles (LNP) and polymer shell nanoparticles (PVA). 
*Measured at nanoparticle concentration of 80 mg/mL and 3 mg/mL for LNP and PVA. Data 
represent mean ± standard deviation (n = 3). 






LNPblank 52 ± 2 0.07 ± 0.02 -3.46 ± 0.60 146.7 ± 12.2 
LNPrifampicin 50 ± 3 0.07 ± 0.02 -2.07 ± 0.62 163.3 ± 7.0 
PVA10%blank 248 ±7 0.12 ± 0.01 -0.21 ± 0.05 5.5 ± 1.2 
PVA10%rifampicin 252 ± 7 0.22 ± 0.03 -0.17 ± 0.10 6.4 ± 1.1 
PVA32%blank 249 ± 5 0.14 ± 0.02 -0.27 ± 0.45 5.9 ± 1.5 
PVA32%rifampicin 261 ± 7 0.22 ± 0.02 -0.26 ± 0.37 6.0 ± 0.9 
PVA56%blank 250 ±6 0.21 ± 0.02 -0.13 ± 0.21 4.7 ± 1.2 
PVA56%rifampicin 258 ± 3 0.24 ± 0.04 -0.22 ± 0.03 5.2 ± 1.1 
2.4.2 HPLC assay 
Calibration curves constructed for rifampicin displayed a high degree of linearity (R
2
> 0.999) 
in the concentration ranges tested (Figure 2.4). Intra-and inter-day variation data indicate the 
precision of the assay (Table 2.2). The average intra-day and inter-day variation data was 1.8% 
and 2.4%. Based on intraday data the limit of detection (LOD) and limit of quantification 
(LOQ) for the rifampicin assays were 2.5 and 8.4 µg/mL respectively.The developed assay 
was found to be fit for purpose in terms of precision and limits of detection and quantification. 























Figure 2.4: Representative calibration curve for rifampicin in methanol. Data represent mean 
± standard deviation (n=3, error bars too small to be seen). 
 




Table 2.2: Intra and inter-day variation in rifampicin peak area as a function of concentration 
in methanol. Intra-day variation data obtained from three days using the same standards (n=3). 
Inter-day variation data obtained over three days (n=9). 





100 0.73 1.09 
50 0.53 1.00 
20 1.31 1.09 
10 2.23 1.78 
5 2.10 2.76 
2 3.85 6.54 
 
2.4.3 Rifampicin chemical stability 
Although no significant peaks referring to degradants were found by HPLC assay, rifampicin 
recovery at PBS buffer 7.4 decreased by approximately 70% over 72 h (Figure 2.5).  
Therefore, rifampicin remaining in the nanoparticles was used to indicate the amount of drug 
release in the following work. 



















Figure 2.5: Recovery of rifampicin in PBS buffer pH 7.4 at 37 °C over 72 h. Data represent 
mean ± standard deviation (n = 3). 
 
 




2.4.4 Optimisation of poly(vinyl alcohol) shell nanoparticles 
As passive release was found in previous literatures, PVA shell nanoparticles with different 
formulations were manufactured to find the best formula. Nanoparticles made from 32% 
hydrolysed polymer had the highest loading efficiency compared to higher or lower 
hydrolysis degrees (Figure 2.6A). Different polymer amounts input also had great impact on 
the drug loading and release as shown in Figure 2.6A. When 50 mg of polymer was used in 
fabrication appeared to have a better formulation with a higher loading efficacy. Thus, 50 mg 
of 32% polymer would be used in the following nanoparticle manufacture to assess the drug 
loading and release.  
Figure 2.6: Passive release of rifampicin from different PVA shell nanoparticle formulations: 
(A) the effect of polymer hydrolysis degrees and (B) the effect of amount of 32% polymer in 
the recipe. Data represent mean ± standard deviation (n = 3). 
2.4.5 Lipid shell nanoparticle drug release 
Rifampicin was loaded into the lipid nanoparticles with an acceptable loading efficiency, 41.0 
± 11.4%. An average drug recovery of 90% was observed in the loading experiments. 
Continuous passive release from the lipid shell nanoparticles was observed at both pH 7.4 (A) 
and pH 4.2 (C) (Figure 2.7). This continuous release, which was presumably initiated 
immediately after manufacture, required the release testing be performed at an identical time 
post manufacture in all the studies. This strategy led to acceptable intra-batch variability 
across the experiments. The data demonstrated both in the presence and absence of the shell 
permeabilisers the drug release showed zero order kinetics (Figure 2.7B, D). However, the 
attempt to hold the drug in the oil to reduce the passive drug release using ion-pairing failed 
(Figure 2.8). 
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Despite the inability to prevent the continuous drug release from the lipid nanoparticles, there 
was still a significant increase in the extent of release at each time point when the shell 
permeabilisers were added to the nanoparticles at pH 7.4 (P<0.05). The drug release rates (k) 
for the lipid shell nanoparticlein the presence of the shell permeabiliser was double that of the 
control system (P<0.05), with the control and permeabilised nanoparticles releasing 
approximate 50% and 80% of their rifampicin load over 24 h. When PBS buffer at pH 4.2 
was used as the release medium, there was no significant difference in release extents and 
rates between permeabilised and non-permeabilised nanoparticle test systems (P>0.05). The 
rate of drug release was suppressed at pH 4.2 compared to pH 7.4, i.e. it reduced from 0.0032 
mg/h to 0.0030 mg/h. 
 
Figure 2.7: Release of rifampicin loaded lipid shell nanoparticles against (A) PBS buffer pH 
7.4 and (C) PBS buffer pH 4.2. Graph (B) and (D) show the application of a linear model to 
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Figure 2.8: Release profiles of rifampicin-stearate and rifampicin – ethyl acetate ion paired 
lipid shell nanoparticles at 24 h against PBS buffer pH 7.4 compared to rifampicin loaded 
nanoparticles. Data represent mean ± standard deviation (n = 3). 
2.4.6 Polymer shell nanoparticle drug release 
The drug loading in the polymer shell nanoparticle was 25.9 ± 2.3%. In a similar manner to 
the lipid shell nanoparticles, at pH 7.4 continuous drug release (k=0.023 mg/h) was observed 
which was enhanced upon exposure to the shell permeabiliser (k=0.034 mg/h) (p<0.05, 
Fig.2.9). An 10% burst release was recorded in the release experiments which seemed low 
compared to previous reports of up 80% burst release with polymer nanoparticle. Almost 80% 
of drug came out the polymer shell nanoparticles which were subject to permeabilisation over 
8 h, which was nearly double the control non-permeabilised system (P<0.05). When the 
release study was assessed in the pH 4.2 medium similar profiles were observed with and 
without the permeabiliser (no significant difference in drug release across the two sets of 
nanoparticles, P>0.05, Figure 2.9). The release rate of non-permeabilised nanoparticles in the 
acidic medium from 0.0023 mg/h to 0.0020 mg/h compared to the neutral release 
environment.  
 





Figure2.9: Release of rifampicin loaded PVA shell nanoparticles against (A) PBS buffer pH 
7.4 and (C) PBS buffer pH 4.2. Graph (B) and (D) show the application of a linear model to 
the corresponding drug release.  Data represent mean ± standard deviation (n = 3). 
2.4.7 Permeabilisation mechanism for lipid shell nanoparticles 
The exposure of lipid shell nanoparticlesto the Pluronic surfactant permeabiliser at pH 7.4 
induced a substantial increase in the carrier size over time (P<0.05), resulting in a mean size 
of 240 ± 1 nm at 24 h (Figure 2.10). No size change was recorded for the exposure at pH 4.2 
compared to non-permeabilised nanoparticles. The light scattering data revealed that the 
Pluronic L62D surfactant displayed a significantly lower CMC (8.1 ± 1.4) at pH 4.2 
compared to pH 7.4 (25.2 ± 2.1) (p<0.05, Figure 2.11), indicating the greater propensity for 
the surfactant to aggregate in the more acidic pH medium. TEM images of control lipid 
nanoparticle suspensions revealed the presence of spherical particles in the 50 nm size range 
(Figure 2.12). Following an 8 hour exposure to Pluronic L62D at pH 7.4 the lipid shell 
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Figure2.10: Lipid shell nanoparticle permeabilisation over time following exposure to 
permeabiliser Pluronic L62D at (A) pH 7.4 and (B) pH4.2. Data represent mean ± standard 
deviation (n = 3). 
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Figure 2.11: Critical micelle concentration (CMC) of surfactant Pluronic L62D in PBS 
buffer at (A) pH 7.4 and (B) 4.2. Data represent mean ± standard deviation (n = 3). 
 





























































Figure 2.12: Transmission electron microscopy (TEM) images of lipid shell nanoparticle 
suspensions (A) before exposure to Pluronic L62D surfactant, (B) 8 h after exposure to 
Pluronic L62D surfactant. 
2.4.8 Permeabilisation mechanism for the polymer shell nanoparticles 
FTIR chemical analysis of the polymer shell nanoparticles showed that there was no 
difference in the intensity of OH peak over time when they were not exposed to the shell 
permeabiliser (Figure 2.13), which suggested the polymer‘s structure was unchanged. For the 
nanoparticle exposed to the shell permeabiliser the intensity of hydroxyl group increased over 
time. TEM showed that the shell permeabliser seemed to have no effect on particle size as 
illustrated in Figure 2.14. These results confirmed the mechanism of this dynamic 
nanosystem was carboxyl functional group hydrolysis caused by the acidic conditions. 
50 nm 100 nm
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Figure 2.13: FTIR spectra for PVA shell nanoparticles permeabilised by (A) buffer pH 7.4 
and (B) buffer pH 4.2. Regions of interest were the OH stretching region (3700-3200 cm
-1
) 
and the C-O stretching region (1200-1000 cm
-1
).   
 
Figure 2.14: Transmission electron microscopy (TEM) images of (A) non-permeabilised 
polymer shell nanoparticles and (B) polymer nanoparticles permeabilised by the addition of 






























































The size and polydispersity of the lipid shell and polymer shell nanoparticles employed in 
this work were consistent with those previously reported using similar preparation methods 
(Chana et al., 2015; Madlova et al., 2009). The simplicity, rapidity and scalability of the 
process makes it well suited to the production of nanoparticles intended for inhaled drug 
delivery. The emulsion-precipitation method of nanoparticle fabrication was shown to 
generate a much higher nanoparticle solid content compared to the injection-precipitation 
method. As anticipated the technique produced a relatively high nanoparticle product yield 
(solid content 160 mg/mL) when compared to alternative fabrication methods (Grenha et al., 
2007). 
Lipid shell nanoparticles have previously been shown to exhibit zero-order drug release 
kinetics (Abdel-Mottaleb et al., 2010; Zhai et al., 2014). Zero-order release suggested that the 
drug release was limited by the nanopacrticle carrier and this provided evidence that the drug 
was encapsulated by the lipid components of the nanoparticle. According to the sizing data, 
in the absence of the Pluronic surfactant the control lipid shell nanoparticles did not change in 
size. Thus, the drug release of rifampicin from the carrier was assumed to be a consequence 
of drug diffusion through the nanoparticle‘s lipid shell. The marked differences in lipid shell 
nanoparticle size following exposure to the Pluronic surfactant suggested nanoparticle 
distension lead to an increase in shell permeability and it was this change in the carrier 
properties, which was responsible for the increase in drug release compared to the control 
nanoparticles. 
However, the release of rifampicin from the lipid shell nanoparticles was much more efficient 
compared to that previous obtained with a rhodamine dye using the same carrier system 
(Chana et al., 2015). It is notable that there was a methodical difference in the two studies 
that determined release from the same lipid shell nanoparticles. Dialysis was used in the 
current study in order to ensure sink conditions were maintained whereas the previous study 
to measure drug release of rhodamine used direct extraction from a nanoparticle suspension. 
However, the difference in the two release profiles was probably not a result of the different 
drug release methodology rather it was probably a consequence of the different 
physicochemical properties of the two release agents. Rifampicin has pKas of 1.7 and 7.9 and 
a log P of 1.1 (Bhise et al., 2010) whilst rhodamine has a pKa of 4.2 and log P of 2.7 




(Lahnstein et al., 2008). Hence rhodamine would be predicted to have a higher affinity to the 
oil core of the particles, which could result in less release of the dye from the nanoparticles. 
Ion-pairing has been previously used to improve the retention of hydrophilic drugs in the 
lipid matrix (Zhao et al., 2016) and it has been shown to modify the drug release kinetics 
without changing the chemical structure of the drug in the nanoparticles (Song et al., 2016). 
However, there does not appear to be any previous work that attempted to apply this strategy 
to the release of rifampicin from nanoparticles. Theoretically rifampicin and the counterions 
are fully ionized at acidic condition respectively so that ion-pairs can be formed. The 
hydrophobicity of the complex should increase as the counterions (log P: ethyl acetate 0.28, 
sterate 3.62, calculated by Marvin Sketch, ChenAxon Ltd, Hungary) neutralise some of the 
polarity of the parent drug and thus increase its affinity for lipid nanoparticle oil core. The 
inability of the counterions used in this work to slow rifampicin diffusion out of the particles 
may have been because the drug did not reside preferentially in the oil core of the carrier. 
Perhaps the rifampicin was arranged at the oil capsule interface and the counterion was 
located in the oil core and it was the ability for these molecules to freely move to their most 
preferential environment within the lipid shell nanoparticle core that preventing them from 
interacting. Alternatively the complex structure of rifampicin may have caused steric 
hindrance that prevented ion-pair formation. 
Even in the presence of the enhanced drug release rate it appeared that the lipid shell 
nanoparticle did not suffer from an initial burst release. There is not a standard method that 
that is used to determine burst release from nanoparticles. In this study the % of drug release 
at t=0.5 h was determined to be the burst release. The lipid shell nanoparticles showed a 5% 
release at t=0.5 h. The encapsulation of the counterions had no effect on this initial release 
percentage. Compared to previous studies using nanoparticles, which usually cite burst 
release to be an issue when they have rapid release of 30-50% of their drug payloads (Sun et 
al., 2013), the lipid shell nanoparticles in this work appeared not to have a significant issue of 
burst release.  
The pH dependent triggering release was observed in this work, which could be due to the 
changes of Pluronic properties at different pHs. An increase in the PO block length and 
PO:EO ratio have been reported to increase the surfactant hydrophobicity and extent of lipid 
bilayer disruption (Firestone et al., 2003). For Pluronic with intermediate PO block lengths it 
is thought that insertion into bilayers is the primary means of membrane interaction. The lipid 




nanoparticles have an external semisolid shell made from phospholipid and when Pluronic 
interacts with this external surface it is expected that the two EO segments of the surfactant 
reside on the apical side of the membrane and the PO chain protrudes into the hydrophobic 
domain (Firestone et al., 2003). The pH-dependent swelling responses to Pluronic L62D 
supported the shell insertion mechanism of action because the increase propensity for the 
PEO-PPO-PEO block copolymer to aggregate in the aqueous solution would diminish its 
affinity for the nanoparticle shell surface (Mao et al., 2001). Yang et al. (2006) investigated 
the effect of acid on the aggregation behaviour of Pluronic P123 (Yang et al., 2006) and 
showed that the PEO block was degraded in strong acids. It is possible that the greater acidity 
of the medium could have resulted in degradation in this work, but at a pH of 4.2, which is 
only mildly acidic compared to the previous work, this effect was thought not to be as 
significant compared to the changes in CMC demonstrated using the light scattering data. 
Several new polymeric nanoparticle technologies have been developed recently that were 
thought to be suitable for drug delivery applications. These include ‗porous nanoparticle-
aggregate particles, dynamic pH responsive nanoparticles and self-assembling nanoparticles, 
but the use of these systems in pharmaceutical products has been limited by scale up and 
toxicity concerns (Kean and Thanou, 2010). PVA is a water soluble synthetic polymer that is 
formed by full or partial hydrolysis of poly(vinyl acetate) (PVAc). It has been proved to be 
safe as a coating agent for pharmaceutical and dietary supplement products, it has a good 
compatibility with lung cells and in comparison to other polymeric systems it has a limited 
potential to cause local lung inflammation (DeMerlis and Schoneker, 2003). Furthermore, the 
production of the nanoparticles using PVA is easily scalable. Therefore, this material is well 
suited to the formation of nanoparticles for clinical applications (Madlova et al., 2009). The 
amphiphilic grades of the polymer (30–60% hydrolysis) are probably the most interesting in 
terms of drug delivery, but they are not readily available. Therefore, PVA was synthesised in 
this study to attain a degree of hydrolysis that would spontaneously generate nanoparticles in 
an aqueous solution (Chana et al., 2008; Madlova et al., 2009). 
It is generally assumed that the main release process from polymeric nanoparticles is 
diffusion through the polymer matrix but release can also occur as a consequence of polymer 
degradation (Soppimath et al., 2001). In the case of the polymer shell nanoparticlesin this 
work the drug is placed in an oil core that is coated with the polymer and therefore the release 
from the carrier most probably occurs by diffusion of the drug through the polymeric shell. If 




this mechanism works well then the drug release should follow the zero-order kinetics as 
observed in this study. 
It was unusual that the low pH conditions, which had previously been shown to induce 
polymer hydrolysis, did not increase the rate of drug release. This result suggested that 
another factor was confounding the potential for enhanced drug release at pH 7.4. Just like 
for the lipid systems the lower aqueous solubility at pH 4.2 (0.75 mg/mL) compared to pH 
7.4 (1.55 mg/mL) (data not shown graphically) could have been responsible for the inability 
for the permeabiliser to influence the drug release at pH 4.2. 
It is well known that ester group of PVA can be hydrolysed to an alcohol under acidic 
conditions (Clayden et al., 2012). Increasing the amount of hydroxyl groups would enhance 
the affinity of the polymer membrane to water and increase surface film solvation, which 
would facilitate drug release via diffusion through membrane pores. It is also possible that the 
polymer molecular weight can be reduced due to hydrolysis which could facilitate drug 
release (Xu and Du, 2003). However, in the time frame of the release experiments it was 
thought that increased PVA film hydration was most probably the primary cause of the 


















Rifampicin loaded lipid shell nanoparticles and polymer shell nanoparticles both provided 
controlled zero-order drug release. The carriers controlled release primarily through their 
outer shells. As a consequence when the nanoparticle shells were permeabilised greater 
quantities of drug diffused out of the carriers. However, although the lipid shell nanoparticles 
were permeabilised using a Pluronic surfactant which inserted into the outer shell, whilst the 
polymer shell carriers were permeabilised through polymer hydrolysis both mechanisms were 
ineffective at pH 4.2. This suggested that the drug solubility, which was lower at pH 4.2 was 
also an important factor in determining the release from these carriers. At the epithelial 
surface of the lung the pH is thought to range between 6.5-7.4. Within this pH range the 
carrier permeabilisation mechanism should result in enhanced drug release and therefore 
these nanoparticles present an attractive means to provide controlled release of drug to the 
airways of the lungs. Even though the nanoparticles showed an active release profile for the 
drug delivered to the lungs they should also penetrate through the mucus and this will be 






































When nanomedicines are administered via the airways the drug release kinetics and 
inflammatory potential are influence by their interaction with the mucus barrier. In order to 
reside in the airway for an adequate period of time to achieve sustained drug absorption, 
nanomaterials ideally should move rapidly towards the lung epithelial surfaces and avoid 
rapid mucocillary clearance and macrophage engulfment. The mucus in the lung airways is a 
semipermeable viscoelastic barrier that is continuously renewed. The major constituent of 
mucus is water (~ 95%). This solvent hydrates a network of crosslinked and entangled mucin 
fibers that are continuously secreted by goblets cells and sub mucosal glands of the epithelial 
barriers (Thornton and Sheehan, 2004). Mucins are glycoproteins with high molecular weight 
ranging from 0.5-40 MDa (Cone, 2009). The polypeptide backbone contains a large number 
of serine, threonine and proline (PTS repeats), making up around 20% of molecular mass 
(Bansil and Turner, 2006). Oligosaccharide side chains attach to serine or threonine along the 
backbone via O-glycosidic bonds (Figure 3.1). Usually the oligosaccharide has 8-10 
monosaccharide residues such as fucose, galactose and sialic acid (Bromberg and Barr, 2000). 
Thus the PTS domains are negatively charged due to negatively charged carboxyl groups of 
sialic acid. Glycosylation is the most important feature of mucin, which governs the 
physiochemical properties of glycoprotein. Multimers can be formed via disulfide bonds in 
cysteine rich regions (Svensson and Arnebrant, 2010). Currently, more than 20 mucin 
glycoproteins have been assigned to the MUC gene family (Dekker et al., 2002). Mucins can 
be divided into two catalogues according to sequence homology: secreted mucins (i.e. 
MUC5AC) and membrane bound mucins (i.e. MUC 1) (Johansson et al., 2011). The 
MUC5AC gene product is a major mucin in the stomach and airways of both humans and 
pigs (Gendler and Spicer, 1995). 





Figure 3.1: Summary of thestructure of mucin at three different magnifications (From Cone, 
2009). 
The thickness of mucus varies greatly depending on the anatomic site where it is produced. 
The stomach and colon have the thickest mucus blanket in the human GI tract, with barriers 
stretching 50-450 μm and 110-160 μm respectively in vivo (Pullan et al., 1994). It has been 
shown that digestive activity influences the thickness of mucus in the GI tract (Brownlee et 
al., 2003). The airway has a much thinner mucus blanket ranging from 5 to 55 μm (Clunes 
and Boucher, 2007), but this can change if the lungs are effects by a disease. In the case of 
cystic fibrosis, a much denser and more highly glycosylated mucus is present in the 
respiratory tract, resulting in increased viscoelasticity of the barrier. The lifetime of mucus is 
relatively short ranging from minutes to hours, due to its continuous secretion, digestion and 
recycling. The thin mucus layers typically show the fastest turnover at the epithelial surface. 
A relatively quick turnover time in the order of 10-20 min has been previously reported for 
the respiratory mucus (Ali and Pearson, 2007). In order to deliver drug molecules beyond the 
mucus barrier, a carrier must be capable of penetrating the mucus, hence particles must have 
a faster diffusion rate than mucus renewal and clearance or release their pay load prior to 
removal by this layer.  
At the molecular level, mucus is an integrated structure of biopolymers. Its physical 
behaviour is complex (non-Newtonian), with highly variable properties that are between 
those of a viscous liquid and an elastic solid referred to as a viscoelastic gel because it 




possesses both flow (viscosity) and deformation (elasticity) properties (Lai et al., 2009). 
Mucin content is the major determinant of mucus rheology as mucin exhibits a tendency to 
aggregate and form gels (mucus) (Bromberg and Barr, 2000). As the matrix of the gel is 
formed by relatively weak non-covalent and strong disulfide bonds between the glycoprotein, 
any factors affecting these linkages will influence the rheological properties of the mucus. 
For example, the strength of selectivity of both native and reconstituted mucin hydrogel can 
be modulated by pH and charged objects (Crater and Carrier, 2010). Experiments with 
negatively charged human immunodeficiency viruses have been shown to be less mobile in 
acidic cervicovaginal mucus (CVM) than at neutral pH (Suk et al., 2009). Similarly, a strong 
retention of charged particles has been observed in low pH mucus. By contrast, free diffusion 
through mucus of neutral particle has been shown at neutral pH (Lieleg et al., 2010). The 
characterization of the physical properties of mucus is often conducted from two different 
aspects: macrorheological and microrheological. The former provides measurements of bulk 
physical properties whereas the latteraffords detailed characterization of the special 
interactions within the biological fluids, accounting for both contributions from the fluid 
within the biopolymer network as well as the network mesh itself (Lai et al., 2009). Advances 
in the rheological characterization of mucus from the macroscopic to nanoscopic levels have 
contributed critical to a better understanding of mucus physiology, disease pathology but as 
yet it has not lead to the commercial development of a new type of drug delivery systems 
designed for use at mucosal surfaces. Nanoparticles seem to offer a means of controlled drug 
delivery in the airways and hence if mucus nanoparticles interactions could be understood 
perhaps these materials could facilitate the commercialization of an effective nanomedicine. 
The diffusion of nanoparticles has been explored in a variety of human mucus secretions, 
including human CF sputum, human CVM and porcine gastric mucus (PGM) using various 
diffusion system (Abdulkarim et al., 2015; Kirch et al., 2012; Lai et al., 2007; Roblegg et al., 
2012). Two major mechanisms namely size filtering and interaction filtering are considered 
to reduce the speed of penetration through mucus (Lieleg and Ribbeck, 2011). The size 
filtering mechanism hinders the diffusion of particles with diameters larger than the mesh 
size between the mucin fibers. Rapid penetration of Norwalk and human papilloma virus 
through cervical mucus suggested the diffusion capacity of particles through low viscosity 
pores within the highly elastic mucin fiber matrix was possible (Olmsted et al., 2001). 
However, the slow diffusion of 59 nm carboxyl-modified polystyrene nanoparticles 
(Diffusion in mucus, Dmuc = 0), which were smaller than the average mucus mesh pore size in 




the same experiment demonstrated size is not the only factor that determines penetration 
through mucus. The relatively rapid diffusion of nanoparticles as large as 500 nm through 
cervicovaginal mucus was observed (the ratio of diffusion in water and mucus, Dw/Dm= 12), 
if particles were densely coated with low molecular weight polyethylene glycol (PEG) (Tang 
et al., 2009). These results suggested that charge interactions between particles and mucus 
hydrogel play an important role in modulating penetration through mucus. The mucin mesh 
network is relatively dense and thus it slows to some extent most foreign particles, 
presumably due to the formation of polyvalent adhesive interactions via hydrophobic and 
anionic forces (Norris and Sinko, 1997). Alternatively, electrostatic interactions contribute to 
polyvalent adhesive interactions. Positively charged particles can form adhesive interactions 
with negative charges impacted by the presence of carboxyl or sulfate groups on the mucin 
proteogycans, resulting in anionic particles diffusing 20-30 times faster than cationic particles 
(Crater and Carrier, 2010). This is critical for the removal of foreign particles smaller than the 
average pore size. In addition to charge interactions there is the potential for hydrophobic 
interactions. The high density of hydrophobic domains, existing in the globular regions, 
allows efficient formation of multiple low-affinity adhesive interactions with hydrophobic 
regions on the surfaces of foreign particulates, which are strong enough to bundle mucin 
strands into thick cables (Lai et al., 2009). The interactions between hydrophobic molecules 
and hydrophobic mucus have been shown to result in significant decreases in the diffusion 
rate of both small and large molecules and this could also occur with particulates.  
Diffusion chambers appear to be described most frequently in the previously published 
literature regarding methods to track nanoparticles translocation across mucus (Norris and 
Sinko, 1997). According to the position of compartments this methodology can be divided 
into two sub-categories: horizontal diffusion chambers such as Snapwell cell layer transport 
system (Sanders et al., 2000) and vertical diffusion chambers including Franz cell chamber 
and Transwell system (Broughton-Head et al., 2007). Both setups allow for quantification of 
diffused particle by measuring their concentration and this results in a concentration vs time 
profile from which a barrier diffusion rate can be obtained. Although the diffusion-chamber 
method is conceptually straightforward and easily set up, it is sensitive to a number of 
parameters that are difficult to control, such as the precise thickness of the mucus layer, the 
uniformity of the mucus distribution across the face of the filters, blockage of the filter pores 
by mucus, and alterations in mucus properties during preparation (Saltzman et al., 1994). 
Alternatively using a particle tracking technique, empirical data for the diffusion of particles 




in mucus gel can be observed directly, which is usually depicted as one dimensional transport 
in a semi-infinite medium and recorded by an in situ analytical device. The availability and 
high sensitivity of fluorescence detection renders nanoparticle labelling and tracking the most 
repeated methods in recent studies. The subsequent development of multi-photon imaging has 
make particle tracking even more rapid and sensitive for example, multiple particle tracking 
(MPT) has shown excellent results (Olmsted et al., 2001; Suh et al., 2005). Particle tracking 
is valuable in obtaining information on how fast particles move through mucus, but it does 
not establish if a particle can translocate across a mucus barrier. As a consequence particle 
tracking studies have so far focused on how nanoparticle surface chemistry influences 
horizontal particle mobility, whereas vertical translocation was not described. The majority of 
these works employed unpurified mucus, thus the identity of the objects captured by the 
camera employed in particle tracking technique remain uncertain. A summary of previous 
study findings with regarding to particle translocation is highlighted in Table 3.1.  
Table 3.1: Mucus particle diffusion study summary (Dmuc: average diffusion coefficients in 
mucus; Dw: the theoretical diffusion coefficient in water; SPS: sulphate polystyrene particle; 
CPS: carboxylated polystyrene particle; APS: amine polystyrene particle; PEG-CPS: 
PEGylationcarboxylated polystyrene particle). 
Experimental 
method 
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Different sourced mucus have similarities in mucins contents and biochemical properties 
(rheology) and have been tested for different administration routes. It is difficult to directly 
compare the results described in Table 3.1 as the methods were not consistent. However, 




individually each report allows an understanding of the effects of surface chemistry on 
particle translocation. Some questions like do smaller particles diffuse faster than larger 
particles still remain unclear. Thus it is difficult to get a solid consensus due to the lack of 
method standardisation which needs to be addressed. 
The main aimof this Chapter of the PhD thesis was to investigate the diffusivity in mucus and 
penetration through mucus by the lipid shell nanoparticles (LNP) and PVA shell 
nanoparticles (PVA). These two nanosystems have been shown good candidates for 
controlled release by permeabilisers in the previous Chapter. In order to achieve this aim a 
novel vertical Transwell diffusion cell system was developed and shown to be fit for purpose 
using polystyrene (PS) nanoparticle with diameters of 50, 200 and 750 nm as reference 
particles Table 3.2). Then the model was employed to study the movement of the dynamic 
nanoparticles through porcine gastric mucus, chosen to represent ‗normal respiratory mucus‘ 
(Celli et al., 2005), and CF mucus harvested from cells derived from CF patients. The mucus 
harvested from the cell line has previously been shown to a good representation of the 
viscous respiratory human CF mucus from patients (Sajjan et al., 2004; Sheehan et al., 2000) 
and therefore although it was derived from a cell line it was termed as CF mucus in this work. 
These two model systems were selected rather than mucus samples directly from patients 
because previous work has shown the patient samples were too heterogeneous to enable 
accurate distinctions between the movement of different particles (Donaldson et al., 2006). 
Finally the multi particle tracking system with a flow cell was used to measure the horizontal 
movements of particles in the mobile mucus gel such that the multidimensional mucus 
diffusion modeling could be performed. 
Table 3.2: Test of mucus penetration using different particles under variable conditions.  
Nanoparticles Size (nm) pH condition 
PS 50 8.5 
LNP 50 8.5 
PS 200 2.5 
PS 200 6.5 
PS 200 8.5 
PVA 200 8.5 
PLNP 250 8.5 
PS 750 8.5 
 





Porcine stomachs were purchased from Mutch Meats (Whitney, UK). The human mucus was 
from Epithelix (EpithelixSarl, Geneva, Switzerland). Fluoresbrite YG carboxylate 
polystyrene microspheres (0.05, 0.2 and 0.75 µm, 2.5% w/v) were sourced from Polysciences 
(Eppelheim, Germany). Materials for nanoparticle manufacture refered to Section 2.2. 
Sodium chloride, ethylene diamine tetra acetic acid (EDTA), phenylmethylsulfonyl fluoride 
(PMSF), sodium azide, N-methyl-2-pyrrolidone, sodium fluorescein salt, nile red, sodium 
phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, thioglycolic acid, 
trypsin, lysozyme, bovine serum albumin (BSA), transferring and haemoglobin were 
purchased from Sigma-Aldrich (Dorset, UK).  
3.3 Methods 
3.3.1 Collection and purification of porcine gastric mucus 
The stomachs of freshly slaughtered pigs were opened along their greater curvature, inverted, 
any food content removed mechanically and washed with double-distilled water. The mucus 
lining the stomachs was gently removed by scraping using a plastic spatula and transferred to 
a container, containing protease inhibiting buffer composed of 200 mM sodium chloride, 
0.02 % (w/v), sodium azide, 5 mM EDTA and 1 mM PMSF. The mucus was mixed well with 
an equal volume of the protease inhibiting buffer to inhibit bacteria growth and homogenised 
with a mixer for 2 min. The mixture then was centrifuged at 11,200 g for 45 min at 4°C. The 
supernatant was poured into visking dialysis tubing (MWCO: 12-14 kDa, Fisher Scientific, 
Loughborough, UK) and dialysed against distilled-deionised water for 24 h. The dialysed 
mucus solution was concentrated in an Amicon ultra-filtration stirred cell (Model 8400, 
Merck Millipore, UK) under nitrogen at a pressure of 40 psi and temperature of 4°C. The 
purified and concentrated mucus was collected into a bottle and frozen at -20°C until used 
(Figure 3.2). 





Figure 3.2: Schematic of the purification of the PGM (From Boontarika Boonyapiwat, 2005). 
3.3.2 Respiratory mucus collection 
The respiratory mucus was secreted by cells harvested from a CF patient that were cultured in 
vitro using MucilAir
TM 
cell model as illustrated in Figure 3.3.  
 
Figure 3.3: Illustration of MucilAir cell model 
3.3.3 Characterisation of purified mucus 
The dry weight of mucus was determined by weighing a sample into a porcelain dish and 
placing it into an oven at 80 °C until a constant weight. The percentage of dry weight was 
calculated as the difference in the weight before and after heating. A known concentration 




was used in all studied. The determination of both elastic modulus (G‘) and viscous modulus 
(G‘‘) of collected mucus was performed on samples of approximately 2 g using the Carri-
Med rheometer (TA Instruments, US). Viscous modulus is the extent to which the gel resists 
the tendency to flow and elastic modulus measures the tendency for the gel to recover its 
original shape following deformation. The viscoelastic properties of the mucus as a function 
of frequency were studied at a constant stress of 1.8 Pa. The purified mucus swelling was 
quantified by applying 1 µL mucus to Transwell insert with 1, 5 and 10 µL polystyrene 
nanosuspension on top and the weight of the donor compartment was measured at a number 
of time points by taking it out of contact with a Tris buffer (50mM, pH 8.5), carefully 
removing the fluid from the surface of the mucus by wicking with a toweland placing the 
mucus-containing Transwell on a balance. The swelling was calculated as the difference in 
the weight over the initial weight. To characterize the molecular weight of collected mucus a 
sample (100 µL, 1 mg/mL) was injected into size exclusion column (TSK Gel 3000 
SW,Tosoh Bioscience LLC, Japan) at the flow rate of 1 mL/min using gel permeation 
chromatography machine equipped with refractive index detector (Malvern Instruments, 
Worcestershire, UK). Phosphate buffer 50 mM with 0.3 M sodium chloride at pH 7 was used 
as a mobile phase. Molecular weight was determined according to the plot of molecular 
weight against retention time obtained for standards (lysozyme, trypsin, peroxidase, BSA and 
thyroglobulin) using Ominsec software (Malvern Instruments, Worcestershire, UK). For CF 
mucus, only the molecular weight was measured. 
3.3.4 Nanoparticle fabrication 
The lipid shell nanoparticles and PVA shell nanoparticles were manufactured via 
precipitation from a stable emulsion following repeated phase inversion and 
nanoprecipitation method as previously described in Section 2.2.2. The freshly manufactured 
nanoparticles were prepared for all the experiments. For the particle tracking, nile red was 
loaded into both nanoparticles by dissolving nile red in organic phase. 
3.3.5 Nanoparticle characterization 
The size of nanoparticles were analysed by dynamic light scattering using a Zetasizer Nano 
ZS (Malvern, Worcestershire, UK). Nanoparticles (250 µg/mL) were suspended in Tris 
buffer solution (50 mM, pH 8.5) and sizes were measured at 37°C. All measurements were 
carried out at a scattering angle of 173° using water as the dispersant. Each measurement 




comprised of 10 to 14 runs and was performed in triplicate for each sample. Zeta potential 
measurements were performed at 37°C with all suspensions diluted in Tris buffer (50 mM, 
pH 8.5) solutions to a final concentration of 250 µg/mL. Each measurement was derived from 
between 50 to 100 runs and the measurements were performed in triplicate. 
3.3.6 Radiolabelling of lipid shell nanoparticles 
To incorporate a radiolabel chelator into the shell of the lipid nanoparticle systems, 0.1% w/w 
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylene triaminepentaacetic acid 
(DMPE-DTPA) (Avanti Polar Lipids Inc, Alabama, USA) was added to the components 
during the coarse emulsion step and the lipid shell nanoparticles were prepared as described 
above (Rubin, 2007). Suspensions were diluted to 12 mg/mL with 0.1 M ammonium acetate 
(pH 6.6). Indium-111 chloride (Mallinckrodt Medical Inc, Petten, The Netherlands), ~50 
MBq (
111
InCl3, half-life 2.83 days), was dissolved in 0.5 M ammonium acetate (pH 5.0) and 
mixed with lipid nanoparticles-DMPE-DTPA at a ratio of 1:2 v/v. The mixture was incubated 
at 37°C for 45 min under gentle shaking. Radiolabeling efficiency was measured by 
quantifying the radioactivity in the supernatant of the washing solution and washed carrier 
residue after three cycles of washing using spin filtration with Amicon ultrafiltration 
centrifuge tubes (Millipore Ltd., Hertfordshire, UK; 30 kDa MWCO). 
3.3.7 Nanoparticle fluorescence assay 
Fluorescence intensities of nanoparticle suspensions were determined using a Perkin Elmer 
luminescence spectrometer LS50B (Cambridgeshire, UK). For polystyrene nanoparticles, 
maximum excitation of 441 nm and emission of 486 nm were used for subsequent analyses 
on standard solutions prepared in the range of 1 μg/mL to 50 μg/mL from a stock solution 
(100 μg/mL). For PVA nanoparticle, fluorescence intensities of nile red solutions in methanol 
were determined with an excitation of 469 nm and an emission of 529 nm. Intra-day, inter-
day variation, LOD and LOQ were detected as described in Section 2.3.6. 
3.3.8 Mucus penetration model set-up 
3.3.8.1 The effect of barrier thickness 
The mucus model was optimised using fluorescein transport to measure the barrier provided 
to small molecular weight solute permeability. The basic set up used a Transwell system (0.3 






 polyester, 3 μm pore size, Corning, UK, Figure 3.3) to support a mucus layer which was 
inserted into a receiver chamber containing 600 μL of Tris buffer (50 mM, pH 8.5). In the 
fluorescein transport studies the mucus thickness was varied such that a barrier with a 
theoretical mucus thickness of 35, 180, 350, 500, 700, 1400, 2100 and 2800 μm was achieved 
by adding known volumes of mucus onto the insert membrane (calculated on the basis that 
the insert was a cylinder with a surface area of 0.3 cm
2
). For the thickness measurement, 
mucus layer on top of the membrane was rapidly moulded and frozen in the liquid nitrogen. 
The block was fixed in the Cryostat (Leica CM3050, Leica Microsystems, UK) and sections 
were cut with a thickness of 30 μm. The actual mucus thickness was measured using a 
microscope (Leica DM2000, Leica Microsystems, UK). Prior to the initiation of the transport 
experiments the mucus was equilibrated in the Transwell at 37°C for 1 h. Then a donor 
solution containing 100 μL of sodium fluorescein (100 μg/mL), in Tris buffer (50 mM, pH 
8.5), was applied onto the surface of the mucus layer to initiate a transport experiment, t=0. 
At regular time points over 30 h, 50 μL samples were removed from the receiver chamber 
and the amount of fluorescein in the samples was determined. Samples were analysed using a 
96-well plate reader (FLx800 Microplate Fluorescence Reader, Bio-TEK Instruments, UK), 
operated with an excitation of 460 nm and an emission of 515 nm. The assay methodology 
was shown to be fit for purpose in terms of precision and limit of detection in previous work 
(Chana et al., 2015). The cumulative mass of sodium fluorescein transferred to the receiver 
chamber per cm
2 
of mucus area was calculated, plotted against the time and the transport rate 
(i.e. flux derived from the linear mass transported vs time graph) was calculated. 
3.3.8.2 The effect of volume  
Once the mucus barrier properties were characterised, the effect of donor solution volume on 
the mucus hydration was evaluated by applying 1, 5 or 10 μL of 10 mg/ml polystyrene (PS) 
nanoparticles to the 35 μm thick mucus barrier and measuring the particle transport rate. The 
effect of barrier thickness on the nanoparticle penetration was then evaluated by employing 
the thickest (2800 μm) and thinnest (35 μm) mucus layers in comparative studies with 1 μL 
of 10 mg/mL polystyrene nanoparticles. Fluorescence intensity was measured to quantify the 
nanoparticle transport. In order to verify that the particles were actually passing through the 
mucus a selected number of samples that were removed from receiver chamber and were 
analysed using Transmission Electron Microscopy (TEM). TEM required placing a 3 µl 
sample onto Formvar coated grid. It was washed with deionized water for 2 min three times 




and then the sample was stained with 1% aqueous uranyl acetate for 3 min at 4
o 
C until dry. 
Images were obtained using a FEI Tecnai G
2
 transmission electron microscope operated at 
200 kV fitted with a GatanUltrascan US1000 (2kx2k) camera. 
3.3.9 Tracking nanoparticle penetration through mucus 
Using the optimal parameters for the mucus barrier transport (i.e., a 35 μm thick mucus 
barrier and a 1 μL donor solution) the diffusion of three different sized polystyrene 
nanoparticles (50 nm, 200 nm and 750 nm) and the two in-house manufactured nanoparticles 
was assessed. Again, 600 μL of Tris buffer (50 mM, pH 8.5) was used as the receiver fluid. A 
particle loading dose of 10 mg/mL was applied onto the surface of the barrier to allow for 
adequate detection in the receiver fluid. When characterising the transport of the distensible 
lipid shell nanoparticles, Pluronic (80 mg/mL) was first mixed with nanosuspension (160 
mg/mL) with a ratio of 1:0.5 w/w to initiate the distension process and then the mixture was 
added on the barrier. Nile red was loaded into PVA shell nanoparticles for tracking. At 
appropriate intervals during an 8 h time course samples were removed and the fluorescence 
of polystyrene nanoparticles was quantified with an excitation of 441 nm and an emission of 
486 nm at room temperature. The lipid shell nanoparticles were quantified by scintillation 
counting. Fluorescence of nile red encapsulated in PVA shell nanoparticles were quantified 
by dissolving particles in methanol and measured with an excitation of 469 nm and an 
emission of 529 nm. In order to study the effect of pH on the transport of 200 nm polystyrene 
nanoparticles, Tris buffer (50 mM) with pH of 2.5, 6.5 and 8.5 was used as the receiver fluid. 
Finally mucus penetration rates were calculated using steady-state flux equation as shown 










is flux, D is diffusion coefficient, C is concentration of the permeant in the donor 
solution and h is thickness of the membrane. 
3.3.10 Multiparticle tracking using nanoparticle tracking analysis 
Lateral nanoparticle diffusion through mucus was measured using a NanoSight LM10 
(Malvern, UK) with an LM14 top-plate, equipped with a green 533 nm laser and syringe 
pump. All the samples used in the vertical diffusion cell were diluted by a factor of 100 (0.28% 




w/w) before being injected into the system. An aliquot of 1 mL was injected into the 
NanoSight, with the 560 nm wavelength cut-off filter in place. Then 6×60 second videos 
were recorded for each particle type and measurements were performed in triplicate, whilst 
samples were being continuously pushed through the top-plate at a speed of 70 AU in order 
to minimise fluorescent bleaching. All measurements were conducted at 37°C. The raw 
diffusion coefficients were determined for each set of videos and averaged across the three 
repeats using NTAv3.0 (Malvern, UK). The diffusion of particles in the liquid was calculated 
using the Stokes-Einstein equation (Equation 3.2): 
D =  
kT
3πηd   
    Equation 3.2 
Where D is the diffusion coefficient, 𝑘  is the Boltzmann constant, 𝑇  is the absolute 
temperature, η is the dynamic viscosity, and 𝑑 is the particle diameter. 
3.3.11 Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. The transport data were 
analysed statistically using one way analysis of variance (ANOVA) testing for the normally 
distributed data and non-parametric Kruskal-Wallis tests for non-normally distributed data. 
Post hoc comparisons of the means of individual groups were performed when appropriate 
using Dunnet‘s test for normal distributed data and Games Howell test for non-Gaussian 
distributed data. For all pair-wise comparison of means, Student‘s independent T-test or 
Mann-Whitney test was applied. Differences were considered to be statistically significant at 













3.4.1 Mucus characterization 
A single batch of porcine gastric mucus (PGM) was prepared for the vertical translocation 
studies. A total of 10 stomachs produced around 16 g of mucus with a solid content of 28% 
w/w. PGM had the molecular weight range of 14 to 860 kDa (Figure 3.4). The PGM showed 
viscoelastic properties with a G‘ (elastic modulus) = 100.3 Pa and G‖ (viscous modulus) = 
57.5 Pa at 10 Hz (Figure 3.5). Cystic fibrosis mucus (CFM) had an average molecular weight 
of 412 kDa with a uniform distribution (Figure 3.6). Its viscoelastic properties could not be 
measured due to the limited sample volume that was available for the studies. 
 
 
Figure 3.4: Molecular weight of (A) standards and (B) PGM determined by size exclusion 
chromatography. Mucin numbers (1-3) were assigned based on the sequence of eluates. 
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Elutes Molecular weight (KDa) Retention volume (mL)
Thyroglobulin  (a) 660 5.2
Bovine serum albumin (b) 66 7.9
Peroxidase (c) 44 8.5
Trypsin (d) 23 10.2
Lysozyme (e) 14 11.4
Solvent (f) 0 11.8
MUC （1） 822 5.1
MUC （2） 59 7.9
MUC （3） 41 8.7































Figure 3.5: Elastic modulus (G‘) and viscous modulus (G‖) of PGM. Data represent mean ± 
standard deviation (n=3). 
 
 
Figure 3.6: Molecular weight of (A) standards and (B) cystic fibrosis mucus (CFM) 
determined by size exclusion chromatography. 

































Elutes Molecular weight (KDa) Retention volume (mL)
Thyroglobulin  (a) 660 5.2
Bovine serum albumin (b) 66 7.9
Peroxidase (c) 44 8.5
Trypsin (d) 23 10.2
Lysozyme (e) 14 11.4
Solvent (f) 0 11.8
MUC 412 6.9











































3.4.2 Fluorescence assay 
Calibration curves of all nanoparticles displayed a high degree of linearity (R
2
> 0.999) in the 
concentration ranges tested. Average intra and inter day variation data (Table 3.3) indicate 
the precision of the assay. Intra-day variation in fluorescence intensities for the calibration 
standards was lower than inter-day variation. Based on intra-day data the LOD and LOQ for 
the all particle assays were summarized in Table 3.4. 
Table 3.3: Average intra and inter-day variations in polystyrene (PS) and PVA particle 
fluorescence. Intra-day variation data obtained from measurements made in triplicate at each 
concentration (n=3). Inter-day variation data obtained over three days (n=9). 
Nanosuspensions Coefficient of Variation (%) 
Intra-day Inter-day 
PS50 at pH 8.5 2.80 ± 2.31 3.65 ± 2.40 
PS200 at pH 2.5 4.61 ± 3.30 4.24 ± 2.91 
PS200 at pH 6.5 4.99 ± 3.71 5.65 ± 4.19 
PS200 at pH 8.5 2.60 ± 3.06 3.33 ± 3.71 
PVA200 at pH 8.5 5.52 ± 1.56 6.71 ± 2.86 
PS750 at pH 8.5 4.03 ± 3.48 4.67 ± 4.50 
 
Table 3.4: LOD and LOQ of different nanosuspensions 
Nanosuspensions LOD (μg/mL) LOQ (μg/mL) 
PS50 at pH 8.5 3.38 11.26 
PS200 at pH 2.5 0.95 3.17 
PS200 at pH 6.5 0.97 3.20 
PS200 at pH 8.5 3.11 10.35 
PVA200 at pH 8.5 1.87 2.43 








3.4.3 In vitro mucus translocation model 
Faster translocation rates of sodium fluorescein were observed when the barrier thickness was 
reduced as shown in Figure 3.7. Without applying any donor solution to the barrier the 
measured thickness was identical to the mathematical calculation (35µm). The images of the 
Transwell supports showed that even the mucus layer that only measured 35 µm still 
appeared to form a confluent barrier. The fluorescein appeared to diffuse freely through the 
Transwell membrane system without significant binding as >95% of the applied dose 
appeared in the receiver chamber 2 h after the application of the sample.   
In preliminary studies of particle penetration through the PGM, PS 200 nm particle 
translocation across thin (35 µm) and thick (2800 µm) mucus layers was measured. The 
measurement of fluorescence intensity in the receiver chamber after particle application to the 
surface of the 35 µm mucus layers indicated an initial rapid phase of particle translocation (0-
0.5 h) followed by a slower phase plateauing towards 24 h (Figure 3.8A). TEM analysis 
confirmed the presence of 200 nm particles in the receiver chamber of the Transwell system 
when the thin layer was used (Figure 3.8A). When the experiment was conducted using the 
thicker mucus layer (2800 µm), the fluorescence signal in the receiver fluid was lower after 
application of the PS particles to the apical surface of the diffusion chamber compared to the 
thin mucus layer. There was also a high fluorescence reading when samples were taken from 
the basolateral side of the thick mucus when no fluorescent particles were applied to its apical 
surface. This fluorescence reading in the absence of particles for the thick mucus barrier was 
attributed to the fluorescence of mucus fragments that had leached into the receiver chamber 
of the Transwell from the barrier, which was confirmed by the TEM images (Figure 3.8B). 
The TEM measurements confirmed that the particle translocation was lower across the thick 
PGM barrier compared to the thin barrier as they showed that it was difficult to isolate 
images of the polystyrene in the receiver chamber fluid samples (Figure 3.8B). 
 





Figure 3.7: Porcine gastric mucus provides a barrier to the penetration of sodium fluorescein.  
(A) Illustrative micrograph showing the thickness of a PGM layer on the permeable 
membrane of a Transwell insert. Scale bar represents 100 µm. (B) Typical profile for 
cumulative mass transfer of sodium fluorescein across a 35 µm PGM layer lining a Transwell 
insert. (C) Flux of sodium fluorescein through PGM as a function of mucus layer thickness.  
Data represent mean ± standard deviation (n = 3). 





























































Figure 3.8: Fluorescence intensity and transmission electron micrograph (inset) of the 
material in the Transwell receiver chamber following the application of PS 200 nm 
nanoparticles or particle-free control Tris buffer pH 8.5 to mucus layers with a thickness of 
(A) 35 µm, and (B) 2800 µm. Data represent mean ± standard deviation (n = 3). The scale bar 
in the images represents 200 nm. 
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Both increasing the fluid application volume in which an increasing sodium fluorescein was 
applied to the surface of the mucus barrier and fixing the fluid volume whist increasing 
sodium fluorescein concentration led to a higher flux compared to the fixed concentration 
(Figure 3.9). Both profiles had linear portions when increased concentration was plotted 
against flux, but they displayed different patterns of data. When the concentration was fixed 
and the volume was variable, distinct linear portions of the graph can be observed, 1 to 10 
and 10 to 75 µL, this suggested that the application fluid volume was swelling the barrier and 
having an influence onits function. The 10 µL was thought to be a critical point where in the 
fluid volume started to have a significant impact on the transport rate. The application of 
small volumes (1-10 µL) of particle suspension to the surface of a 35 µm mucus layer 
resulted in a similar extent of mucus gel swelling irrespective of the sample volume applied 
(Figure 3.10A). However, the volume in which the PS 200 nm particles were applied to the 
surface of the mucus layer greatly affected the rate of translocation of the material into the 
receiver fluid (Figure 3.10B). When applied in a 1 µL aliquot the nanoparticle translocation 
was complete within 8 h, whereas only 25-30% of particles transferred into the receiver 
chamber over the same time period when 5 or 10 µL sample volumes of the particles were 
applied to the surface of the mucus (p<0.05;Figure 3.10). For subsequent studies, the smallest 
sample volume (1 µL suspension) and the thinnest mucus layer (35 µm) were used as these 
conditions appeared to constitutea robust model for particle penetration and were thought to 
mimic the conditions in vivo (Mühlfeld et al., 2008). 
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Figure 3.9: Transport of increased donor solution concentration (C) and volume (V) through 
PGM barrier. Data represent mean ± standard deviation (n = 3). 





Figure 3.10: Effect of the volume (1-10 µL) of PS 200 nm nanoparticle suspension applied to 
the surface of a 35 µm porcine gastric mucus layers on (A) mucus swelling and (B) the 
translocation of PS particles across the mucus layer. Data represent mean ± standard 




























































3.4.4 Nanoparticle translocation through pig gastric mucus 
The carboxylated polystyrene nanoparticles were verified to be of the size described by 
manufacturer‘s specification and they exhibited a negative charge (Table 3.4). Both particle 
size and pH of the applied vehicle were determinants in the rate of nanoparticle translocation 
through mucus (Figure 3.11). In order to compare with the data obtained from NanoSight, 
unit of nm
2
/s was used for data obtained from static model. The particle transport rates 
showed that the 200 nm particles moved through the barrier three times faster than 50 and 
twice as fast as 750 nm particles (p<0.05; Figure 3.11A). According the polystyrene particle 
experiments the mucus barrier was more restrictive at acidic pH. The fastest penetration rate 
of 200 nm PS nanoparticles was observed at pH 8.5, which was 2- and 8-fold faster compared 
to pH 6.5 and pH 2.5, respectively (p<0.05; Figure 3.11B). Lipid shell nanoparticles had the 
fastest penetration rate through the mucus, translocating across the mucus barrier 3 times 
faster than equivalent sized negatively charged polystyrene particles (p<0.05; Figure 3.12A). 
The fabricated lipid shell nanoparticles were 50 nm in diameter with a neutral surface.  
However, the diffusion rate of 200 nm PVA shell nanoparticles was 10-fold lower than 200 
nm PS nanoparticles (p<0.05; Figure 3.12B). When the lipid shell nanoparticle 
permeabilisation process was achieved the penetration rate was equivalent to controlled 
nanoparticles, indicating that surfactant-induced nanoparticle distension had little effect on 
mucus penetration (Figure 3.13).  
Table 3.5: A summary of nanoparticle characteristics (PS: polystyrene; LNP: lipid 
nanoparticle; PLNP: permeabilised lipid nanoparticle; PVA: poly vinyl alcohol nanoparticle) 
and their diffusion through porcine gastric mucus (PGM) and cystic fibrosis mucus (CFM) 
using static and mobile mucus models. Data represent mean ± standard deviation (n = 3). 
Symbols indicate a statistical difference when comparing the results across the groups which 
differed in *particle size, 
#
pH, and surface chemistry (p<0.05). 




























PS50 in pH 8.5 53 ±  1 -35.9 ± 0.8 9.87 ± 0.61 329 ± 166 1.14 ± 0.20 
PS200 in pH 8.5 187 ± 2 -48.4 ± 1.4 19.93 ± 5.47 267 ± 99 0.88 ± 0.10 
PS750 in pH 8.5 778 ± 3 -61.5 ± 1.0 6.67 ± 1.28* 140 ± 77* 0.30 ± 0.02* 
PS200 in pH 6.5 185 ± 2 -41.8 ± 3.9 9.54 ± 3.26 198 ± 34 0.38 ± 0.03 
PS200 in pH 2.5 183 ± 2 -33.2 ± 1.1 2.98 ± 0.74
#
 107 ± 7
#
 0.18 ± 0.08
#
 
LNP50 in pH 8.5 52 ± 2 -3.5 ± 0.6 30.08 ± 2.49△ 494 ± 4 28.99 ± 3.28△ 
PLNP50 in pH 8.5 52 ± 2 -2.4 ± 1.0 27.10 ± 3.84△ 397 ± 38 29.51 ± 2.13△ 
PVA200 in pH 8.5 225 ± 5 -1.5 ± 0.8 1.64 ± 0.37 N/A N/A 






Figure 3.11: The transport of (A) 1 µL of 50, 200 and 750 nm PS NP at pH 8.5 through a 35 
µm PGM barrier and (B) 1 µL of 200 nm PS NP at pH 2.5, 6.5 and 8.5 through a 35 µm 





































































Figure 3.12: The translocation of (A) 50 nm lipid shell nanoparticles (LNP) through a 35 µm 
PGM barrier at pH 8.5 compared to 50 nm PS NP and (B) 200 nm PVA shell nanoparticles 
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Figure 3.13: The translocation of permeabilised and non-permeabilised 50 nm lipid shell 
nanoparticles through a 35 µm PGM barrier at pH 8.5 with associated nanoparticle 
permeabilisation process (inset). Data represent mean ± standard deviation (n = 3). 
3.4.5 Multiparticle tracking of lateral diffusion 
When lateral particle diffusion was measured in mucus, the mean particle diffusion rates were 
up to thirty times greater compared to the diffusion calculated in the static model (Figure 
3.14). This difference in the diffusivity when the particle tracking data and the Transwell data 
were compared was not consistent across the different particles types. Although both pH and 
particle size influenced the particle movement in both mucus diffusion systems, there were 
significant differences in the trends across the two data sets. Unlike the Transwell diffusion 
data in the horizontal studies the 50 nm sized nanoparticles moved through the gel at the 
fastest rate (329 ± 166 nm
2
/s) and the 700 nm particles the slowest (140 ± 77 nm
2
/s, p<0.05, 
Figure 3.14, Table 3.5). Furthermore, the mucus gel was sensitive to the lipid shell 
nanoparticle size distension process, with the distensible nanoparticles passing through the 
mobile mucus system at a slower rate (397 ± 38 nm
2
/s) compared to the none-distending 
carriers (494 ± 4 nm
2
/s, Figure 3.13, Table 3.4). The effects of pH were similar across the two 
different mucus model data sets (Figure 3.14, Table 3.5). 















































Figure 3.14: The lateral diffusion profiles of nanoparticles in porcine gastric mucus (PGM) 
displaying (A) the effect of polystyrene particle size, (B) effect of media pH on 200 nm 
polystyrene nanoparticles, (C) permeabilised and non-permeabilised lipid shell nanoparticles 
and (D) surface charge. 
3.4.6 Nanoparticle diffusion through cystic fibrosis mucus 
The diffusionof particles in cystic fibrosis mucus in the Transwell inserts was slower 
compared to PGM for all the polystyrene particles (p<0.05; Table 3.5; Figure 3.15A and B). 
The magnitude of diffusion retardation was between 10 to 20-fold compared to the rates 
recorded in PGM (p<0.05; Table 3.5). The pH had a similar effect on the mucus transport 
compared to the PGM, but interestingly the 50 nm particles permeated at the quickest rate 
compared to 200 and 750 nm particles (p<0.05; Table 3.5). The lipid shell nanoparticles 
again exhibited the most rapid translocation rates in the cystic fibrosis mucus, its diffusivity 
was ~ 25-fold higher compared to similar sized polystyrene particles (p<0.05), irrespective of 
the trigger conditions (Figure 3.15C and D). The lipid shell nanoparticle diffusivity was not 





































Diffusion coefficient (E4 nm
2
/s)
 50 nm pH 8.5
 200 nm pH 8.5
 750 nm pH 8.5





























Diffusion coefficient (E4 nm
2
/s)
 200 nm pH 2.5
 200 nm pH 6.5
 200 nm pH 8.5









































































Diffusion coefficient (E4 nm
2
/s)
 50 nm PS 
 50 nm LNP





Figure 3.15: Nanoparticles penetration through respiratory cell-derived cystic fibrosis mucus, 
showing the effect of (A) polystyrene nanoparticle (PS) size at pH 8.5, (B) the pH of the 
vehicle in which PS 200 nm were applied, (C) permeabilisation of the lipid shell 
nanoparticles (LNP) at pH 8.5, and (D) the surface properties of the nanoparticles at pH 8.5. 
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In this Chaptera novel means to determine the manner in which nanoparticles translocate 
across a mucus barrier was developed in order to understand how dynamic nanoparticles 
passed through respiratory mucus.The mucus-particle interactions were understood through 
comparison of the lipid shell nanoparticles and PVA shell nanoparticles with polystyrene 
nanoparticles in two types of mucus. 
A major role of the respiratory mucus gel is to trap inhaled particles so that they can be 
removed from the airways by mucocilliary clearance, thereby defending the lungs against 
inhaled pathogenic microorganisms and toxic materials (Thornton et al., 2008). The mucus 
that lines the airways provides a challenge to efficient nanoparticle delivery to the lungs due 
to the poor penetration of most conventional particle systems through this barrier. The 
particle systems developed in Chapter 2 therefore must cross the mucus barrier if they are to 
be effective drug delivery systems. 
As in previously published studies the diffusion data in this Chapter indicated that the 
nanoparticles transport through the mucus barrier was influenced by particle size, surface 
charge and surface hydrophobicity (Lieleg and Ribbeck, 2011). In the Transwell mucus 
penetration assay, 200 nm PS particles translocated the mucus barrier at a much faster rate 





/s, was similar to a previous study,which measured the particle diffusion in human 
cervical mucus using a particle tracking technique (Cu and Saltzman, 2008). In the current 
study the particle tracking diffusivity was consistently approximately thirty times higher 
compared to the Transwell system diffusivity values. Although both techniques measured 
diffusivity, the particle tracking technique measured only horizontal movement. The 
Transwell system diffusivity was a consequence of three dimensional movement and hence 
accounts for any effects of gravity. 
The fact that rank order of particle translocation rate based on size in the Transwell assay was 
different to that obtained from the particle tracking system suggests that the mucus barrier 
was different in the two techniques. The horizontal particle tracking system appeared to obey 
an ideal Stokes-Einstein equation type behaviour, i.e. that smaller particles were subject to 
faster diffusion. However, in the Transwell assay the 200 nm particle moved through the 
mucus more rapidly than the 50 nm particle and this suggests this diffusion was influenced by 




other factors such as gravity and diffusion path tortuosity. Lai who studied the transport of 
particles ranging from 100 to 500 nm in human cervicovaginal mucus using particle tracking 
showed similar results to those recorded in this study (Lai et al., 2007). In that study 100 nm 
sized particles were found to be almost completely immobile in mucus, whereas 200 and 500 
nm sized particles had a higher diffusion coefficient. The horizontal movement tracked by the 
camera was estimated to be around 20 µm and this was quite similar to the vertical 
translocation which was ca. 35µm (although it is accepted there was some swelling of the 
barrier), therefore the difference was attributed to the dilution of the mucus sample and the 
application of shear breaking up the mucus structure in the horizontal particle tracking 
measurements (Lai et al., 2010). If the mucus is sensitive to dilution then each mucus which 
has a unique structure could be influenced by the total solid content of mucins in the test 
systems. This could be one explanation why the particle tracking data appears to be very 
heterogeneous when previous studies are reviewed. For example, particle tracking 
measurements have shownan ideal Stokes relationship between diffusion and particle size 
using human lung mucus (Schuster et al., 2013) and murine luminal mucus penetration 
(Maisel et al., 2015), but there are other works using pig intestinal mucus (Abdulkarim et al., 
2015) and human chronic rhinosinusitis mucus (Lai et al., 2011) that do not show this 
relationship. In none of these studies has the effect of mucin concentration been studied. 
When nanoparticle transport in mucus in alkaline conditions (pH 8.5) was investigated, the 
mucus gel was more permeable in both the penetration assay and lateral particle tracking. The 
results are consistent with the suggestion that pH regulates the electrostatic interactions 
between the mucin polymers and diffusing particles. Studies using different analytical 
methods have found that lower pH facilitates mucus-particle interaction (Svensson et al., 
2008) and as a consequence more rigid mucus network is formed at acidic pH (Bromberg and 
Barr, 2000; Hong et al., 2005; Maleki et al., 2008). This was observed for both the porcine 
gastric mucus and the cystic fibrosis mucus in this study when tested in the Transwell insert. 
Cystic fibrosis generally results in an increase in the viscoelasticity of mucus, owing in part 
to reduced water content and an increased fraction of glycoproteins (Boucher, 2004; Rubin, 
2007). Cystic fibrosis sputum undergoes significant shear-thinning with representative steady 
shear viscosities of ∼14 Pa-s at shear rates of 1s-1, whereas the viscosity of porcine gastric 
mucus has been reported to be only ∼0.085 Pa-s at a shear rate of 1.15 s−1 (Lai et al., 2009). 
In this study, the transport of PS particles through mucus derived from a respiratory cell line 




from a human donor with cystic fibrosis was 20 times slower than across PGM. The much 
slower movement of polymeric particles in the respiratory mucus compared to the PGM has 
previously been reported. It was demonstrated that diffusion coefficient of amine modified 
particles in native gastric mucus were 40-fold lower compared to the theoretical diffusivity of 
the same particles in water (Crater and Carrier, 2010), and 5600-fold lowerin CF sputum (Suk 
et al., 2009). These results corresponds to the findings here that the respiratory CF mucus was 
much more restrictive than PGM. The structure of CF sputum has previously been studied by 
scanning electron microscopy (SEM) and this has led to pore size estimates of 100-400 nm 
(Sanders et al., 2000). The SEM technique however has several limitations when trying to 
assess the pore size of mucus due to the manner in which the samples are prepared. The 3D 
mesh spacing of physiological human CF sputum with minimal perturbation during sample 
preparation was probed and an average mesh size of 200 nm was reported (Suk et al., 2009). 
This suggested very slow rate of 750 nm sized particle diffusion was most likely attributed to 
extensive steric obstruction imposed by the smaller mesh spacing of CF sputum.  
It is believed that the primary mechanism by which mucus gels interact with particles is 
through the formation of polyvalent adhesive interactions (Cone, 2009). However, the high 
density of hydrophobic domains within mucin fibres can efficiently form multiple low-
affinity adhesive interactions with hydrophobic regions on the surfaces of particulates. 
Theoretically negatively charged mucin fibers showhigh affinity with positively charged 
particles and thus negatively charged particles may favour particle transport in the relatively 
hydrophilic pores of the mucus mesh. However, the carboxylate groups of the particle will 
provide opportunity for hydrogen-bonding interactions with mucin (Peppas and Huang, 2004) 
and higher transport rates for cationic particles than anionic particle within intestinal mucus 
has been reported (Abdulkarim et al., 2015). Neutral particles have advantages over charged 
particles as the electrostatic interactions and hydrogen bonding can be greatly reduced. The 
slow movement of 50 nm carboxyl modified hydrophobic particles through both types of 
mucus in this study was consistent with this mechanism and similar conclusions made in 
previous studies (Olmsted et al., 2001). Interestingly, similarsized neutral lipid nanoparticles 
had higher diffusion rates compared to the polystyrene particles suggesting the particles have 
less interactions with the mucin fibres in the mucus which similar results were previously 
reported (Nafee et al., 2014). Lipid shell nanoparticles comprise triglycerides dispersed in a 
saline solution, stabilised at the droplet interface with phospholipids and a PEG based 
surfactant (Heurtault et al., 2002). Wang et al. (2008) reported that nanoparticles coated with 




low molecular weight poly(ethylene glycol) (PEG) possess hydrophilic and near neutrally-
charged surfaces that minimize mucoadhesion by reducing hydrophobic or electrostatic 
interactions (Wang et al., 2008). Low PEG MW and dense PEG surface coverage were both 
required for rapid mucus penetration of coated particles. This has recently been confirmed by 
Jones et al (2014) using the lipid nanoparticles employed in this study (Jones et al., 2014) 
who characterised the surface hydrophobicity of nanoparticles using hydrophobic interaction 
chromatography (HIC) and classified the particles using a developed hydrophobicity scale: 
the HIC index. The results demonstrated that polystyrene nanoparticles (0.96 ± 0.04) 
displayed a higher HIC index than that of lipid shell nanoparticles (0.50 ± 0.09). The results 
from this study confirm that hydrophobicity of nanoparticles is also a significant factor in 
transport through mucus.  
It was hypothesized that permeabilized particles could be immobilised in the mucus due to 
their size distension process. However, no effect of the distension process was observed on 
the diffusion. This result may be related to the kinetics of the particle distension process. The 
permeabiliser allows the nanoparticles to swell from 50 to 200 nm over a period of 8 h. 
However, the mucus penetration was rapid and mainly occurred over the first hour after 
application to the mucus. Significant higher transport rates were obtained compared to 
polystyrene particles, indicating that this dynamic lipid shell nanoparticle system was a 
robust mucus penetrating nanosystem that could be used for the controlled drug delivery of 
antibiotics even when the airway mucus became viscous. 
 
When polyvinyl alcohol (PVA), a relatively hydrophilic and uncharged polymer routinely 
used as a surfactant to formulate drug carriers weas used to manufacture the nanoparticles, 
their diffusion in PGM were severely retarded compared to lipid shell nanoparticles and PS 
NP. This suggests that incorporating PVA in the particle formulation process may lead to the 
formation of mucoadhesive carriers. The influence of surface coating by PVA on the 
transport of nanoparticles in fresh human cervicovaginal mucus was investigated (Yang et al., 
2014).  PVA-coated polystyrene (PS) particles were immobilized, with speeds at least 4000-
fold lower in mucus than in water, regardless of the PVA molecular weight or incubation 
concentration tested. As partially hydrolyzed PVA was used during the particle fabrication, 
both the hydroxyl groups and the residual acetyl groups may form hydrogen bonds with 
mucus constituents. In addition, the residual acetyl groups are also capable of establishing 




hydrophobic interactions with the mucus mesh due to the hydrophobic terminal methyl group. 











































In this Chapter lipid shell nanoparticles were shown to be capable of penetrating both PGM 
and CF mucus and PVA shell nanoparticles were shown to be immobilized in PGM. The 
multidimensional mucus diffusion modeling performed in this work was an easy and robust 
means to assess the movement of particles through mucus. The penetration of polystyrene 
particles suggests that particle size, hydrophobicity and medium pH are significant factors in 
nanoparticle translocation. The rapid transport of lipid nanoparticle system coupled with prior 
knowledge that they were slow to move into epithelial cells and well tolerated in vivo 
suggests that have the potential to be developed for the delivery of a drug in a controlled 
manner in the airways of the lungs. These nanoparticles must however be encapsulated into a 


























Co-administration of nanoparticles with a shell 










There have been studies that have dosed RIF, INHand PZA to the lungs using solid lipid 
particles (SLPs) and that were incorporated into a powder with a favourable mass median 
aerodynamic diameter suitable for bronchoalveolar drug delivery (Pandey, 2005). Pandey et 
al. (2003) demonstrated that sustained therapeutic effect was obtained when anti-TB drugs 
were loaded into PLGA nanoparticles that were nebulised as micro-droplets into the lung 
(Pandey et al., 2003). Doan et al. (2011) has also shown that rifampicin-loaded microspheres 
are suitable for lung delivery as sustained-release microsphere aerosol (Doan et al., 2011). A 
mixture of these two systems, i.e., nanoparticle-aggregate particles (PNAP), containing 
rifampicin, have also produced beneficial effects (Sung et al., 2009). Alginate nanoparticles 
have been shown to be capable of encapsulating INH, RIF andPZAand the delivery of these 
agents has shown promise in in-vivo models (Zahoor et al., 2005). These studies have 
established the proof of principle data that ATD dosing is favourable and possible, but none 
of the previous work in the field has gone on to make products. One reason for this is that 
although these systems provide controlled release they still cannot achieve the required drug 
levels in the lung macrophages to cut down the length of clinical treatment with ATDs 
(Zahoor et al., 2005).  
In Chapter 2, it was demonstrated that encapsulating rifampicin into lipid shell nanoparticles 
increased drug chemical stability and this drug delivery system was shown to have the 
potential to release drug in a controlled manner through a carrier distension process. These 
nanoparticles could provide a solution to the current issues with carriers designed to deliver 
ATDs to the lungs and target macrophages as if they are administered in a microparticle 
which quickly dissolves, the nanoparticles can be permeabilised and the growth of the 
carriers could facilitate uptake by macrophages once in the lung. A dry powder inhalation for 
ATDs seems to be the most sensible choice given the drug‘s potential to chemically degrade 
(Sosnik et al., 2010) 
Several particle engineering technologies have been applied for pulmonary powder 
production such as milling, spray drying, spray freeze drying and supercritical fluid 
technology (Shoyele and Cawthorne, 2006),spray drying (SD) is probably the most well-
established method in pharmaceutical applications (Abdelwahed et al., 2006; Malcolmson 
and Embleton, 1998). It is one of the most sophisticated drying techniques and offers many 
possibilities for modification to facilitate novel particle engineering (Vehring, 2008). 




Furthermore, spray drying is applicable tomany different liquid systems including 
nanopartcile suspensions. For example, previous study produced rifampicin/PLGA 
nanoparticle-containing microspheres using a modified spray drier (Ohashi et al., 2009). 
Spray drying offers the possibility of mixing fluids immediately prior to particle formation 
during the atomization process (Vehring, 2008). Furthermore, spray drying permits the 
controlled production of particles of different morphologies by changing the spray drying 
process conditions (Chew et al., 2005).  
As spray drying seemed like the most flexible particle fabrication process, it was thought 
beneficial to develop a spray drying method, which could hold the surfactant permeabiliser 
and the nanoparticles separately until the microparticle carrier dissolved and allowed the two 
to mix freely. It was hypothesized that developing rapidly dissolving nanoparticle-
permeabiliser containing microparticles, with an aerodynamic diameter between 1 and 5 µm, 
would facilitate controlled drug release and macrophage recognition. Therefore, the aim of 
the work in this Chapter was to design a novel spray drying method for the 
microencapsulated lipid shell nanoparticles and then investigate the ability of the surfactant to 
permeabilise rifampicin release from microencapsulated lipid shell nanoparticles in simulated 
lung fluid. To achieve this aim the lipid nanoparticles were spray dried, they were 
characterize with respect to particle size, nanoparticle size recovery, drug content and 
morphology. Finally, the effect of permeabiliser inclusion in the dry powder formulation on 













Lactose was purchased from Sigma-Aldrich, UK. Other materials were as described in 
Chapter 2. 
4.3 Methods 
4.3.1 Preparation of nanoparticle 
Blank and rifampicin-loaded lipid shellnanoparticles were prepared and purified according to 
the methods detailed in Section 2.3.1. 
4.3.2 Microparticle fabrication 
Spray drying was performed with a mini-spray drier (Buchi Laboratoriums-Technik, Flawil, 
Switzerland), which operated using a twin nozzle of air and liquid spraying in a parallel flow. 
For the preparation of blank and rifampicin containing nanoparticles loaded microparticles, 
nanosuspensions (1 mL) were mixed with lactose solutions (3% w/v) using magnetic stirring 
for 10 min. The Pluronic L62D, used to permeabilise the nanoparticles was dissolved in the 
second feed solution. The two feed stocks were supplied to the spray drier at the same speed 
using a T shaped connector using the operational conditions detailed in Table 4.1. The dried 
powders were recovered and stored at room temperature, protected from light, in the presence 
of a dessicant potassium pentoxide.  
Table 4.1: Operation conditions for the spray-drying technique 
Spray drying parameters Operational conditions 
Inlet air temperature (C) 160 
Aspiration setting (%) 85 
Feed flow rate (mL/min) 2 
Air flow rate (L/h) 700 
Atomising air pressure (psi) 80 
 
 




4.3.3 Particle size analysis 
The particle size distribution (PSD) of each sample was evaluated using a 
SympatecHelos/Rodos laser diffraction particle size analyser (Sympatec, Germany). 
Approximately 20 mg of powder was introduced to the dry dispersion feeder system using a 
vibratory feed tray. The dispersion pressure was set at 4 Bar. The laser diffraction system, 
equipped with the appropriate lens for the sample‘s particle-size range was used to measure 
the PSD of the sample. The volume mean diameter (VMD), D10, D50 and D90 (cumulative 
undersize below 10%, 50% and 90% of the size frequency plot) were calculated using the 
Sympatec software.  
4.3.4 Particle morphology 
Microparticles were mounted on 0.5 inch aluminium stubs using double sided adhesive tap 
discs. The samples were spatter coated at an electrical potential of 2.0 kV, a current of 20 mA 
and at high vacuum (0.02 Torr) for 2 min. This procedure resulted in a film of gold, 
approximately 10 to 20 nm thick, being deposited on the specimen. The electron micrographs 
were recorded on 220 size Ilford FP4 film using a scanning electron microscope (SEM) 
(Zeiss, Germany).  
4.3.5 Nanoparticle recovery from dry powders in aqueous medium 
A 100 mg aliquot of spray dried powder was dispersed in a bottle containing 5 mL of PBS 
7.4 under magnetic stirring at a temperature of 37°C. The particle size of released LNPs from 
each formulation was measured by PCS under the conditions previously stated in Section 
2.3.5. 
4.3.6 Encapsulation efficiency and release study 
Drug uniformity content for each formulation was determined by dissolving the dry powder 
in PBS buffer at pH 7.4. An aliquot of this solution was transferred to an Amicon centrifuge 
tube to separate nanoparticles from dispersing medium (see the methodin Section 2.3.8). For 
the release study, the suspension was placed into dialysis tubing and it was dialysed against 
PBS buffer pH 7.4. At a number of different time intervals, samples were withdrawn from the 
tubing. The drug content remaining in the particles was analysed by HPLC and the drug 




release was determined by difference (due to the chemical instability of rifampicin in aqueous 
media.  
4.3.7 Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. The normality (Sapiro-Wilk) 
and homogeneity of variances (Levene‘s test) of the data were assessed prior to statistical 
analysis. The release data were analysed statistically using T-test or Mann-Whitney test. 





















4.4.1 Characterization of spray dried microparticles 
Microparticles fabricated by spray drying had a median size of approximately 4 µm as shown 
in Table 4.2. Incorporating lipid shell nanoparticles or rifampicin-loaded lipid shell 
nanoparticles into microparticles did not have effect on particle size.  
Table 4.2: Particle sizes of different spray dried powders obtained by laser diffraction: B-
LNP-MP (blank lipid shell nanoparticles contained microparticles); RIF-LNP-MP 
(rifampicin-lipid shell nanoparticles contained microparticles); B-PLNP-MP (blank lipid shell 
nanoparticles contained microparticles with permeabiliser); RIF-PLNP-MP (rifampicin-lipid 
shell nanoparticles contained microparticles with permeabiliser). Data represent mean ± 
standard deviation (n=3). 
 Particle size (µm) 
Formulation X10 X50 X90 VMD 
B-LNP-MP 1.19 ± 0.02 3.36 ± 0.37 6.92 ± 0.88 3.80 ± 0.42 
RIF-LNP-MP 1.32 ± 0.29 3.69 ± 0.23 7.45 ± 0.09 4.19 ± 0.14 
B-PLNP-MP 1.21 ± 0.05 3.93 ± 0.26 7.84 ± 0.41 4.31 ± 0.24 
RIF-PLNP-MP 1.47 ± 0.29 4.06 ± 0.06 8.36 ± 0.14 6.43 ± 0.69 
 
4.4.2 Morphology of microparticles 
Microspheres were obtained with yields of approximately 50%. As can be observed in the 
SEM microphotographs depicted in Figure 4.1, the spray drying technique led to the 
production of well-defined microspheres with spherical shape. The sizes observed in the 
SEM images were similar to those obtained by laser diffraction. The incorporation of the 
Pluronic surfactant permeabiliser in the powder had no effect on the morphology of 
microparticles.  
 





Figure 4.1: SEM microphotograph of representative microparticles prepared with (A) and (B) 
rifampicin-nanoparticles and (C) and (D) rifampicin-nanoparticles with permeabiliser.  
4.4.3 Drug uniformity content and nanoparticles recovery from dry powders 
The spray dried particles dissolved instantly when dispersed in aqueous solution. The mean 
particle size of the nanoparticles in the suspensions was found to increase by approximately 
100% for both formulations without the addition of Pluronic (Table 4.3). Significantly 
swelled sizes were observed when Pluronic was included into the microparticles (p<0.05). 
The amount of rifampicin encapsulated in the microparticles was similar for the batches with 









Table 4.3: Lipid shell nanoparticle size before spray drying and after microparticle 
dissolution in aqueous solution and rifampicin content in microparticles. Data represent mean 
± standard deviation (n=3). 
Formulation  Particle size before 
spray drying (nm) 




rifampicin in 100 
mg powder (µg) 
B-LNP-MP 47 ± 1 95 ± 4 N/A 
B-PLNP-MP 47 ± 1 198 ± 26 N/A 
RIF-LNP-MP 49 ± 0 92 ± 5 135.7 ± 17.5 
RIF-PLNP-MP 49 ± 0 202 ± 16 144.7 ± 10.8 
 
4.4.4 Drug release 
The incorporation of the Pluronic surfactant into the microparticles had a significant effect on 
the drug release from nanoparticles (Figure 4.2). The microparticle containing the Pluronic 
released almost 60% of its rifampicin load within 1 h, but after this time point the drug 
release was very gradual up to 8 h. To assess the stability of the microparticles, the release 
experiments were carried out at different time points post-manufacture (Figure 4.3). No 
signficant changes in release rates were found, from 0.0043 mg/h and 0.0244 mg/h for non-
Pluronic permeabilised and Pluronic permeabilised groups initially to 0.0033 mg/h and 
0.0213 mg/h respectively after 30 days when the nanoparticles were suspended in a 
microparticle (p>0.05). However, a significant difference was observed when the drug was 
stored as a simple nanosuspension in an aqueous vehicle over the same 30 day time period 
(Figure 4.3). More than 50% of rifampicin was lost from the nanoparticles upon storage in 
liquid (p<0.05). The release rates for non-permeabilised and permeabilised groups at day 1 
were 0.1218 mg/h and 0.1688 mg/h respectively, which significantly reduced to 0.0716 mg/h 
and 0.0846 mg/h 30days after manufacture (p<0.05).  






















Time (h)  
Figure 4.2: Rifampicin release from lipid shell nanoparticles included into microparticles 
with and without the permeabiliser. Data represent mean ± standard deviation (n=3). 
 
Figure 4.3: Rifampicin release from non-permeabilised and permeabilised lipid shell 
nanoparticles at day 1 (A) and day 30 (B). Graph (C) and (D) showed the release from 
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It was previously demonstrated that rifampicin is prone to continuously diffuse out of lipid 
shell nanoparticles post manufacture when stored in an aqueous solution (Section 2.4.5). In 
this Chapter the incorporation of lipid shell nanoparticles in a dry powder formulation 
stabilised the nanoparticles, whilst still allowing the particle distension process to be 
triggered. Therefore, the data demonstrated that spray drying is a suitable method to load 
lipid shell nanoparticles into a lactose microparticle. A carbohydrate was selected for the 
microparticle matrix as it is approved by the Food and Drug Administration (FDA) for 
inhaled delivery and widely applied in aerosolised formulations (Ober et al., 2013). SEM 
micrographs revealed that lipid shell nanoparticles containing microparticles were spherical 
in shape and had a smooth surface. The aerodynamic diameter, which is a combination of the 
particle size and density, was not measured in this work because in previous work lactose 
microspheres have been shown to be easily aerosolised into the lungs when the particles are 
of a suitable size (Karavasili et al., 2016; Singh et al., 2015). The microspheres produced in 
this work had a diameter of 2 to 5 µm, which was considered to be suitable for delivery to the 
lower airways (Loira-Pastoriza et al., 2014). A similar sized microsphere has been previously 
engineered to deliver lipid nanoparticles using lactose (Freitas and Müller, 1998). However, 
the particles in the current work were different to the literature as they also contained the 
Pluronic surfactant in the microparticle matrix.  
Drug content uniformity data showed that the encapsulation efficiency for both the distending 
lipid shell nanoparticles and non-distending lipid shell nanoparticles in the microparticles was 
high. However, the total drug loaded into the microparticles (~0.14% w/w) was still low 
compared to standard oral doses. A standard single adult oral dose is 600 mg (Donald et al., 
2011). But there is some evidence that the inhaled dose would not need to match the oral dose. 
Directly exposing the alveolar macrophagesto the drug may improve its efficacy. In addition, 
the relative systemic bioavailability after inhaled nanoparticle-encapsulated microparticle 
delivery has previously been shown approximately 10-20 times higher than that of same dose 
of the orally dosed drug (Ahmad et al., 2006; Pandey et al., 2003; Sharma et al., 2004). There 
is also the possibility to improve the drug loading and or deposition efficiency in the lung 
using an advanced delivery device (Claus et al., 2014; Hoppentocht et al., 2014). This could 
be the subject of further work in this area. 




In the current study, the ability of the obtained dry powder to deliver the lipid shell 
nanoparticles following incubation in PBS pH 7.4 was investigated. This pH was chosen in 
an attempt to perform the assay in a pH close to that of the airway surface liquid, which is 
approximately 7  (Walters, 2002). It was observed that after the microparticles incubation in 
aqueous medium under low stirring, the lactose dissolved, resulting in nanoparticle 
suspension which could be measured by light scattering. In spite of the slight enlargement of 
the nanoparticles after release from the microparticles they remain in the nano-range and thus 
retained the capacity to control drug release effectively. The swelling of particle size after 
spray drying was also found for powders prepared with lactose and gelatin nanoparticles in 
previous work, which attributed the changes the heat applied to the system during the spray 
drying process (Sham et al., 2004). When the permeabiliser was included in the microparticle 
it did not affect its stability, i.e., it did not induce drug release from the solid microparticle, 
but it still allowed the size distension process to occur according the particle sizing results. 
This suggested that it was possible to spray dry both drug and Pluronic permeabiliser 
simultaneously using the established method. From the results of this study it could be 
hypothesised that after reaching the lung, the lactose would dissolve in the lung lining fluid, 
releasing nanoparticles,which would release some drug, grow in size, as a result of the co 
dissolution of the Pluronic permeabiliser from the microparticle, release some drug prior to 
being engulfed by macrophages. 
Considering the previous information on the release of lipid shell nanoparticles, it was 
expected that these would release rifampicin in a more controlled manner, in comparison to 
the nanoparticles, because of the extra barrier the drug has to overcome before release (Hasan 
et al., 2015). The introduction of the permeabiliser to the formulation successfully enhanced 
the release of the drug from the nanoparticles. There is a significant difference between the 
release profiles of permeabilised and non-permeabilised formulations. The pattern correlated 
well with the data obtained when the nanoparticles were presented as suspensions (see 
Section 2.4.5). There are some strategies that could be employed to try and improve the 
affinity between the nanoparticles and the loaded drug, including, changing the nanoparticle 
oil, adding a co-solvent or manipulating the properties of the drug through ion-pairing, these 
strategies could be employed in future work to try and optimise the system that has been 
developed in this work. 
 





The data presented in this Chapter has demonstrated the feasibility of incorporating lipid shell 
nanoparticles into respirable micronized carrier particles. The spray dried powders had a 
suitable size and shape for airway deposition. After depositing and reaching lung surface, 
according to the in vitro data generated in this Chapter the carrier is expected to dissolve 
instantly in the surface lining fluid and release the nanoparticles. The microparticles seemed 
to stabilize nanoparticles removing the capability of the loaded drug to passively release upon 
storage. The results suggested that rifampicin could be formulated into nanoparticle-based 
inhalable sustained drug delivery system for better management of pulmonary tuberculosis, 
but to support this suggestion is important to understand the interaction of lipid shell 
























Cellular bio-distribution of lipid shell 
nanoparticles in in vitro models of the airways 
















The fate of nanomedicines following inhalation is a major determinant of both their safety 
and efficacy (Nel et al., 2006). The administration of lipid shell nanoparticles to the airways 
of the lungs could potentially lead to the particles being distributed to a number of different 
biological compartments. The process of biodistribution of inhaled nanoparticles is heavily 
dependent on both mucociliary clearance and macrophageuptake. Mucociliary clearance is 
the predominant clearance mechanism for particulate matter in the tracheobronchial region 
and results in the upward movement of particles towards the larynx where they are eventually 
removed to the gastrointestinal tract (Lansley, 1993). Clearance of inhaled particulates by 
macrophages dominates in the alveolar regions but macrophage uptake also occurs in the 
ciliated airways (Zhang et al., 2011). Once internalised particles may undergo degradation 
within lysosomes or be transported by the macrophage to the lymphatic system or the 
mucociliary escalator (Oh and Swanson, 1996).  
The nanoparticle fate following administration is critical to the delivery of its encapsulated 
therapeutic agent. The drug will be released following administration so it can reach its site of 
action but the release occurs optimally when it is proximal to its site of action whether this be 
at the epithelial surface for locally acting antibiotics or mucolytics (Ungaro et al., 2012), the 
underlying smooth muscle for beta agonists (Barnes, 2002) or the systemic circulation for 
proteins such as insulin (Yang et al., 2013). In order to achieve targeted delivery it is 
important to track the nanoparticle and the drug within the lung tissue.  
The fate of the deposited nanoparticles is known to depend to a large extent on the 
physiochemical characteristics of the particles and the nature of their interaction with the 
surfactant film at the air-liquid interface. Previous work has shown particle hydrophobicity 
(Hu et al., 2007), particle size and surface charge (He et al., 2010) can all influence bio-
distribution. Lipid shell nanoparticles have been shown to have surface properties that allow 
their preferential localisation in the lung rather than clearance into the gastrointestinal tract 
(Patel et al., 2016). However, there have not been any studies to date to investigate the 
cellular bio-distribution of the lipid shell nanoparticle system. 
Lipid shell nanoparticles can be internalised by epithelial cells and translocated through the 
epithelial barrier. Non-phagocytic eukaryotic cells have also been shown to endocytose 
nanoparticles that do not possess specific targeting ligands via clathrin-coated pits and 




caveolae in a size-dependent manner (Rejman et al., 2004). Therefore, even though there are 
almost 40 different cell types in the lung, it is reasonable to consider the epithelial cells and 
the macrophages to be two very important compartments into which molecules can distribute 
post-deposition.  
Given the complex interaction of nanoparticles with the airway epithelium and the number of 
competing pathways that can occur in vivo, it is difficult to find a system capable of modelling all 
the processes in a manner that their effects on the nanoparticles fate can be elucidated. In vitro 
cell culture models offer simplicity and a high level of experimental control and they can 
therefore be powerful initial tools to assess selected nanoparticle-cell interactions. Nanoparticle 
internalization can be studied using monocultures, but the possibility of spatial interaction 
between cell types may change the observed effects. Therefore, co-cultures are preferred as 
they are thought to result in a more realistic evaluation of the potential fate of nanoparticles. 
As the pulmonary system is highly heterogeneous it is accepted that even a state-of-the-art 
co-culture system is still far from completely mimicking an in vitro tissue, but compared to 
monocultures, co-culture systems allow cell-to-cell communications to be factored into the 
particle distribution process (Klein et al., 2013). Two-dimensional (2D) culture systems have 
been used for in vitro studies though cell–cell and cell–matrix interaction are largely lost 
under these simplified conditions and therefore three-dimensional (3D) in vitro culture has 
emerged as a favoured approach to mimic the in vivo airway environment (Choe et al., 2006). 
3D models have been shown to induce cells to behave in a manner that was a step closer to 
the natural conditions (Ravi et al., 2014). Compared to 2D model, cells grown in a 3D 
model have proven to be more physiologically relevant and showed improvements in 
several studies of biological mechanisms like: cell viability, morphology, proliferation, 
differentiation, response to stimuli, gene expression and general cell function (Zhang et al., 
2016). 
It was previously demonstrated that rifampicin released efficiently from lipid shell 
nanoparticles by Pluronic permeabilisation (Chapter 2) and the lipid nanoparticles can 
penetrate through mucus rapidly (Chapter 3). The aim of the work in this Chapter was to 
investigate the cellular bio-distribution of permeabilised lipid shell nanoparticles upon 
administration to the lung airways in vitro. A three-dimensional (3D) in vitro culture system 
was developed using the Calu-3 cell line, routinely used as an in vitro model of pulmonary 
human epithelium cell line (Forbes and Ehrhardt, 2005) and the human macrophage cell line 




U937, which is widely used as model system for monocytes and macrophages. The system 
was setup using data from previous co-culture epithelial macrophage cell models which have 
been used to study bacterial infections (Bodet et al., 2006) and microparticle uptake (Rothen-
Rutishauser et al., 2005). The co-culture uptake was compared to similar experiments in 
mono-cultures in order to understand the effects of the co-culture system. The uptake of lipid 
shell nanoparticles by single cells was studied in these mono-culture systems by fluorescence. 
The co-cultures were characterized prior to use and the distribution of lipid shell 
nanoparticles in this system was investigated with confocal laser scanning microscopy 




















Calu-3 human bronchial cells and U937 human macrophage cells were obtained from ATCC 
(Rockville, USA) and reagents for cell culture and the MTT cell viability assay were 
purchased from Sigma-Aldrich (Dorset, UK). These included Dulbecco's Modified Eagle's 
Medium/Nutrient F-12 Ham‘s 50/50, fetal bovine serum (FBS), L-glutamine, non-essential 
amino acids, gentamicin, trypsin-EDTA (0.25% trypsin, 0.05% EDTA), 
penicillin/streptomycin, RPMI medium, phorbol-12-myristate-13-acetate (PMA), MTT (3-
4,5-dimethylthiazol-2-yl-2,5- diphenyltetrazolium), Hanks' Balanced Salt Solution (HBSS), 
trypan blue, dimethylformamide (DMF) and Triton X.  Phosphate buffered saline (PBS) was 
prepared from PBS tablets (Oxoid, Hampshire, UK) using ultrapure water. Sodium dodecyl 
sulphate (SDS) solution (20% w/v) was purchased from Fisher Scientific (Leicestershire, 
UK). Rabbit anti-human CD11b (EPR1344) and rabbit IgG FITC isotype control (EPR25A) 
were from Abcam (Cambridge, UK). Goat anti-rabbit dylight 488 (ab96883) and Hoechst 
33324 were from Thermo Fisher Scientific (Leicestershire, UK). Mouse IgG 1 k PE isotype 
control (P3.6.2.8.1) and CD326 antibodies (G8.8) were from eBioscience (Altrincham, UK). 
Materials for nanoparticle fabrication refer to Section 2.2. 
5.3 Methods 
5.3.1 Lipid shell nanoparticle fabrication, characterization and loading 
Lipid shell nanoparticles were manufactured and characterized as previously described in 
Section 2.3.1. Rifampicin or nile red was loaded into nanoparticles and an Amicon 
centrifugal device was used to determine the loading efficiency referred to Section 2.3.8. 
5.3.2 Calu-3 cell culture 
The Calu-3 human bronchial epithelial cell line was used between passages 30-45 and 
cultures were maintained in a humidified 5% CO2/ 95% atmospheric air incubator at 37°C. 
Cell culture medium comprised 50:50 Dulbecco's Modified Eagle's Medium/Nutrient F-12 
Ham‘s (500 mL) supplemented with 10% FBS, 1% L-glutamine (200 mM) and 0.1% 
gentamicin. Medium was exchanged every 2-3 days and cells were passaged weekly at a 1:3 
split ratio using trypsin-EDTA solution. Cell culture was carried out in a Class II safety 
cabinet. 




Cells cultured on Transwell cell supports (0.33 cm
2
, 3 µm pore size, Corning, UK) using air-
interfaced conditions were seeded at a density of 1.65×10
6
 cells/mL and were introduced into 
the apical surface of the Transwell cell culture support in 0.1 mL medium with 0.5 mL 
medium added to the basolateral chamber. The cells were incubated at 37°C, 5% CO2 for 2 
days. After this time, medium was replaced in the basolateral chamber and subsequently 
every 2 days. 
5.3.3 Transepithelial electrical resistance (TER) measurements 
Transepithelial electrical resistance (TER) measurements were made to check the cell line 
confluence on the Transwell inserts by using chopstick electrodes and an EVOM 
voltohmmeter (STX-2 and EvomG, World Precision Instruments, Stevenage, UK) on cells 
immediately upon removal from the incubator. Warmed medium (0.1 mL, 37°C) was added 
to the apical chamber before returning them to the incubator to equilibrate for a further 30 
min, and then measuring the electrical resistance. TER was calculated by subtracting the 
resistance of a cell-free culture insert and correcting for the surface area of the Transwell cell 
culture support. 
5.3.4 Permeability of Calu-3 cell layers 
To prepare the cell layers on the day of transport studies, TER was taken and the medium on 
the apical and basolateral chambers was aspirated and the cell layers washed twice with warm 
HBSS (37°C). HBSS (0.1 mL pH 7.4) was introduced to the apical chamber and (0.5 mL) to 
the basolateral chamber. The cells were returned to the incubator at 37°C for 1-2 h to 
equilibrate. The TER was measured after this equilibration period and immediately prior to 
experimentation. 
For the drug transport studies rifampicin was dissolved in warm HBSS to produce a 0.75 
mg/mL solution. Rifampicin loaded lipid shell nanoparticles were diluted in warm HBSS to 
obtain a suspension with the same concentration as the rifampicin solution. Rifampicin was 
chemically unstable and it degraded at a rate of 20 µg/h. During the time course of these 
experiments (8 hrs) the estimated loss due to chemical degradation when the drug was not 
encapsulated in the LNC was 0.3 %, this amount of degradation was not considered to have a 
significant effect on the study results. The HBSS in the apical chamber of each well was 
aspirated, and the experiment was initiated by introducing the test solution (200 µL). A 




sample of this solution (100 µL) was then immediately removed for determination of the 
initial starting concentration. Basolateral sampling (100 µL) was carried out for 8 h, with 
samples being replaced with fresh warmed HBSS (37°C, 100 µL). At the final time point, a 
100 µL sample was also removed from the apical chamber. TER was measured after the final 
sample was taken. All samples were transferred to HPLC vials and subject to HPLC assay 
Apparent permeability coefficients (Papp) were calculated by Equation 5.1, where F is flux 
(rate of change in cumulative mass transported), A is surface area of cell culture support, and 
C0 is the initial concentration in donor chamber. 
𝑃app = F  
1
AC0
      Equation 5.1 
To assess the transport of the lipid shell nanoparticles, nile red loaded nanoparticles were 
used. Previously nile red had been shown not to be released from lipid shell nanoparticles 
both with and without the addition of the lipid shell permeabiliser (Chana et al., 2015). The 
transport of the nanoparticles through cell-free Transwell culture supports was investigated 
prior to them being evaluated in the epithelial cell lines. Particle suspensions (1 mg/mL in 
HBSS pH 7.4, 100 μL) were administered to the apical compartment (t0) in triplicate, with 
0.5 mL HBSS in the basolateral chamber, in a humidified incubator at 37°C. After 8 h the 
apical and basolateral chamber contents were removed for assay. Ethanol (200 μL) was added 
to the insert to recover any residual lipid shell nanoparticles and those trapped in the pores of 
the semi-permeable membrane of the Transwell culture support. Samples from the apical and 
basolateral chambers were diluted with ethanol to dissolve the lipid shell nanoparticles and 
they were assayed. To track the nile red loaded lipid shell nanoparticles after application to 
confluent Calu-3 cell layers a similar methodology was used. Cell culture medium in the 
basolateral chamber was first removed via aspiration and replaced with fresh medium (0.5 
mL) pre-warmed to 37°C. The particle suspensions (1 mg/mL in HBSS pH 7.4, 100 μL) pre-
warmed to 37°C were administered to the apical compartment (t0) of the Transwell chambers 
and the cell layers were then returned to the incubator. After 1 h the apical chamber contents 
were homogenised using a pipette taking care not to touch the cell layer, and the liquid was 
removed for assay. Fresh HBSS (100 μL) was added to wash the cell layer and recover any 
remaining nile red in the apical compartment. Basolateral chamber contents were aspirated 
and the cell layer was solubilised by applying 10% SDS (200 μL) and incubating overnight at 
37°C. The process was repeated with replicate cell layers, with analysis at 8 time points up to 




8 h exposure. To test the permeabilised nanoparticles the lipid shell nanoparticles were mixed 
with Pluronic L62D at the ratio of 1:0.5 w/w prior to application to the cells. 
All samples from the nanoparticle transport studies were processed by mixing with an 
appropriate volume of ethanol to dissolve the nanoparticles and 200 μL aliquots were 
carefully transferred to black 96-well plates with clear flat bases suitable for fluorescence 
spectroscopy (Corning, through Sigma Aldrich, Gillingham, UK). Plates were read using an 
Infinite 200 Pro microplate reader (Tecan, Mannedorf, Switzerland) using excitation and 
emission wavelengths of 559 and 629 nm, respectively. The assay methodology was shown 
to be fit for purpose in terms of precision and limit of detection in previous work (Chana et 
al., 2015). 
5.3.5 Macrophage U937 cell culture 
The macrophage U937 cell line was used up to passage 24. The cells were grown in 162 cm
2
 
cell culture flasks using cell culture medium (RPMI supplemented with 10% v/v FBS, 1% v/v 
L- glutamine and 1% penicillin/streptomycin) within a humidified environment supplied with 
5% CO2 at 37°C. The cell culture medium was changed twice a week. Cells were subcultured 
when 90-100% confluency was reached at a split ration of 1:5. Differentiation of the U937 
cells were achieved by incubating them in 8 nM PMA for 48 h in a 96-well plate, then adding 
fresh PMA medium and for culturing another 48 h, then finally adding fresh medium and 
culturing for 24 h to finish the differentiation. 
5.3.6 Metabolic activity test (MTT) 
Biocompatibility with the Calu-3 cell line had already been established in previous work 
(Chana et al., 2015). Therefore, only the U937 cell viability following exposure to the 
nanoparticles and surfactant used to permeabilise the particles was assessed using the MTT 
assay according to the methods of Grenhaet al.(Grenha et al., 2007). The U937 cells were 
seeded at a series of densities in 96-well plates and cultured for 24 h in cell culture medium 
(100 μL) to evaluate the optimum seeding density for the experiments. All test samples were 
prepared in pre-warmed cell culture medium prior to administration to the cells. Cells were 
either exposed to the test condition or control solutions (cell culture medium was the negative 
control, 1% Triton X-100 solution was the positive control) for 1 or 8 h. After this time all 
medium was removed from the wells, it was replaced with fresh cell culture medium (200 




μL), the MTT solution was added (5 mg/mL in PBS pH 7.4, 50 μL) and the plates were 
placed in an incubator at 37°C. After 4 h the fluid was removed from all the wells and 
replaced with SDS solution (10% w/v in 50:50 DMF: water, 100 μL) to solubilise any 
formazan crystals generated. Absorbance from each well was measured 16 h later using a UV 
spectrophotometer (SpectraMax 190, Molecular Devices, USA) at 570 nm, and corrected for 
background absorbance at 650 nm. For each test well the absorbance of the corresponding 
cell free well was subtracted and the residual absorbance was used to determine the relative 
cell viability (%) by comparing to the negative and positive controls, as follows Equation 5.2: 
Viability  % =
Abstest −Abspositive
Absnegative −Abspositive
 Equation 5.2 
Where Abstest is the absorbance corresponding to treated cell, Abspositive is the absorbance 
obtained for the positive control (Triton X-100 treated cells), Absnegative is the absorbance for 
the negative control (untreated cells). 
5.3.7 Macrophage U937 cell uptake 
Cells were differentiated in 96-well plates as described above at the density of 3.3 × 10
5
 
cells/mL. On day 6, the cell culture medium was removed and replenished with 100 μL fresh 
cell culture medium containing nile red loaded nanoparticles (1 mg/mL in HBSS pH 7.4) and 
nanoparticles mixed the permeabiliser Pluronic L62D with a ratio of 1:0.5 w/w. Negative 
controls comprised of cells treated with 100 μL fresh cell culture medium. Plates were 
incubated for different times over 8 h, after which the medium was removed, cells were 
washed three times with 1 mL PBS (37 °C) per well to remove excess particles which were 
not strongly associated to the cells and the cell layer was solubilised by applying 10% SDS 
(200 μL) and leaving overnight in an incubator. The number of nanoparticles associated with 
the cell monolayer was calculated by quantifying the encapsulated nile red.  
5.3.8 Co-culture model development 
Calu-3 cells cultured on Transwell cell culture supports were seeded at a density of 1.65 × 
10
6 
cells/mL and were introduced into the apical surface of the Transwell cell culture support. 
Experiments were conducted between days 9 to 13. U937 cells were differentiated in the 
flask as previously described and added on the apical surface of the epithelial monolayer with 
a seeding density of 3.3 × 10
5
 cells/mL based on the evaluation of their in vivo distributions 
(Stone et al., 1992). Cells were allowed to attach for 4 h. Upon attachment the medium was 




removed from the upper compartment and the co-culture was cultivated for 24 h prior to 
exposure. 
Transepithelial electrical resistance (TER) was measured with the Millicell-ERS system 
(MERS 000 01; Millipore AG, Volketswil, Switzerland) as previously described. In addition, 
the barrier of the epithelial cells in the presence of the U937 cells was determined using a 
solution of sodium fluorescein (10 μg/mL in HBSS pH 7.4) which added into the apical 
compartment of the Transwell holding the co-culture system. The cultures were then 
incubated for 240 min at 37 °C. Empty inserts without cells served as a control. Basolateral 
sampling was carried out for 4 h, with samples being replaces with fresh warmed HBSS. All 
samples were transferred to a black 96-well plate. Fluorescence was measured via excitation 
and emission wavelengths of 495 and 520 nm by using a fluorometer (Cytoflour, Series 
40000, Foster City, CA, USA) and the permeability was calculated using equation 5.1. 
To verify the localisation of the cells in the 3D culture the cells were washed twice in PBS 
and fixed for 15 min at room temperature in 4% formaldehyde in PBS solution. Fixed cells 
were incubated for 30 min with 10% bovine serum albumin (BSA) in PBS to block 
unspecific binding. After blocking, rabbit anti-human CD11b and goat anti-rabbit daylight 
488 (green) were diluted in PBS  pH 7.4 (1:1000 v/v) and applied to the system to identify 
the differentiated macrophages cells (Klein et al., 2013). The cell nuclei were stained with 
Hoechst 33324 (blue) and the fluroscence images were taken with a Zeiss LSM 510 with an 
inverted Zeiss microscope (Zeiss, Germany). 
5.3.9 Bio-distribution of lipid shell nanoparticles in co-culture model 
Two methods were used to analyse the bio-distribution of lipid shell nanoparticles in the co-
culture. First, the co-culture model was incubated for 1 h with 50 nm lipid shell nanoparticles 
suspended in HBSS medium. Then the cells were fixed and stained with Hoechst 33324 and 
anti-CD11b-antibody and analysed via CLSM imaging as described above. As with only 
imaging it has previously proven difficult quantify the particle uptake in cells, cell flow 
cytometry was used to quantify the cell uptake of the lipid shell nanoparticles in the co-
culture. To facilitate the flow cytometry measurements after the cells had been exposed to the 
nanoparticle suspensions for 1 and 4 hour the apical solutions were removed and epithelial 
and macrophage cells were incubated with a 1:100 dilution of human CD326 and human 
CD11b antibodies, respectively. Two cell types were distinguished by specifically binding to 




fluorescence labelled antibody. For the isotypic control rabbit IgG FITC and mouse IgG 1 k 
PE were used. After 1 h incubation at 37°C, samples were centrifuged to remove excess dye 
and subjected to flow cytometry (Epics XL; Beckman Coulter). Basically an unstained 
sample and appropriate isotype controls were included in each analysis to address 
autofluorescence and non-specific binding. Raw data were analysed using CXP software 
(Beckman Coulter). Internalization % was used to indicate the amount of cells associated 
with the nanoparticles.  
5.3.10 Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. The normality (Sapiro-Wilk) 
and homogeneity of variances (Levene‘s test) of the data were assessed prior to statistical 
analysis. The data were analysed statistically using T-test or Mann-Whitney test. Differences 


















5.4.1 Nanoparticle characterization 
The fabricated lipid shell nanoparticles had a mean diameter of ca. 50 nm with neutral surface 
charge (Table 5.1). Rifampicin was loaded into the lipid shell nanoparticles with a loading 
efficiency of 41.0 ± 11.4%.  
Table 5.1: Size, polydispersity, zeta potential and solid content for unloaded and rifampicin-
loaded lipid shell nanoparticles (LNP). Data represent mean ± standard deviation (n = 3). 






LNPblank 52 ± 2 0.07 ± 0.02 -3.46 ± 0.60 146.7 ± 12.2 
LNPrifampicin 50 ± 3 0.07 ± 0.02 -2.07 ± 0.62 163.3 ± 7.0 
5.4.2 Calu-3 cell culture 
By day 4, Calu-3 monoculture cell layers grown using air- interfaced conditions on Transwell 
inserts were confluent (Figure 5.1). They produced an effective barrier to the hydrostatically 
driven passage of the cell culture medium from the basolateral to apical well. The TER of cell 
layers increased above baseline values after 2-3 days in culture and reached a plateau of 
approximately 300 Ω cm2 at around day 5 post-seeding which is in agree with previous study 
(Grainger et al., 2006). The maximum TER values occurred between days 11 and 13 and this 
was therefore selected as the timeframe in which to conduct the transport studies. 
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Figure 5.1: Transepithelial electrical resistance of Calu-3 cells cultured on 0.33 cm
2 
cell 
culture supports as a function of time from three separate experiments. Data represent mean ± 
standard deviation (n=18). 
5.4.3 Rifampicin transport across the Calu-3 cell lines 
The rifampicin permeability, irrespective of the type of administration system, was similar for 
the first 7 hours of the transport study (Figure 5.2). The time points between 2 h to 8 h were 
used to calculate the permeability as the initial time period looked like lag time. After the 8 
hour time point the permeation of rifampicin through the cells when administered as a 
solution appeared to deplete, but the nanoparticles provided a reservoir that prolonged the 
drug release (p<0.05). There was no significant difference between the drug release from the 
permeabilised and non-permeabilised nanoparticles throughout the experiment (p>0.05). 





Figure 5.2: (A) Transport profiles and (B) permeability of rifampicin (RIF), non-
permeabilised lipid shell nanoparticles (LNP) and rifampicin-loaded permeabilised lipid shell 
nanoparticles (PLNP) and across Calu-3 cell layers in mono-culture. Data represent mean ± 






















































5.4.4 Lipid shell nanoparticle transport across Calu-3 cell lines 
Following the application of nile red loaded lipid shell nanoparticles to cell-free Transwell 
culture supports for 8 h at 37°C, no penetration to the basolateral chamber was detected. 
After this period 82.3 ± 7.6% of the applied nile red was recovered from the apical 
compartment and 0.5 ± 0.4% was extracted from the culture support using ethanol. This is in 
line with previous reports of negligible nanoparticle penetration through Transwell using 
similar sized fluorescent polystyrene nanoparticles (Geys et al., 2006). On this basis the 
basolateral chamber was not sampled in the subsequent particle localisation experiments 
conducted with epithelial cell layers and a 90% recovery was set as an acceptable standard by 
which to gauge the subsequent experiments with the cells. When the transport of the nile red-
loaded lipid nanoparticle suspensions was assessed over 8 h at 37°C less than 10% of the 
applied particles moved into the cells (Figure 5.3). There was a significant increase (p<0.05) 
in cell associated nile red from 1% at 1 h to 3% at 8 h when the nanoparticles were added to 
the cell without the permeabiliser. Adding the Pluronic to the nanoparticles at the airway 
epithelial interface resulted in a significantly higher percentage of cell associated nile red 
being observed compared toan equivalent dose of controlled nanoparticles at all time points 
(p<0.05). 
































Figure 5.3: Amount of permeabilised and non-permeabilised lipid shell nanoparticles 
associated with Calu-3 cell layers over 8 h. Data represent the mean of three experiments. 
Data represent mean ± standard deviation (n=12). 
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5.4.5 Macrophage U937 cell viability 
The macrophage U937 cell uptake experiments could not be conducted in Transwell plate in 
order to make it comparable to the uptake by Calu-3 cell because whilst the macrophage cells 
reside on the apical surface of the Transwell support membrane they do not form tight 
junctions and hence if a drug solution was applied to the U937 cells on the surface of the 
Transwell support the drug would rapidly pass through the membrane and only co-reside with 
the cells for a very short period of time. This does not represent in vivo conditions. As a 
consequence a 96-well plate was used to assess the lipid shell nanoparticle uptake in the 
U937 cell line. The cell concentration within the range at which MTT conversion was 
proportional to the number of viable cells was used to establish the optimum seeding density 
(3.3 × 10
5
 cells/mL) for the experiments (Figure 5.4). The cells were found to be viable after 




























Figure 5.4: U937 seeding density in 96-well plate against absorbance using MTT assay. Data 
represent mean ± standard deviation (n=6). 
 





Figure 5.5 A: Relationship between applied lipid shell nanoparticles concentration and U937 
cell viability (%) after 8 h exposure. B: Relationship between applied Pluronic L62D 
surfactant concentration and U937 cell viability (%) as in the presence of a fixed 
concentration of nanoparticles (1 mg/mL). Data represent mean ± standard deviation (n=6). 
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5.4.6 Lipid shell nanoparticle uptake by macrophage U937 cells 
Association of lipid shell nanoparticleswith cells was found within 1 h, which was followed 
by a gradual increase during subsequent time points (Figure 5.6). There was a small but 
significantly different uptake of the non-permeabilised and permeabilised nanoparticles over 
60 to 90 min time frame (p<0.05). The highest uptake of the permeabilised systems appeared 
to be within 2 h, which could have been related to the size growth. After the 2 h time point 
the system seemed to reach the equilibrium. 































Figure 5.6: Amount of permeabilised and non-permeabilised lipid nanoparticles associated 
with U937 cell layers over 8 h. Data represent the mean of three experiments. Data represent 
mean ± standard deviation (n=12). 
5.4.7 Co-culture development and characterization 
At day 11, the cell layer TER of the Calu-3 cells reached a plateau of around 300 Ω cm2. 
There was no difference between the TER of the Calu-3 monoculture and co-cultured 
systems (Figure 5.7). The penetration of Flu-Na through the bilayer showed no statistically 
significant differences between monolayer and co-culture systems (Figure 5.8). The epithelial 
cell nuclei, stained with blue Hoechst 33324 and the macrophage-like cells, which were 
counterstained with a green anti-CD11b-antibody, were both clearly visible in the images of 
the co-culture (Figure 5.9). Cross-section views of the image demonstrated that Calu-3 cells 
seeded on the bottom side of the insert covered the membrane and a small proportion of U937 
cells were attached to the surface of epithelial cells (Figure 5.10). 
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Figure 5.7: TER of monolayer and co-culture during experiments. Data represent the mean 
of three experiments. Data represent mean ± standard deviation (n=4). 
 


















Figure 5.8: Permeability of sodium fluorescein through monolayer and co-culture. Data 
represent the mean of three experiments. Data represent mean ± standard deviation (n=4). 
 
 





Figure 5.9: A: The staining of two types of cells in the co-culture system captured by 
inverted confocal. U937 cells are stained with anti-CD11b-antibody (green); nuclei are 
counterstained with Hoechst 33324 (blue). B: 3D reconstruction of the co-culture system 
based on the results of the z-stack image of series to analyse the distribution of U937 cells 
and Calu-3 cells in the co-culture present in the apical compartment of the insert. 
 
Figure 5.10: Respective side views of the distribution of Calu-3 and U937 cells on sides of a 











5.4.8 Bio-distribution of lipid shell nanoparticles 
Images of the co-cultured system with the nanoparticles showed there are two ways that 
particles associated with the cells (inside the cells or attached to the cell surface) (Figure 
5.11A). Some particles did not interact with the cells and seemed to aggregate to form 
clusters in the model. It seemed that there was no difference in the cell association between 




Figure 5.11: The bio-distribution of (A) lipid shell nanoparticles and (B) permeabilised lipid 
shell nanoparticles in the co-culture present in the apical compartment of the system. Three 
individual channels displayed at the bottom. Particles are found in (small triangle) or attached 
to (arrow) or detached to (big triangle) cells. Scale bar represents 20 µm. 
To compliment the confocal images the distribution of nanoparticles in the co-culture model 
was also quantified by flow cytometry. From the quantitative interpretation of the flow 
cytometry data it was observed that the lipid shell nanoparticles preferentially distributed in 
macrophage cells rather than epithelial cells in the co-culture system, especially at the 1 h 
time point. The epithelial cell association with the nanoparticles increased during 4 h (Figure 
A B 




5.12A). The permeabilisation significantly enhanced the epithelial cell association within first 
1 h (p<0.05) compared to controlled system, but the distribution profile of the permeabilised 
and non-permeabilised particles were similar (Figure 5.12B). 
 
Figure 5.12: Amount of (A) epithelial cell and (B) macrophage cell associated with lipid 
shell nanoparticles in the co-culture model analysed by flow cytometry. Data represent the 









































































Knowledge of the cellular distribution is important when developing nanomedicines for 
pulmonary use because it can help evaluate the potential for long term toxicity issues (Nel et 
al., 2006) and it can inform strategies to load the carrier systems with the optimal therapeutic 
agents (Azarmi et al., 2008). In this work the cellular distribution of lipid shell nanoparticles 
was studied using rifampicin as a model drug. Drug distribution into both the epithelial cells 
and macrophages is thought to be beneficial in the treatment of pulmonary tuberculosis with 
rifampicin. As a consequence the distribution into both cell types was characterised. 
The permeation rate of rifampicin when applied to Calu-3 airway epithelial cells as a solution 
was similar to values previously reported in literature (Tewes et al., 2008). The increase in 
permeation rate when rifampicin was incorporated into nanoparticles also accorded with the 
work of Roger et al. (2009) who found that paclitaxel-loaded lipid nanocarriers improved 
permeability of paclitaxel across intestinal epithelium (Roger et al., 2009). There have been 
several different reasons cited why lipid shell nanoparticles can improve the permeation of a 
drug across a cell layer (Beloqui et al., 2013). Usually the mechanism of action is specific to 
the drug. In this case rifampicin is known to be chemically unstable in water and it was 
thought that the most likely reason for the increase in the Calu-3 permeation was the 
protection of the drug inside the nanoparticles, which acted as a drug reservoir to release the 
drug across the cells. 
In the Calu-3 monoculture model, lipid shell nanoparticles were found to persist at the 
epithelial surface over an 8 h period, less than 10% of the applied particles were associated 
with cells. The transport data suggested that the epithelial barrier remained resilient over the 
time course of the experiment when both permeabilised nanoparticle and non-permeabilised 
nanoparticle system were applied to the Calu-3 cells. This suggested that the non-ionic 
surfactant trigger had no deleterious effects on the cells. The data from other studies of 
uptake suggest that airway cells line have a limited capacity to take up nanoparticles. For 
example, 12% internalization by lung epithelial cells was observed over 8 h exposure to 
poly(lactide-co-glycolide) (PLGA) NPs (Mura et al., 2011) and 5% of fluorescently-labelled 
nanoparticles by airway epithelial cells (Vllasaliu et al., 2012). In the majority of studies that 
have reported upon the nanoparticle kinetics by airways cells it seems that the process 
proceeds until the cells reach a capacity, which is often < 10% of the applied dose. The 




remaining 90% of the carriers reside on the cell surface and are available for macrophage 
engulfment. 
Following lipid shell nanoparticle exposure to the Pluronic permeabiliser it appeared that 
epithelial cell uptake increased with approximately double the cell association of that 
observed for the equivalent controlled nanoparticle dose. This may be a result of the larger 
nanoparticles being more efficiently endocytosed by caveolae-mediated and clathrin 
dependent processes (Rejman et al., 2004). An alternative explanation is that the Pluronic 
molecules were acting as a cellular uptake enhancer. Pluronic block copolymers can 
incorporate into cell membranes (Batrakova and Kabanov, 2008), and this has previously 
been shown to be capable of enhancing cellular internalization in vitro (Park et al., 2013). 
Pluronic L62D used in this study has a small size of PEO block. It has been shown that the 
nanocarriers with shorter Pluronic PEO blocks were internalized by HeLa cells at a higher 
level than the carriers with larger PEO block length (Arranja et al., 2016). Therefore, it is 
likely the Pluronic had some effect on cell uptake, but it is difficult to say exactly how much 
of the overall enhancement was related to this effect. 
Macrophages are one of the main hosts of pathogens in chronic infectious diseases, they 
represent a therapeutic target for intracellular delivery of anti-infective agents and thus there 
have been a number of studies that have monitored nanoparticle uptake (Pei et al., 2015). The 
data generated by these studies suggest that particle physicochemical properties such as size, 
surface charge and shape influence macrophage uptake of particles (Chou et al., 2011). The 
neutral non-distended 50 nm LNPs were associated to low extent (2-4%) by macrophage cells 
due to their small size (Chono et al., 2006). The LNPs contained a hydrophilic neutral PEG 
coating which is also thought to reduce recognition by phagocytic cells (Fromen et al., 2015; 
Walkey et al., 2012). When the size distension process was complete the particles displayed a 
size of 200 nm. In a previous study when LNPs were incubated at a high concentration with 
macrophages, an increased uptake rate was observed with increasing particle size 
(Vonarbourg et al., 2006). Although the distension process could increase the ability of 
macrophages to recognise these particles they are still quite small for macrophages to 
recognise and this may explain the only small change of particle association (2%) when the 
distending particles were applied to the cells (Hirsjärvi et al., 2013). However another study 
found that the surfactants of the lipid nanoparticles instead of size had an influence on 
macrophage uptake (Schöler et al., 2001). Interestingly the initial uptake of distensible 




particles (50-100 nm) reached the peak within 2 h and a slight decrease was observed. The 
enhanced association was supported by previous work assessing the same particle uptake by 
RAW264.7 cells (Vonarbourg et al., 2006). The drop of uptake after 2 h suggests an optimal 
LNP size for cell internalisation. For example the uptake of 14, 50 and 74 nm gold 
nanoparticles was investigated in HeLa cells (Chithrani et al., 2006). It was found that the 
kinetics of uptake varied with the different-sized nanoparticles with 50 nm particles being the 
most efficient in their uptake, indicating that there might be an optimal size for efficient 
nanomaterial uptake into cells. On the other hand, the changed particle properties due to 
distension could also affect the uptake. Particle shape also plays a role in phagocytosis 
(Champion and Mitragotri, 2006). Upon distension, the Pluronic surfactant permeabilised the 
shell of the particle and it swelled by 4 times compared to original size. The shape of particles 
might change which influences phagocytosis by macrophages through varied cell attachment 
and internalization (Sharma et al., 2010). The overall process of phagocytosis is a result of 
the complex interplay between shape and size. The mechanism for shape and particle 
dependence of phagocytosis of LNPs requires further examination. 
The distribution of some nanoparticlesat the surface of the cells and some within the cells 
agrees with previous work that evaluated nanomaterial uptake using a three-dimensional 
airway cellular model (Rothen-Rutishauser et al., 2005). Nanomaterial uptake begins with an 
initial adhesion of the materials to the cell via interactions with the lipids, proteins, and other 
components of the cell membrane. This is followed by the activation of an energy-dependent 
uptake mechanism (Chithrani et al., 2006), which allows the nanomaterials to be internalized 
into the cell. The initial nanomaterial adhesion to the cell membranehas been shown to be 
critical to uptake (Chithrani and Chan, 2007; Lesniak et al., 2013) and therefore the data in 
this study, which showed LNPs on the cell surface as well as inside the cells was expected. 
 
As it was difficult to quantitatively visualize nanoparticle bio-distribution in the co-culture 
model using fluorescence microscopy, flow cytometry was used to quantify the particles. The 
uptake ratioof the nanoparticles by Calu-3 cells compared to macrophage cell in the 
monoculture system was approximately equivalent, but in the co-culture system more of the 
macrophage cells contained the particles compared to the Calu-3 cell. The permeabilised 
particles showed a different trend, as in the monoculture system the uptake was more 
extensive in the Calu-3 cells whereas in the co-culture system the uptake was even across 
both cell types. These interesting variations in bio-distribution profile could be due to the 




cell-cell interactions in the co-culture model. Cell–cell contact in the pulmonary tract has 
previously been reported to play an important role in the mechanisms of particle cellular 
uptake (Blank et al., 2007). In our model, the interactions between macrophages and 
epithelial cells may therefore modulate responses to particle exposure. It has been proved 
that  interaction of alveolar macrophages and airway epithelial cells following exposure to 
particulate matter produces mediators that stimulated the bone marrow (Fujii et al., 2002). 
Granulocyte macrophage colony stimulating factor (GM-CSF) expression was more rapidly 
induced in co-cultured cells compared with mono layers. Enhanced level of GM-CSF has also 
been observed in human alveolar macrophages and bronchial epithelial cells when exposed to 
ambient particles (Ishii et al., 2005). GM-CSF is an important factor determining the 
differentiation of macrophages in vivo and contributes to the macrophage activation (Gordon, 
2003). This could be the reason more nanoparticles were associated with macrophages in co-
cultured system compared to monolayers. Cell-cell communication may also have reduced 
the effect of permeabiliser on particle uptake in co-culture system. The uptake of hematite 
particles into human epithelial (A549) and macrophage (THP-1) cells was studied and results 
obtained from monoculture and co-culture was compared (Wottrich et al., 2004). The co-
culture showed an increased sensitivity to particles concerning the cytokine release in 
comparison to the monocultures of each cell type. Similarly Muller et al. (2009) revealed an 
altered response of IL-8 release following particle exposure on a triple cell co-culture of 
A549 with macrophages and dendritic cells compared to the respective monocultures (Müller 
et al., 2009). The release of inflammatory markers could have impact on cytotoxicity 
especially when exposed to the permeabiliser for long period time. Thus co-culture model 
was better at simulating the real situation in the lung than monocultures as it reflects a 













Using the co-culture and monoculture systems in this work it has shown that the kinetics of 
particle uptake were rapid and the particles retained in both the epithelial cell line 
compartments and the macrophage compartments, which enables the naosystem situable for 
controlled pulmonary drug delivery. Co-culture model provided a better tool to investigate 
the nanoparticle distribution at the cellular level compared to monoculture. Thus when cell 
distribution occurs rapidly with the lipid shell nanoparticle system in vitro cell culture is the 
only reliable method of tracking the kinetics of particle uptake. This relatively even 































The lungs provide an attractive, non-invasive route for both local and systemic drug delivery. 
The high local concentrations of active agents that can be achieved rapidly following 
inhalation make it the mainstay of routine therapy for respiratory disorders such as asthma 
and COPD (Mansour et al., 2009). However, selecting this route for drug therapy can result 
in a short duration of clinical effect and thus a medicinal product with cumbersome multiple 
daily dosing regimens (Sung et al., 2007). This is in part attributable to the swift removal of 
aerosolised dosage forms from the respiratory tract, by rapid absorption of solubilised drugs 
or the indiscriminate action of innate defensive clearance mechanisms on particulate matter. 
These clearance pathways perform a vital function in removing the array of potentially 
noxious airborne particulates that penetrate into the lungs and should not themselves be 
disrupted. Therefore, when intending to design inhaled formulations with the objective of 
extending the biopharmaceutical profile of drugs the formulations must incorporate a specific 
strategy to avoid local clearance.  
The use of nanoparticles as drug delivery vectors is one strategy that may be capable of 
increasing the residence time of drugs in the lungs. Nanoparticles could serve as a local 
reservoir to control the delivery of actives to the epithelial surface, sub-epithelial structures or 
the wider body via the circulation. The small size of nanoparticles is thought to confer the 
ability to reduce clearance by mucociliary and macrophage pathways (Geiser et al., 2008; 
Maisel et al., 2015; Moller et al., 2008). However, there are a number of technical challenges 
when developing nanoparticles to act as local drug reservoirs for pulmonary drug delivery. 
For example, a reproducible manufacturing technique, employing biocompatible excipients 
and generating high process yields for large scale pharmaceutical production (Petros and 
DeSimone, 2010; Riehemann et al., 2009). Drug loading and retention within the 
nanoparticles during storage must be optimised, but efficient release in situ must be realised 
to ensure adequate bioavailability (Sun et al., 2012). The simplest presentation of 
nanoparticles remains a nanosuspension, most often using water as the continuous phase. 
Such a system requires the active agent to have a high affinity to the carrier to prevent 
premature release, i.e. prior to being administered, but the drug must alsobe liberated at the 
site of action in order to be bioavailable and exert its pharmacological effects. The use of a 
nanoparticle permeabiliser can facilitate the switching of nanoparticles that is optimised for 
drug retention to a state that is optimised for drug release state. Nanoparticle permeabilisers 
could provide a practical approach to meeting the conflicting demands of good payload 
retention prior to dosing yet efficient in situ release following administration. If a co-




administered nanoparticle-permeabiliser system could be developed and the fate, safety and 
efficacy of nano-carriers could be determined then a nanoparticle may be able to generate a 
highly effective inhaled medicine. 
The aim of the work presented in this thesis was to understand and explore the feasibility of 
developing an active drug release nanoparticle system for controlled pulmonary drug delivery. 
A simple, scaleable fabrication technique was employed to generate lipid shell nanoparticles 
and polymer shell nanoparticles. These two formulations were selected based on their 
biocompatible components, high process yields and desirable resultant particle characteristics. 
Active drug release from nanoparticles was achieved using a surfactant (lipid nanoparticles) 
and a pH-induced (polymer nanoparticles) shell permeabilisation. Upon administration it was 
envisaged that the engineered nanoparticles would be released from microparticles, they 
would translocate through mucus rapidly and they would be retained at the mucus-epithelium 
interface.  
In this thesis the lipid shell nanoparticles were produced using a previously reported emulsion 
phase inversion-precipitation fabrication technique (Heurtault et al., 2002) and polymer shell 
nanoparticles were produced using a nanoprecipitation method (Madlova et al., 2009) 
(Chapter 2). Lipid shell nanoparticles had previously been shown to be biocompatible upon 
the deposition onto lung airway cells (Jones et al., 2014) and the PVA shell nanoparticles 
were found to retain their original size (ca. 220 nm), maintain a neutral surface charge in cell 
culture medium for 24 h and were not acutely toxic to respiratory cells in vitro (Madlova et 
al., 2009). Rifampicin was loaded into the nanoparticles as a model drug. The two 
formulation processes were capable of reproducibly generating nanoparticles with an average 
size of 50 and 250 nm respectively, low polydispersity, neutral surface and high loading 
efficiency (40% for lipid shell nanoparticles and 30% for polymer shell nanoparticles). The 
nanosuspensions generated in this work possessed a high solid content making them 
amenable for pharmaceutical use without the need for further ‗concentrating‘ steps during 
large scale processing. Nanoparticle size was characterised using water in Chapter 2 just to 
investigate the properties, while this was carried out by different medium in the following 
work in a more speficid context. Data showed that medium had no effect on particle 
characterisation. 
The materials used to generate the nanoparticles in this work were anticipated to facilitate the 
drug release in a controlled manner. Promisingly, the drug release profiles from two 




nanoparticle formulations were enhanced by the application of the two different nanoparticle 
shell permeabilisers. This was in agreement with previous work which has demonstrated that 
lipid shell nanoparticles were able to release drug following exposure to Pluronic surfactant 
(Chana et al., 2015). Passive release was observed from both particle formulations which was 
a disadvantage of the systems.  
 
Figure 6.1: Permeabilisation mechanism for lipid shell and polymer shell nanoparticles and 
the corresponding release profiles.  
Mucus is a complex viscoelastic, adhesive hydrogel that coversthe epithelial surfaces in the 
lungs. It is considered as a critical barrier that must be overcome to achieve effective 
controlled drug release (Cone, 2009). Trapped particles are typically removed from the 
mucosal tissue by mucuciliary clearance or macrophage engulfment, thereby strongly 
limiting the duration of sustained drug delivery to the lungs. Therefore it is important to 
understand the nanoparticle-mucus interaction (Lai et al., 2009). In this work a vertical 
translocation model was established to assess the penetration of fabricated nanoparticle 
through the mucus barrier (Chapter 3). To study how dynamic particles interact with mucus 
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method accordingly to the studies reviewed and discussed for this work (Chapter 3). Vertical 
particle transport across mucus is most relevant to the pharmaceutical context of drug 
delivery to the lungs as it best represents the mucus barrier in vivo. The data generated by this 
system indicated that the nanoparticle transport through the mucus barrier was influenced by 
both particle size, surfacecharge and hydrophobicity, which agreed with previous studies 
(Norris and Sinko, 1997; Svensson et al., 2008). Data generated from vertical model have 
been found to have similar trend to values obtained by nanoparticle tracking analysis. The 
diffusion model has an advantage over particle tracking as a small volume of sample is 
needed, which facilitated the performance of the study using a human CF cell-line derived 
mucus sample. Interestingly, the rank order of particle translocation rate in the mucus 
penetration assay was different to that obtained from the particle tracking system. This could 
be due to different measuring mechanisms as the particle tracking technique measured only 
lateral movement while the Transwell system permeation was a consequence of three-
dimensional movement.  
Permeabilised lipid shell nanoparticles were found to be capable of penetrating CF mucus 
much more rapidly compared to similar sized polystyrene nanoparticles (Figure 6.2). Lipid 
shell nanoparticles had higher diffusion rates probably because ofthe reduced hydrophobic 
adhesive interactions with mucin fibres. Lipid shell nanoparticles comprise triglycerides 
dispersed in a saline solution, stabilised at the droplet interface with phospholipids and a PEG 
based surfactant (Heurtault et al., 2002). This structure matches previous strategy for mucus 
penetrating particles design that nanoparticles coated with low molecular weight 
poly(ethylene glycol) (PEG) possess hydrophilic and near neutrally-charged surfaces that 
minimized mucoadhesion by reducing hydrophobic or electrostatic interactions (Wang et al., 
2008b). It was hypothesized that permeabilised particles would have faster diffusion rate than 
non-permeabilised particles due to the permeabilisation generating 200 nm size particles that 
were shown to have the highest diffusion rate. However, no effect of the permeabiliser on the 
diffusion was observed. This was probably because the permeabilisation and subsequent 
particle swelling process occurred over 8 h and rapid mucus penetration was observed within 
initial 1 h. The PVA nanoparticle diffusion in PGM was severely retarded compared to lipid 
shell nanoparticles and PS NPs. This suggests that incorporating PVA in the particle 
formulation process may lead to the formation of mucoadhesive particles which had strong 
interactions with mucins through hydrogen bonding and hydrophobic interactions (Yang et al., 
2014). Thus it is believed that PVA could inhibit particle diffusion in mucus. Although PVA 




nanoparticles might be not a good carrier to meet the project criteria, the finding that PVA 
particles are strongly immobilized in PGM provides implications for developing new mucus 
penetrating particles. The rapid transport of dynamic lipid shell nanoparticle coupled with 
prior knowledge that they were slow to move into epithelial cells offers a potential for the 
development of controlled release formulations to provide prolonged residence times of the 
therapeutic agents within the respiratory tract. Thus lipid shell nanoparticles were selected for 
use in all the subsequent studies in the thesis.  
 
 
Figure 6.2: Interactions between permeabilised lipid nanoparticles and mucoadhesive PVA 
nanoparticles with mucus.  
The feasibility of loading lipid shell nanoparticles into microparticle systems was assessed in 
Chapter 4. In this Chapter it was shown that the incorporation of lipid nanoparticles in a dry 
powder formulation increased the shelf life of the formulation during storage and minimized 
drug diffusion out of the nanoparticles before administration (release rate k = 0.071 mg/h for 
nanoparticles and 0.003 mg/h for microparticles). Spray drying was shown to be a suitable 
method to load lipid shell nanoparticles into lactose microparticles. The microspheres 
produced in this work had a diameter of 2 to 5 µm which was considered to be suitable for 
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delivery to the lower airways. Similar size particles havepreviously been reported for spray 
dried lipid nanocapsules with lactose (Freitas and Müller, 1998). Lipid shell nanoparticles 
were easily recovered from microparticles. The permeabiliser, nebulized into powder together 
with the nanoparticles, still functioned once mixed in the medium. This suggests that it is 
possible to spray dry both drug and permeabiliser simultaneously using the established 
method. From the results of this study it could be hypothesised that after reaching the lung, 
lactose will dissolve in the lung lining fluid, releasing nanoparticles which can be 
permeabilised at the same time.  
The introduction of the permeabiliser to the formulation successfully enhanced the release of 
the drug from the nanoparticles as shown in Figure 6.3. There was a significant difference 
between the release profiles of permeabilised and non-permeabilised formulations. The 
release profiles correlated well with the data obtained when the nanoparticles were presented 
as suspensions (Chapter 2). Concerning the permeabilisation, the differences in release rates 
of microparticles over 30 days were much larger than those from nanosuspensions (Figure 
6.3), proving that the release from the encapsulated carriers was much more controlled and 
the active drug release system was more effective in the microparticle formulation than in the 
nanosuspension due to the reduced passive release experienced by the latter. These results 
indicated the potential of rifampicin-loaded microparticle formulations delivered directly to 
the lungs for the treatment of tuberculosis. Although the loading of rifampicin is low 
compared to the usual oral dosage, considering the enhanced bioavailability of inhaled drug it 
would still be possible to deliver effective concentrations of rifampicin-loaded lipid shell 
nanoparticles to the lungs to increase local drug levels and reduce the dosing frequency for 
treatment of pulmonary tuberculosis. 





Figure 6.3: Imaging of lipid nanoparticles and lipid nanoparticles loaded-microparticles. 
Release profiles of rifampicn from lipid nanoparticles and lipid nanoparticles loaded- 
microparticle under permeabilised and non permeabilised conditions after 1 and 30 days.  
Upon deposition on the lung lining surface, lipid nanoparticles can be released from 
microparticles and penetrate through the mucus rapidly. It is hypothesised that lipid 
nanoparticles can reside at the mucus-epithelium interface where upon triggered release can 
occur. Understanding the fate of nanomedicines in the lungs is important not only due to 
related toxicity, but also because the fate of the carrier and therapeutic action are closely 
linked. For instance, the rapid uptake of particles by alveolar macrophages can be a way of 
targeting anti-tuberculosis drugs to this cell type. Compared to an in vivo approach, in vitro 
methods offer the simplicity, robustness and better control in experiments and their data 
acquisition. In addition, considering the potential of the nanoparticles to rapidly distribute 
into cells the in vitro cell culture was considered to be the most reliable method of tracking 
the kinetics of particle uptake of the cellular distribution in the airways of the lung. An in 
vitro co-culture model was selected for these studies as it was thought to best mimic the in 
vivo cell environment. 
In this work an in vitro human airway epithelial Calu-3 cells and macrophage U937 cells 
were used to represent the in vivo pulmonary epithelial barrier in mono and co-culture models 
(Forbes and Ehrhardt, 2005). Free rifampicin permeability across the epithelial cell was close 
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to values generally reported in the literature (Tewes et al., 2008). Encapsulation of rifampicin 
into nanoparticles resulted in an increase in rifampicin flux by 20% over 8 h. Lipid shell 
nanoparticles had been found to retain at the mucus epithelium interface after deposition, 
where drug can be liberated gradually from the reservoir provided by the nanocarriers (Chana 
et al., 2015). This result confirmed to previous studies that lipid nanoparticles could enhance 
the permeability of poorly water-soluble drugs across epithelium (Beloqui et al., 2013; Roger 
et al., 2009).  
Following the application of labelled nanoparticles to the air-interfaced epithelial cell layers 
approximately 90 % of the administered dose was recovered from the apical cell surface over 
an 8 hour incubation period (Chapter 5). The observed retention of nanoparticles at the 
epithelial surface is highly desirable from the perspective of achieving sustained drug 
delivery as it offers the opportunity for these systems to act as reservoirs from which drug can 
be released in a controlled manner. Literature relating to nanoparticle fate following 
inhalation appears contradictory due to differences in the particle systems tested (size, 
materials), the lung models used (animal, human, in vitro/in vivo) as well as the scientific 
disciplines that have assessed these parameters. Very small nanoparticles have shown a 
propensity to translocate cell lines following inhalation (Choi et al., 2010). However, data 
from the majority of human studies suggests the translocated fraction is low (< 1 %) and that 
a large proportion of the inhaled dose can be  retained for more than 24 h (Geiser and 
Kreyling, 2010; Kreyling et al., 2002). Hence it appears that nanoparticles uptake by lung 
epithelial cells has a saturation capacity. The lower internalization coupled with previous data 
that lipid nanoparticles penetrated the mucus rapidly suggested that they can reside in the 
lung airways for a period of time and as act as drug reservoirs. 
In the current study the effect of the active drug release process on particle cellular uptake 
was considered important. The results showed the epithelial barrier was resilient against the 
permeabilised nanoparticle system and the permeabilisation process was robust enough to 
occur at this mucosal interface. Permeabiliser-responsive release was found to be efficacious 
following in situ testing at the air-epithelium interface.The ‗on-demand‘ system resulted in 
more drugs being released from the nanoparticles and a greater extent (2X) of nanoparticles 
associated with the epithelial barriercompared to control lipid nanoparticles. This could be 
due to increased particle size (Rejman et al., 2004) or enhanced permeability induced by the 
Pluronic surfactant (Batrakova and Kabanov, 2008). Pluronic block copolymers with short 




PEO block were shown to be potent biological response modifiers capable of enhancing 
cellular internalization in vitro (Park and Na, 2013). In light of the low cellular uptake, the 
efficacy of the permeabilised nanoparticle system demonstrates its potential for further 
development as a controlled inhaled pharmaceutical product.  
When macrophage cells were exposed to lipid nanopaticles, similar results were obtained to 
the Calu-3 cell monocultures with less than 5% of the particles being internalized. The 
permeabilisation process had a small but significant effect on internalization in the in vitro 
macrophage system. Macrophages are one of the main hosts of pathogens in chronic 
infectious diseases and represent a therapeutic target for intracellular delivery of anti-
infective agents and thus there have been a number of studies that have monitored 
nanoparticle uptake. The data generated by these studies suggests that particle 
physicochemical properties such as size, surface charge and shape influence macrophage 
uptake of particles (Chou et al., 2011). Lipid shell nanoparticles are not expected to be 
internalized by macrophage cells due to too small size (Chono et al., 2006). In spite of the 
particles swelling in size from 50 to 200 nm during the exposure to permeabiliser, they are 
still small for phagocytic uptake. Our findings are consistent with the literature (Hirsjärvi et 
al., 2013).  
Overall lipid nanoparticles were found to be distributed in the Calu-3 cells and macrophage 
cells after administration (Figure 6.4). However the amounts of nanoparticles associated with 
epithelial cells and macrophage cells cultured as monocultures were similar while there were 
small differenties in the co-culture system. The effect of permeabiliser on nanoparticle 
internalisation was also differentin the co-culture system compared to the monoculture 
system. These interesting variations in distribution profile could be due to the cell-cell 
interactions in the co-culture model. Cell–cell contact in the pulmonary tract has previously 
been reported to play an important role in the mechanisms of particle cellular uptake (Blank 
et al., 2007). Response following particle exposure on a cell co-culture model compared to 
the monocultures is different due to the communication between cells. In the model, the 
interactions between macrophages and epithelial cells may therefore modulate responses to 
particle exposure. Thus a co-culture model is better at simulating the real situation in the lung 
than monocultures as it enables cross-talk between the different cell types which may affect 
outcomes. 





Figure 6.4: Bio-distribution of lipid nanoparticles (LNP) and permeabilised lipid 
nanoparticles (PLNP) in the co-culture lung cells model.  
The main findings of the current work are depicted in Figure 6.5. The generated data 
contribute to the current understanding of the fate of inhaled permeabilised drug delivery 
nanoparticles. The apparent compatibility of lipid shell nanoparticles with the airway 
epithelium and macrophage supports the hypothesis that certain engineered nano-particulates 
do not cause acute orchronic toxic effects like those observed for inhaled environmental 
ultrafine particles and therefore may be suitable for biomedical applications. The 
permeabiliser-induced release from nanomedicines in the airways seemed to be useful. The 
encapsulation of nanoparticles into microparticles demonstrated that rifampicin could be 
formulated into nanoparticle-based inhalable sustained drug delivery system for better 
management of pulmonary tuberculosis. The preliminary localisation data obtained suggest 
that permeabilised lipid shell nanoparticles can be retained at the mucus epithelium interface 
over a considerable time period, which enhances their availability to serve as drug reservoirs 
for the purposes of sustained delivery. 



































































Figure 6.5: Schematic of main findings of current work: 1. Lipid nanoparticles (LNP); 2. Lipid nanoparticles permeabilised by Pluronic 
surfactant; 3. Mucus penetration of lipid nanoparticles; 4. Cellular bio-distribution of lipid nanoparticles. 
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CHAPTER SIX: General discussion 
 
Future work 
The degradation pathways and clearance mechanisms of the lipid nanoparticles in the lung 
are unknown at present and warrants further investigation. Although the intention of the 
nanoparticle system developed in this work was its retention in order to facilitate sustained 
drug release at the respiratory epithelium its prolonged bio-persistence is undesirable as its 
potential for long-term toxicity is unknown. This is particularly important when considering 
the regular nature of dosing that would be required to manage a chronic disease state. It is a 
possibility that the nanoparticle permeabilisation by Pluronic surfactant may gradually 
transform the nanoparticles to a size range more amenable to phagocytic and mucociliary 
clearance, such that they are efficiently removed from the lungs following the delivery of 
their payload. Another hypothesis is that the nanoparticle permeabilisation will eventually be 
followed by particle fragmentation such that the lungs could clear the endogenous constituent 
components (i.e. phospholipids and triglycerides) through normal pathways. 
Pre-clinical experiments would be the next logical step in confirming the fate and safety 
profiles of the inhaled dynamic nanosystem demonstrated in the current work. Preliminary in 
vivo investigations involving lipid nanoparticles intra-tracheal administration have been 
performed by the Drug Delivery and Pulmonary Pharmacology research groups at King‘s 
College London with promising results. In this ongoing study, lipid nanoparticles formed by 
the same emulsion phase inversion-precipitation process, followed by labelling with a 
radioactive tracer, were aerosolised in the trachea of mice using a microsprayer. These 
nanoparticles were found to be well distributed within the lungs where they were retained 
over a 24 h period. Small amounts of radioactivity were detected in the intestines, liver and 
faeces at 48 h, perhaps representing the portion cleared by mucociliary clearance and 
subsequently transferred to the gastrointestinal system organs (Patel et al., 2016). The lipid 
nanoparticles, administered in the absence of a permeabiliser, were found not to induce an 
inflammatory response in the lungs of mice or cause toxicity to macrophages (Jones et al., 
2014). However, the effect of the permeabilisation process on the fate and safety of lipid 
nanoparticles needs to be investigated in vivo to enhance the understanding of the active 
release nanoparticle system biodistribution 
Another relevant area of future investigation could be the further characterisation of 
nanoparticle loaded microparticles. Physicochemical properties such as crystallisation, 
solvent content and powder gravity could be further investigated. Also twin stage impinger 




(TSI) could be used to study the aerosolisation property and microparticle deposition in the 
lungs. As rifampicin load in the particles used in the project probably needs to be increased 
which could be another area for development. A lot of strategies have been tested to bring 
high doses of drug to the lung (Claus et al., 2014). On the other hand, the development of 





 (Novartis AG, Basel, Switzerland) reached the market with 
the total amount of 112 mg of tobramycin formulation being administered by the inhalation 
of four capsules twice a day (German Summary of Product Characteristics). Thus the 
possibility to deliver high doses of lipid nanoparticles to the lung can be test using 
sophisticated systems.  
It is possible that rifampicin might not be a good drug candidate for this formulation 
approach due to the low drug loading and passive release. It may be better to use a more 
hydrophobic drug that has a high affinity to nanoparticle core in order to reduce passive 
release.  
Last but not least more biogical studies could be performed to enhance the understanding of 
the developed formulation. For example, mucus penetration study can be assessed at pH ~7.0 
to more mimick the real situation and the system could be tested in vivo. 
Conclusion  
The data in this thesis have demonstrated that lipid shell nanoparticles formed by a simple, 
scalable technique have considerable potential as active delivery vectors for inhaled 
therapeutic agents. The nanoparticles can be loaded into microparticles. Upon deposition, 
they can penetrate through mucus rapidly and be retained at the epithelial cell surface, where 
they are available to serve as drug reservoirs. The release of drug from these reservoirs was 
increased by a co-administered Pluronic
 
nanoparticle shell permeabiliser, which preferentially 
inserts into the lipid shell nanoparticles over cell membranes to fluidise them. Fluidisation 
leads to the enhanced release of entrapped drug, which is then available to performe a local 
action in the lungs. Therefore, the lipid shell nanoparticles developed in this work have the 
potential for targeted delivery to the lungs for the specific treatment of tuberculosis or other 
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